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SLE Systemic lupus erythematosus
Smlg +ve Surface membrane immunoglobulin positive
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SRBC Sheep red blood cells
SUMMARY
The autologous mixed lymphocyte reaction was 
studied in normal individuals, in hospital out-patients 
suffering from the autoimmune disorder myasthenia gravis 
(MG) and to a limited extent in patients with rheumatoid 
arthritis (RA ) .
The results of a comprehensive study indicated that 
normal individuals' responses may fall into one of three 
groups - high, medium and low responses. The AMLR 
response was shown to be reproducible on repeat assay
for any responder type, although individual response
variation within a group may be relatively high. No 
correlation between the normal AMLR and the normal 
response to the mitogens concanavalin-A (Con-A), or 
phytohaemagglutinin-P (PHA-P) was found.
The AMLR response was shown to be statistically 
significantly depressed in patients with MG (P <  0.0001) 
and in patients with RA (P<0.0001), when compared to 
the responses of healthy control individuals. No 
differences were found between the kinetic AMLR
responses of normal individuals and those of MG patients
or RA patients. The proliferative responses to the 
mitogens' PHA-P and Con-A of ' myasthenic ' lymphocytes' 
(P<0.0001 and P < 0  . 006 respectively) and of rheumatoid
lymphocytes (P<0.0001 and PC0.001 respectively) were 
also found to be statistically significantly depressed 
in comparison to normal responses.
In an attempt to determine the cellular defects 
that may occur in the autoimmune process, the animal 
model of MG, experimental autoimmune myasthenia gravis 
(EAMG), was induced and maintained in New Zealand white 
rabbits by using purified acetylcholine receptor from 
the electric ray, Torpedo marmorata.
The AMLR responses of the rabbits with EAMG were 
statistically significantly decreased (P <0.04) in 
comparison to normal rabbit AMLR. No differences were 
found between pre- and post-immunisation mitogen 
responses in the test rabbits.
The rabbit model of EAMG is not considered to be a 
useful model for studying cellular immunoregulat ion 
because of the low normal rabbit cellular reactivity.
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11 . INTRODUCTION
"the organism has contrivances by means of 
which the immunity reaction, so easily produced 
by all kinds of cells, is prevented from reacting
against the organism's own elements and so give
rise to autotoxins .... Only when the internal 
regulating contrivances are no longer intact can 
great dangers arise."
Paul Ehrlich (1901).
Historically, immunologists have taken the 
view that the specificity of an immune response 
is the most distinguishing and important feature 
of the system. Thus, disorders of the immune 
system can be considered in terms of alterations 
in specificity, and there should be a specific 
antibody or cell-mediated immune response that is
heightened or decreased to account for the
disease process.
The immune system is a complex network of 
interactions whose internal regulation requires 
self-recognition. Regulation may involve cells, 
antibodies',' ' amplification ' systems ' (e.g. 
complement) and combinations of these elements.
21.1. Controlled self-reactivity______ (tolerance to
self-antigens) in the normal individual
1.1.1 Clonal deletion
The view that the immune system is in a 
constant state of self recognition has only 
recently evolved. Early concepts required that an 
organism could not react against its own 
antigenic determinants and Burnet (1959) proposed 
that natural self tolerance, the absence of
reactivity to self-antigens, required either the 
absence of lymphocytes with receptors for self 
or the inaccessibility to lymphocytes of 
self-antigens.
Autoimmunity was thought to result either 
from the development, by somatic mutations, of 
self-reactive lymphocytes or from contact of
lymphocytes with normally inaccessible self 
antigens (Burnet, 1959). This hypothesis received 
enthusiastic support and remains a possible
mechanism for the loss of tolerance. However, 
more recently, the existence of self-reactive 
lymphocytes has been demonstrated in normal 
healthy animals and humans (Bankhurst et al, 
1973; Baxley' et ' al ,' 1973'; ' Cohen' and' Wekerle, 
1973). Elimination of particular clones of
3lymphocytes may nevertheless have a role, 
together with other self-tolerising processes, as 
no lymphocytes have been found with receptors for 
albumin, which circulates freely in high
concentration in the peripheral blood (Nossal et 
al, 1973).
1.1.2 The role of blocking factors
There is much logic in the notion that 
non-immunogenic self-antigens act to block 
potentially self-recognising lymphocytes. The
constant turnover and shedding of normal cell 
membrane components would seem to provide a 
constant source of soluble fragments of 
self-antigens to compete with immunogenic 
membrane bound forms of these antigens 
(Doljanski, 1973). Indeed, only after
significant tissue trauma would sufficient
quantities of immunogenic membrane-bound antigens 
be released and provoke the afferent sensitising 
stage of an anti-self immune response. Also, the 
concentration of blocking self-antigens would be 
highest near those cells which bear the 
respective immunogenic self-antigens. Thus, 
negative feedback blocking would be ensured to 
be most effective at the critical point when a
4potentially self-recognising lymphocyte
approaches the cell (Baxley et al , 1973).
1.1.3 Effects of immune complexes
Immune complexes might be expected to form 
as soon as autoantibodies are secreted and act as 
a further line of defence against autoimmunity. 
Such complexes, soluble because of the relative 
excess of self-antigens, may block cytotoxic 
effects [as they may do in the case of tumour 
cells (Baldwin et al , 1972)], and the production 
of autoantibodies by B cells. They may also 
induce the generation of T suppressor cells 
(Gorczynski et a l , 1974), adding a positive
regulatory control to the peripheral blocking of 
autoreactivity.
1.1.4 Antigen concentration dependence
Tolerisation of T and B cells has be.en shown 
to be dependent on the concentration of antigen 
present (Chiller et al , 1971); T cells can be 
readily tolerised at low concentrations of 
antigen. Thus, although B cells may remain 
immunocompetent they are prevented from producing 
antibody by the lack of help from the tolerised T 
cells. The experiments of Triplett, (1962)
5showing adult rejection of the frog hypophysis 
removed at the larval stage would argue for a
requirement for the persistence of self-antigen
in order to maintain tolerance. However, Rose 
(1983) showed that unoperated control animals 
were as responsive to native thyroglobulin as
were tnyroidectomised animals. Thus, tolerance
to some self-antigens is maintained even when the 
antigen is removed whereas tolerance to other
self-antigens may cease.
1.1.5 Sequestration of self-antigens
Sequestered self-antigens such as those of
the testes, brain and lens of the eye are not
normally in contact with circulating lymphocytes. 
However, trauma or infection may expose these 
antigens to the immunocompetent cells, inducing 
an autoimmune response.
Binding and response to these antigens does 
not preclude the clonal deletion theory, as these 
antigens have presumably been sequestered 
throughout the life of the animal and deletion of 
the reactive cells in the neonate would not have 
occurred. Thus, sequestration of certain
antigens' may' provide' the ' tolerance' to ' these 
antigens in the normal animal.
61.1.6 The role of regulatory T cells
It is now well documented that specific or 
non-specific stimulation of the immune system 
generates a population of T lymphocytes with 
suppressor activities. Such suppressor T cells 
(T ) have been demonstrated following antigen 
priming (Tada et a l , 1975), tolerance induction 
(Basten et a l , 1975), and idiotype suppression 
(Eichmann, 1975 ) .
Antigen-specific suppressive factors have
been extracted from T cells, obtained froms 7
various sources (Tada et al, 1975; Tanaguchi and 
Miller, 1977). These are glycoproteins of 
molecular weight 35,000-50,000 and do not possess 
Ig determinants but do have a determinant coded 
for by the I-J region of the MHC. This factor
can replace Tg cells both in vivo and in vitro
(Tanaguchi and Miller, 1977).
In view of the findings presented above, the 
mechanisms underlying the establishment of self 
tolerance and the development of autoimmunity 
must be reassessed. Burnet proposed that 
tolerance results from clonal deletion of self­
reactive clones in the neonate and that
7autoimmunity results from the generation of 
self-reactive somatic mutations. It appears more 
likely that the induction and maintenance of 
tolerance arises from the Tg cell activity
described above and that autoimmunity results
from a breakdown in the control exerted by these 
cells, or by cells which induce the Ts activity.
Tolerance to self MHC antigens is learned
during the intra-thymic differentiation of T
cells (Miller, 1978; Zinkernagel, 1978).
Tolerance to other self components and antigens
for T and B cells is more likely to result from
the active suppression by T rather than by the
3
inflexible deletion of cells from a system which 
must encounter modified self antigens, previously 
sequestered self antigens and cross-reactive
antigens.
1.1.7 Idiotypic network
The network theory of the immune response
proposed by Jerne (1974) suggests that antigen
stimulates the formation of an antibody
expressing an idiotype (Ab^) to which
anti-idiotypic (Ab^) antibodies are generated.
An t i - i'd io ty'p i'c antibodies' (Ab^) interfere
not only with the production of additional
8quantities of antibodies of the corresponding
specificity but may also block antigen-binding 
sites on the surfaces of T lymphocytes. These 
idiotypic interactions may serve to protect the 
organism, but cross-reaction of certain idiotypes 
may lead to an autoimmune response (Cooke et 
al., 1983).
1.1.8 Tolerance breakdown
A combination of autoantigen and exogenous 
antigen may form immunogenic units capable of
stimulating T cell help that can activate the
immunocompetent B cells to produce autoantibody 
(see Figure 1. ). Virus particles, bacteria and
drugs may each provide the stimulus for this T 
cell help by either cross-reaction or by forming 
altered self-determinants on the surfaces of
target cells. Cross reaction between antigens 
present on the myocardium and antigens present on 
group A ^J-haemolytic streptococci can lead to an 
autoimmune response directed against this tissue 
in susceptible individuals (Kaplan and Svec, 
1964 ) .
A possible mechanism for the development of 
autoimmunity by T cell bypass because of ' the 
generation of new carrier determinants or by
9SELF TOLERANCE NEW CARRIER
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T or B cells
AUTOIMMUNE 
RESPONSE
Figure 1. By-pass mechanisms for the induction of 
Autoimmuni ty.
1. Self-tolerant state: tolerisation, clonal deletion
or suppression of the self-reactive T helper cell.
2. Provision of new carrier determinants through
intramolecular cross reacting antigen, drug or 
virus particle.
3. Provision of new carrier determinants through
membrane associated cross reacting antigen, drug or 
virus particle.
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cross reaction may be represented by Figure 1. ,
as suggested by Cooke et al, (1983). If normal
immunoregulatory circuits are intact, the 
autoantibody formed following stimulation of a T 
cell helper signal by self-antigen can be
interrupted by suppressor T cells. Deficient
suppressor T cell activity or a reduced number of 
these cells may allow the autoimmune response to 
proceed and result in the pathogenesis of an
autoimmune disease.
1.2. The autologous mixed lymphocyte reation (AMLR)
It is clear that, in certain cases,
self-reactivity does occur in vivo . Smith and
Steinberg, (1983), proposed that controlled 
self-reactivity represents a normal event and
that self-reactions are important mechanisms of 
normal immune reactivity and immunoregulat ion. 
The autologous mixed lymphocyte reaction (AMLR)
may represent one such mechanism. Quantitative 
abnormalities can be seen to account for disease 
development represented by the degree of stem 
cell proliferation, autoantibody generation or 
immune complex formation. Rather than being 
caused by a single factor, autoimmune diseases 
are now considered as being ' mult'i-factorial ' in 
aetiology. Individual genes, environmental
11
factors and hormonal balance may contribute to 
disease predisposition and development.
Stimulation of or interference with normal 
immunoregulat ion coupled with an alteration in 
hormonal homeostasis may lead to manifestation of 
autoimmune disease.
Efficient disposal of foreign antigens from 
the body requires the participation of both T and 
B lymphocytes. It is known that this 
participation requires the activation of the T 
cells by antigen presented in association with a 
surface marker on non-T leucocytes and that the 
antigen presenting cell must bear Major 
Histocompatibility Complex (MHC) encoded
antigens matching those of the responding cell.
It has been confirmed (Glimcher et al, 1980)
that antigen alone cannot activate T helper (Tu ) 
cells and that a cell bearing specific surface 
markers must also co-operate. These surface 
markers or Immune associated (la) antigens have 
been shown in the murine system to be coded for 
by the immune response (Ir) genes (Rosenthal et 
al, 1973; Thomas et a l , 1977; Benacerraf, 1981)
which are products of the H-2 locus of chromosome 
17. This locus' is analogous to the' HLA-D' region 
on chromosome 6 in man.
12
Bain et al, (1964) and Bach and Hirschhorn
(1964) observed that mixtures of lymphocytes from 
two genetically non-identical individuals are
capable of stimulating each other in vitro (the 
mixed lymphocyte reaction). The subsequent 
genetic and immunological analysis of this 
phenomenon (Bach and Amos, 1967; Albertini and
Bach, 1968; Amos and Bach, 1968; Zoschke and 
Bach, 1971) established the mixed lymphocyte 
reaction as a means of measuring the degree of 
histocompatibility at la loci between individuals 
and has provided an important tool for the study 
of immunobiology and genetics of tissue 
transplantation.
What is perhaps much more suprising is that 
la bearing cells can induce autologous T cell 
proliferation; a finding which indicates that the 
immune system contributes more than just a 
mechanism for the removal of foreign antigen from 
the body. This phenomenon has been termed the
Autologous Mixed Lymphocyte Reaction (AMLR) and
was first observed as a significant proliferative 
response in the background thymidine
incorporation in the mixed lymphocyte reaction 
(Etheredge et al, 197*3). Subsequently Opelz et 
a l , (1975) demonstrated that the proliferative
13
response of unfractionated lymphocytes in culture 
could be dramatically enhanced by increasing the 
ratio of non-T cells to T cells. The AMLR
displays the classical attributes of an immune
response; memory and specificity (Weksler and 
Kozak, 1977; Sakane and Green, 1979)*
1.2.1 Responding and stimulating cell types
Much controversy has been generated over the 
exact nature of the stimulating and responding
cells in the AMLR. The responding cells were
found to be T lymphocytes and the stimulating
cells non-T leucocytes (Opelz et al, 1975; Kuntz 
et al, 1976).
The techniques used to prepare T cells have 
identified characteristics of those T cells that 
proliferate in the AMLR. They are low density 
lymphocytes (Stober and Loehnen, 1978) that form 
early rosettes with sheep red blood cells (SRBC) 
(Yu, 1978) and express receptors for autologous
erythrocytes (Fournier and Charriere, 1981).
They react with the 0KT4 monoclonal antibody 
(Kozak et al . , 1981) and respond to
Concanavalin-A (Con-A) (Sakane and Green, 1979)* 
Indeed,' 90% of ' autologous erythrocyte-rosette'd ' T 
cells react with 0KT4 monoclonal antibody whereas
14
only 60% of normal T cells react in this way.
Numerous marker antigens have been described 
to define various subpopulations of T cell 
lineage. These include the presence of receptors 
for immunoglobulin isotype Fc (Gupta, 1982),
sensitivity of SRBC-T cell rosette formation to 
theophylline (Shore et al., 1978), and rosette 
formation between T cells and autologous RBC
(Sandilands et al ., 1974). These subpopulations 
have been suggested as forming different 
responding subsets with regard to the stimulating 
antigen. The proposed relationship between these 
cells may be seen in Figure 1.1 ., as suggested by 
Weksler et al., (1981).
Heterogeneity of autologous responding T 
cells was reported by Hausman et al . , (1980), with
regard to the nature of the responding and
stimulating cell pairs. Hausman et al (1980), 
reported that one subset of human .T cells, 
identified by the monoclonal antibody T29, were 
responsive to stimulation by macrophages that 
display the surface determinant recognised by the 
monoclonal antibody Mac120. T cell subsets not 
displaying the T29 marker i.e. T29 > were found 





Figure 1.1. Relationship between ConA activated (T ConA) 
T cells, allogeneic cell activated (T alio) T cells, 
autologous cell activated (T auto) T cells, T cells 
that form rosettes with autologous erythrocytes (Tar) 
and T cells that develop suppressor activity in the 
presence Of ConA' (Ts Con).' The area Of' the circle's ' is 
not intended to reflect the sizes of the T cell subsets.
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The OKT series of anti-(human lymphocyte) 
monoclonal antibodies have been used for the
phenotypic identification of T cells as they
progress through their maturational development 
and acquire different functions (Fig 1.2). 0KT4 
antibody reacts with a population of T cells
(0KT4+ ) that is believed to define a subset
containing helper/inducer functions for B cell Ig 
production, whereas 0KT8 antibody reacts with a 
subset of T cells (0KT8+ ) that contains
suppressor/cytotoxic functions (Reinherz and 
Schlossman, 1980). By using subset-specific 
antibodies and complement, various groups have 
shown that 0KT4 + T cells are the major responders 
in the AMLR (Kozak et al ., 1977; Gupta 1983).
Auto-activated T cells, fractionated following a 
primary AMLR using a Percoll density gradient
centrifugation procedure, were shown to react 
with 0KT4 antibody at levels of 90%. However, 
only 10% of the same auto- activated cells
reacted with the 0KT8 antibody (Kozak et al,
1981 ) .
The differential ability of Mac120+ and not 
Mac120~ macrophages to act as stimulators for 
T29+ cells' could' ' indicate ' expression' of ■la 
antigen on Mac120+ but not on Mac120 cells, or a
17
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difference in the density or affinity of these 
antigens. The heterogenous non-T cell population 
contains B cells, monocytes, null cells, 
dendritic cells and macrophages and various
reports (Royston et al, 1974; Kuntz et a l , 1976;
Sakane et al , 1978; Gottlieb et a l , 1979;
Palacios and Moller, 1981) have suggested maximal 
proliferation caused by using one or a
combination of the possible stimulators. Shen et 
al (1983), found that macrophages recognised by 
the monoclonal antibody 0KM5+ , but not 0KM1+ , 
were stimulatory in the AMLR, although no
quantitative difference was found between 0KM1+ 
AND 0KM5+ macrophage la expression. Both Mac120~ 
(Hausman et al, 1980) and 0KM1 + macrophages have 
been shown to be effective stimulators of an 
allogeneic MLR, indicating the presence of la 
antigens.
That la antigens play a central role in T 
cell activation in the AMLR was demonstrated by 
Mingari and Moretta (1982), when la positive but 
not la negative autologous peripheral blood 
mononuclear cells were shown to function as 
effective stimulating populations. Stimulating 
capacity is not restricted to the non-T cell 
population' because Ia+ (mixed lymphocyte culture 
or mitogen activated) T cells are equally
19
effective (Ferrone, 1980, Mann and Sharrow, 1980, 
Russo et al , 1981, Mingari and Moretta, 1982). 
Addition of two different monoclonal antibodies
directed against la strongly inhibited cell 
proliferation in autologous mixed lymphocyte
cultures.
Although it has been established that the
major responding cell in the AMLR is the Tun
(O K T ) cell (Smolen et al, 1981), the 0KT8+
subset, which exerts potent suppression of Ig 
synthesis, could exhibit substantial
proliferation when exogenous Interleukin-2 (IL—2; 
T cell growth factor) is supplied ’in vitro' or 
when co-cultured in the presence of irradiated 
0KT4+ cells. Triggering of T cells by an la 
positive cell may result in the expression of 
IL-2 receptors. Any procedure that inhibits or 
blocks the expression of IL-2 receptors in T 
cells or causes a decreased production or 
availability of IL-2 would impair the 
proliferation of activated T cells. Equally, 
reduced expression and/or presentation of la by 
Ia+ cells will affect the activation and 
subsequent IL-2 responsiveness of T cells.
The degree'of activation of'responding ' cells 
in the AMLR has been shown to be greater than ' the
20
number of T cells induced to proliferate (Smolen 
et al, 1982). Also, analysis showed that a 
very small percentage of responder T cells (less 
than 1%) respond initially to signals from 
autologous non-T cells. There is a three day 
delay before substantial proliferation and
activation takes place providing time for 
amplification and suppressive regulatory
processes to occur.
1.2.2 Effector functions of the AMLR
The secondary immunological consequences of 
T cell activation in human AMLR and in the murine 
analogue, the syngeneic mixed lymphocyte reaction 
(SMLR), are now known to be the induction of both 
T helper and suppressor cell functions although 
doubt remains over the demonstration of
auto-cytotoxic T cell generation.
Several reports have failed to detect 
cytotoxicity in the AMLR (Vande Stouwe et al, 
1977; Smith, 1978; Katz et al , 1978). However,
Tomonari (1980) observed the generation, in the 
AMLR,of cytotoxic T cells (Tc ) having similar 
characteristics to natural killer (NK) cells.
Maximal cytotoxicity was observed on day '8-9 of a'
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mixed lymphocyte culture and DNA synthesis and
cell proliferation were required for Tc cell
generation. These observations have since been
supported by the findings of Goto and Zvaifler
(1983) who described the AMLR T cell asc
expressing the PAN T cell marker 9.6 and the
activated T cell marker AF2 and closely
resembling NK cells. The generation of 
immunoglobulin secreting cells (ISC) during the 
AMLR was initially described by Gatenby et al,
(1982) and subsequently confirmed by Romain and 
Lipsky (1983). As with other AMLR effector
functions, ISC activity could be augmented by
foetal calf serum (FCS ) in the culture medium.
1.2.3 The role of the AMLR
The AMLR has been regarded for some time as 
little more than a laboratory curiosity.
Several workers have suggested that the AMLR 
might result from perturbations of the responding 
or stimulating cells during cell fractionation or 
exposure to xenogeneic antigens in the separation
procedures or during culture (Huber et al, 1982;
Kagan and Choi, 1983; MacDermott and Bragdon,
1983) but these findings have been questioned.
Moody et a l , (1983) and Naides et al , (1985) have
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used cell populations separated by passage over 
nylon wool to demonstrate that xenoantigen is not 
required for an AMLR although others have shown 
that xenoantigens may enhance the AMLR 
proliferative response of some, but not all, 
normal healthy individuals tested (Indiveri et 
al, 1985). When the AMLR was described by Kuntz 
et al (1976), a potential role for this reaction 
in the regulation of the immune response was 
suggested. Subsequent support and acknowledgement 
of the AMLR as a true immune phenomenon and 
evidence for its immunoregulatory role came with 
the demonstration of memory and specificity 
(Weksler and Kozak, 1977, Sakane and Green, 
1979), of helper activity (Hausman and Stobo, 
1979), of suppressor activity (Sakane and Green, 
1979; Innes et al, 1979; Smith and Knowlton, 
1979) and of cytotoxic activity (Tomonari, 1980). 
Soluble factors with immunoregulatory functions 
were also demonstrated in vitro (Yu et al , 1980;
Lattime et al , 1981).
The impaired AMLR observed in many patients 
with diseases possibly associated with abnormal 
immunoregulation may lend additional support for 
an immunoregulatory role of the AMLR. Impaired 
AMLR in patients with autoimmune diseases (Smith 
and De Horatius, 1982; Sakane et al , 1978;
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Miyasaka et al , 1980; Hafler et al , 1985;
Richards et a l , 1986), immunodeficiency states 
(Engleman et al, 1980; Gupta et al , 1984) and
immunoproliferative disorders (Knight et al, 
1983; Smith et al , 1977) have been demonstrated, 
although conflicting observations have been 
reported by other groups. Notably, increased
AMLR have been reported in a group of patients
with multiple sclerosis (Birnbaum and Kotilinek,
1981) and also in patients with myasthenia gravis
(Greenberg et al, 1985), both autoimmune
diseases. This latter report will be further
explored in the Discussion section.
The recent findings of Kotani et al (1984), that 
a part of the AMLR may represent an important 
pathway for the activation of a feedback
suppressor mechanism among T cells expressing the 
0KT4 marker, argues for a central role of the
AMLR in antigen non-specific immunoregulation, in 
the normal, clinically healthy individual. When, 
for any reason, this immunoregulatory mechanism 
breaks down, the "horreur autotoxicus" described 
by Ehrlich may be established and manifest itself 
as one of many different autoimmune states.
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1.3. Autoimmune diseases
If the immune system can be called into 
action to protect the host from potential 
environmental threats, then it must also be 
endowed with mechanisms to prevent an 
immunological attack on its own tissues. As 
discussed in section 1.1, self/non-self
discrimination may be controlled via one or a 
combination of possible mechanisms.
Recent developments in autoimmunity suggest 
that there are three stages in response to self. 
These may be called autorecognition, autoimmunity 
and autoimmune disease. The first is now 
regarded as normal and fundamental to a network 
theory of immunological control that is based 
upon the recognition of idiotypes and antigens 
related to the MHC. Autoimmunity is, as the term 
implies, a state of controlled reactivity, against 
self-antigens whereas autoimmune disease is the 
result of a breakdown in the mechanisms that 
maintain immunological homeostasis through 
autoimmuni ty.
Human autoimmune disease states may be 
broadly classified into a spectrum having
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organ-specific disorders such as Hashimoto’s 
thyroiditis at one end, and non-organ-specific
disorders such as systemic lupus erythematosus
(SLE) at the other. Organ specific disorders 
appear to involve immunological attack on a 
particular organ by virtue of a response directed 
against a target antigen restricted to that organ. 
Non-organ specific disorders involve lesions which 
are widespread throughout the body. A wide
overlap may occur within diseases at each end of 
the spectrum. For example, patients with 
autoimmune thyroid disease may have a high 
incidence of gastric autoantibodies, whereas 
patients with rheumatological disorders tend to 
have a combination of rheumatoid arthritis with 
some features of SLE.
Many diseases that are immune-mediated are 
influenced to some extent by the genetic 
background of the individual and the prevailing 
state of the immune system. The abnormality that 
results in autoimmune disease expression may lie 
in the self-antigen, the immune process, or both. 
Thus, one may have an abnormal self-antigen with a 
normal immune response to it, an abnormal response 
to a normal self-antigen, or an abnormal response 
.to an abnormal antigen. ..............................
26
The presence of auto-antibodies, or even 
their distribution in tissues, does not
necessarily imply that the cause of lesions and of 
the clinical symptoms of the disease is
the autoimmune process itself. However, the
uncontrolled generation of anti-self antibodies
or of auto-aggressive cells does infer a lack of 
immunological regulation.
Humoral responses may take the form of
deposition of antibody-antigen complexes in the 
tissues, activating complement and resulting in 
inflammation (type II and type III
hypersensitivity). Cell-mediated lesions may be 
caused by cytotoxic T cells or by antibody-
dependent, cell-mediated cytotoxicity of killer 
cells and macrophages.
A comprehensive review of the AMLR in health 
and disease states in man by Gupta (1983),
discussed the cellular responses in various
autoimmune states, and the likely basis for the 
observed defects. The vast majority of the 
observations reviewed by Gupta (1983) and those 
up to the present date appear to support the 





One of the earliest observations of MG was 
recorded in 1683 in a book written by Dr Thomas
Willis under the heading "The Habitual and
Spurious Palsies” . Many accounts of myasthenia
have since been reported and are reviewed by
Harrison and Behan (1986), the most comprehensive 
account is that of Campbell and Brarawell (1900). 
Some of the early observations are summarised
below.
Wilks, (1877) described a female with
weakness, an unexplained squint and difficulty in
speaking (dysarthria). Death was due to 
respiratory paralysis. Erb, (1879) reported
three patients with drooping of both
eyelids (bilateral ptosis), and weakness of neck 
muscles. Fluctuations in severity and the 
apparent recovery of 2/3 patients argued against 
progressive bulbar palsy. Goldflam, (1893) found 
neuromuscular weakness without muscular atrophy 
in several patients. Good sphincter control and 
normal palatal reflex differentiated
1Erb-Goldf1 am complex' from true bulbar palsy.
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Jolly, (1895) described 'Myasthenia gravis 
pseudoparalytica' in two young boys with 
decremental response of muscles to tetanic 
indirect electrical stimulation. The term 
'myasthenia gravis' was generally adopted in 
1899. Bell, (1917) and Holmes, (1923) both found 
association of thymic tumours with MG.
Following the account of Campbell and Bramwell 
(1900) in which ocular and vocal muscle 
involvement was commented on, independent 
conclusions were drawn with regard to the fact 
that the prime site of disease in MG was the 
muscle (Weigert, 1901; Herzog, 1917; Marburg, 
1931 ; Norris, 1936 ) .
Sir Henry Dale (1936) elucidated the 
mechanisms of normal neuromuscular function, 
describing the release of acetycholine at the 
neuromuscular junction in response to a nerve 
impulse. An enzyme, choiinesterase, was shown to 
destroy the neurotransmitter, and Walker (1934) 
showed that an inhibitor of cholinesterase, 
physostigmine, was capable of alleviating the 
muscle weakness characteristic of MG.
That MG may b e a n  autoimmune disease was' 
first suggested by Smithers, (1959), who noted
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histological similarities between the myasthenic 
thymus gland and the thyroid gland of thyroiditis 
patients. Immunological disorders of MG were 
described by Nastuk and co-workers (Nastuk et al., 
1956, I960), who reported altered serum complement 
levels in myasthenic individuals, and by Strauss 
et a l . , (I960), who reported the presence of
complement-fixing antibody binding to skeletal 
muscle in vitro. Indirect evidence that MG is an 
autoimmune disease came from the observation of 
the increased association of MG with other 
disorders which were thought to be autoimmune 
(Simpson, I960).
Since I960, our understanding of the 
physiological defect that causes the symptoms of 
MG has been greatly improved. The defect at the 
neuromuscular junction was shown to be localised 
at the post-synaptic membrane. A simplified 
morphology of the post-synaptic membrane (Engel 
and Santa, 1971) and reduced numbers of 
acetylcholine receptor (AChR) on that membrane 
(Fambrough et al ., 1973; Ito et al , 1978a) were
observed. The target of the autoimmune response 
was confirmed to be the AChR, both by generation 
of a rabbit model of MG following injection of 
purified receptor (Patrick and Lindstrom, i 9 7 3 ) . 
















Muscle Figure 1.3 L,
Figure 1.3 (a) 8. (b ) A diagrammatic representation
of the normal neuromuscular junction la) and the
simplified post-synaptic membrane (b) observed in
patients with myasthenia gravis. Note the reduced
numbers of acetyl choline receptors (AChR) on the 
post-synaptic membrane in Figure 1.3 ( b ).
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simplification of the post-synaptic membrane and 
the reduction in the numbers of AChR described 
above.
1.3.3 The Acetylcholine Receptor (AChR)
AChR, isolated from the electric organs of 
the electric eel, Electrophorus, and the electric 
ray, Torpedo, has been the subject of extensive
characterisation studies which have been 
comprehensively reviewed (Changeux, 1981; 
Conti-Tranconi and Raftery, 1982; Barrantes,
1983; Raftery et al., 1983; Anholt et al. ,
1984). These studies have depended on the
properties of certain snake venoms known as
(X -toxins, which bind almost irreversibly and
with high specificity to the acetylcholine
binding site (Lee, 1972). The purity of AChR 
preparations is usually expressed in terms of the 
number of or- toxin binding sites per gram of
pro tein.
The AChR purified from both Torpedo and
Electrophorus contains four different subunits,
a . p . f  , and 6  with apparent molecular weights of 
40,000, 50,000, 60,000 and 65,000. The
acetylcholine binding site is' located on the
or -subunit (Tzartos and Changeux, 1984; Wilson et
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al., 1984 Cahill and Schmidt, 1984). A
quaternary structure of (X^ P i f 6  was proposed by 
Reynolds and Karlin, (1978) for Torpedo AChR 
monomers. This structure is represented in its 
membrane environment in Figure u . The linkage of 
two monomers by disulphide bonds between the 
(Jsubunits is thought to constitute the 
functional unit in vivo (Schindler et al., 1984).
The roles of the ^3, if and 5  subunits are 
unknown although one or more of them may be 
involved in the regulation of the centrally 
placed cation-channel (Karlin et al . , 1983).
Because of the limitations placed on the 
availability of material, much less is known 
about the AChR of human muscle. The
acetylcholine binding site of mammalian AChR is 
known to be present on the Of -subunit (Lyddiatt 
et a l . , 1979) and early studies on human
(Lindstrom et al., 1978) bovine (Lindstrom et 
al . , 1979; Einarson et a l ., 1982) rat (Einarson
et al., 1982) and more recently amphibian 
(Sargent et al., 1984) AChR preparations have 
indicated the presence of Of , /3 > if and
<5subunits. The subunits of foetal calf muscle 
AChR also showed considerable homology with the 






Figure u • Diagrammatic representation of AChR in 
the membrane (taken from Harrison and Behan, 1986).
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(Conti-Tronconi et al., 1982a). Homology was
shown between the Of-subunits of chicken muscle 
and Torpedo AChR (Barnard et a l ., 1983).
Interspecies differences were, however,
observed (Gullick and Lindstrom, 1982a; James et 
al., 1983)
More recently, Turnbull et al ., (1985) found
no major differences between foetal and adult AChR 
in humans, both of which showed subunits with 
apparent molecular weights of 44,000, 57,000,
58,000 and 66,000.
1.3.4 Disease characteristics
Approximately 1 in 20,000 of the worldwide
population is affected by MG, with no increased
frequency in any particular ethnic group. The 
disease may present over a wide range of ages, 
although a separate disorder, congenital MG, may 
occur in males less than 2 years old (Vincent et 
al, 1981). Myasthenia occurs more frequently in
females than males (ratio of 3:2 respectively) 
and females predominate in cases presenting under 
the age of 40 years, whilst males predominate in 
cases presenting over the age of 40. Osserman
and Genkins (1971), reported modal values of the
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third decade for females and the seventh decade 
for males. Cases presenting with thymoma have no 
obvious sex distribution and modal age of onset 
is in the fifth decade.
1.3.5 Symptoms and disease associations
The characteristic symptom of MG is muscle 
weakness after repeated use which recovers, 
although not always completely, with rest. 
Symptoms are often noticed following an infection 
or after a period of psychological stress 
(Campbell and Bramwell, 1900). Penicillamine 
therapy for rheumatoid arthritis may also induce 
MG (Bucknall, 1977).
Any striated muscle may be affected;
extraocular muscles commonly being the first to
become involved. More than half of MG patients
present with ptosis or diplopia (double vision),
and the majority have eye muscle involvement at 
some stage of the disease (Simpson, I960).
Difficulty in chewing, swallowing, and breathing
occurs, and in severe cases, bowel and bladder 
sphincter muscles may become involved.
Diagnosis and assignment of disease severity
is often performed according to a scale proposed
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by Osserman and Genkins (1971) whose degrees of 
severity range from asymptomatic to I (Ocular 
signs and symptoms only) to IIA, IIB and IIC. 
The most severe form IIC, involves severe 
generalised weakness with a compromise of
respiratory function.
The major functional restrictions that are 
observed are reduced muscular utility apparent 
upon electrical stimulation of the affected
muscles. Abnormally low end-plate potentials 
(epps) (Elmqvist et al ., 1964) were found in
myasthenic patients. Although a pre- or 
post-synaptic lesion could account for the
reduced epps and mepps, the observations of Engel 
and Santa (1971) and Fambrough et al , (1973)
favour the post-synaptic lesion theory.
Myasthenia has been reported in association 
with rheumatoid arthritis (Simpson, I960),
thyroiditis (Aarli et a l ., 1978), Sjogrens
syndrome (Brown et al., 1968) pernicious anaemia 
(Blecher and Williams, 1967), polymyositis (Behan 
et al. , 1982) and other immune associated
disorders. Associations between the development of
lymphoid neoplasms in MG patients (Silberstein, 
1970) and MG in patients with lymphoma (Davis and 
Schumacher, 1979) have also been reported.
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1.3.6 Association with histocompatibility antigens
Disease susceptibility and the presence of 
certain major histocompatibility complex (MHC) 
antigens has been linked for over 20 years. Lilly 
et al , (1964) demonstrated that the
susceptibility of mice to Gross virus-induced 
leukaemia is determined by genes linked to the
H-2 locus (analogous to the human HLA locus).
Strong associations have since been observed 
between many autoimmune diseases and the presence
of specific HLA determinants (eg HLA-B27 and
ankylosing spondylitis, Winchester et al., 
(1975) ) .
Myasthenia shows a strong association with 
HLA-A1 and -B8 (Pirskanen et al., 1972; Fritze et
a l . , 1974; Behan, 1980). A comprehensive review
of the detailed HLA associations with MG has been 
carried out (Harrison and Behan, 1986). The
associations that have been observed may differ 
for various races. The HLA-DR3 antigen has also
been associated with MG, although with less 
frequency than the -B8 antigen (Kaakinen et al ., 
1975; Dawkins, 1978). However, a recent report of 
■ HLA- antigens ■ ■ in myasthenic ■ American ■ blacks 
suggested an association of MG with HLA-A1 and/or
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-B8 with an increase in -DR5 rather than -DR3
(Christiansen et al. , 1984). In the various races 
studied, alleles at the -A and -B loci are more
prominent than those at the -DR locus.
1.3.7 The role of the thymus in the development of MG
The high incidence of thymitis and thymoma
(Castleman, 1966, Namba et a l ., 1978), in MG and
the beneficial effects of thymectomy in many
cases of MG (Papatestas et al, 1971a)
have indicated the importance of the thymus in
the pathogenic progess in MG.
Thymic hyperplasia (thymitis) is found in
about 80% of all MG cases and is characterised by
the presence of germinal centres in the thymic 
medulla. This condition is generally taken to be 
diagnostic for MG although small numbers of
germinal centres in the thymus have been noted in 
cases of hyperthyroidism (Vetters and Simpson, 
1974) and in a variety of autoimmune diseases
(Habu et al., 1971; Tamaoki et al ., 1981).
Thymoma generally occurs in patients over the age 
of 40 and the prognosis is poor (approximately 30%
of all MG cases) (Mulder et al, 1974).
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1.3.8 Humoral responses in MG
MG patients have an increased incidence of 
autoantibodies directed against targets other 
than the AChR. This also occurs in other 
autoimmune diseases and similarly results in
accompanying immunological disorders. The
incidence of non-AChR directed autoantibodies has 
been reviewed by Harrison and Behan (1986).
Increased in vivo polyclonal B cell activity 
has been suggested by Levinson et al., (1981 a,b)
with the demonstration of increased levels of
spontaneous Ig-secreting cells in 30% of MG
patients. However, Harfast et a l ., (1981) found
no spontaneous Ig production in MG patients and 
Kelly et al ., (1981) observed no differences in
the spontaneous Ig synthesis by PBL between MG
patients and control subjects.
The polyclonal stimulator of B cells, 
pokeweed mitogen (PWM), is dependent upon T cell 
processing for its mitogenic properties and this 
system has been shown to be a useful model for 
studying regulatory mechanisms of Ig synthesis in 
vitro (Janossy and Greaves, 1975; Fauci, 1979). 
Harfast et al., (1981) reported increased 
PWM-induced Ig production in MG patients compared
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to control subjects. Limberg et al., (1985)
however, found normal Ig synthesis in MG patients 
but this was accompanied by decreased IgM 
synthesis. Kelly et al., (1981) observed no
differences in PWM-induced Ig synthesis between 
thymectomised and non-thymectomised MG patients, 
both of which were normal.
The spontaneous production of Ig by the 
peripheral blood lymphocytes (PBL) of MG 
patients was not observed until day 4 in vitro, 
the kinetics of this resembling that of
PWM-induced synthesis (Limburg et al., 1985).
This observation was interpreted as a possible T
cell involvement in the spontaneous synthesis of
Ig.
The ability of unstimulated PBL from patients 
with generalised MG to synthesise anti-AChR
antibodies in vitro has been reported (Lisak et 
al. , 1983; Willcox et al ., 1984). However,
Newsom-Davies et al ., (1981 a,b), reported little
or no in vitro anti-AChR antibody synthesis by 
PBL from MG patients, with or without stimulation 
by PWM. A thymic cell line producing monoclonal 
anti-AChR antibody has been established from the 
•thymocytes- of an MG patient (Kamo et al., • 1982 ) * 
Whereas only 5-8% of normal subjects synthesise
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detectable amounts of anti-AChR antibody after 
PWM stimulation of PBL (Lisak et al ., 1983,
1984), the majority of MG patients PBL synthesise 
anti-AChR antibody (Lisak et a l ., 1983) following 
such stimulation.
Lisak et al ., (1984) showed an increase in
the anti-AChR antibody secretion by PBL of MG 
patients after depletion of 0KT8+ cells and 
following PWM stimulation.
1.3.9 Cellular responses in MG
Selective enhancement by irradiated thymic cells, 
of anti-AChR antibody production by autologous 
PBL from myasthenic patients Was deserve^
(Newsom-Davis et al, 1981a) and, using monoclonal 
antibody depletion studies, Willcox et al , (1984)
have suggested that this enhancement is mediated 
by antigen presenting cells rather than by 
AChR-specific thymic T helper cells. Thomas et 
al, (1982), proposed that HLA-DR+ interdigitating 
cells were involved in antigen presentation 
although Willcox et al, (1984) argued that
germinal centre follicular dendritic cells were 
•primarily responsible for the' presentation of ' the 
autoantigen. Immuno- histological studies by
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Lisak and colleagues showed that some, but not
most Ia+ cells in the thymus, express T cell 
markers. The results presented by Willcox et al,
(1984) were interpreted as supporting the
hypothesis that the MG thymus might present AChR 
in a particularly stimulatory fashion and provide 
a source of potent help to autologous 
AChR-reactive B cells. A significant increase in 
the percentage of Ia+ cells in thymic cell 
suspensions from MG patients has been observed 
(Lisak et at, 1983) although Ia+ cells were not
detected by Bhan et al,(1980).
Abdou et al, (1974), Lisak et al, (1978),
Richman et al , (1976) and Opelz et al, (1978)
have found that thymic cell suspensions from 
myasthenic patients stimulate autologous PBL to 
proliferate in one-way mixed lymphocyte 
reactions, particularly when these cells are 
obtained from patients with thymic hyperplasia 
(Abdou et al, 1974). The stimulus for such an 
’autologous MLR 1 is not known, although the 
possibilities of a virally induced neoantigen 
(Lisak and Zwieman, 1976; Lisak et al , 1976)
elaboration of a soluble activator or altered 
thymic AChR have been suggested (Lisak et a l , 
1976; Newsom-Davis et al, 1981 b), and would be 
supported by the absence of such an 'AMLR'
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between these cells in normal subjects.
Ia+ cells are potent stimulators of both 
allogeneic and autologous MLR between PBL 
(Mingari and Moretta, 1982) and this is of 
interest when one considers that AChR or altered 
AChR presented by an Ia+ dendritic cell could 
serve as the stimulator.
Surface marker studies, especially those 
measuring Fc receptors on T cells (T^ and Tp) 
(Lisak et al, 1979), T cell markers (0KT4 and 
0KT8) (Reinherz et al, 1980; Newsom-Davis et al , 
1981 a; Lisak et al, 1982; Tindall, 1982; Lisak 
et al., 1983) and B cell markers (EAC rosettes) 
(Staber et al., 1975), (IgM/IgD) (Kornstein et 
a l ., 1 9 8 3 ) have not yielded clear conclusions as
to the proportions of these immune cells within 
the myasthenic thymus. Tables of all the reported 
changes in T and B cell, suppressor cell and 
helper cell numbers in MG patients compared to 
normal controls have been compiled by Harrison 
and Behan (1986). Conflicting results are 
apparent, although the majority of reports 
indicate increased B-cell and decreased T-cell 
populations, in both the thymus and PBL in MG. 
Measurements of ' the helper cell and suppressor 
cell population sizes by surface marker studies
uwere found to yield inconclusive results.
Functional assays of suppressor cell activity 
have indicated impaired suppression by both 
unstimulated and Con-A stimulated myasthenic 
lymphocytes on mitogen-stimulated autologous cells 
(Zilko et al., 1979; Salzner et al., 1981) or on 
the mixed lymphocyte reaction (Berrih et al .,
1981). Defective suppressor cell activity could 
account for the elevated levels of anti-AChR 
antibody in MG patients (Miller and Schwartz
1982), but removal of suppressor T cells does not 
induce anti-AChR antibody synthesis by the PBL of 
normal individuals (Lisak et a l ., 1984).
Studies of the responses of myasthenic 
lymphocytes to non-specific mitogens have been 
shown to be both normal (Abdou et al., 1974; Lisak 
and Zweiman, 1975; Kalden et al ., 1976;
Conti-Tronconi et al., 1979; Trotter et al., 1982) 
and impaired (Zilko et al. , 1979; Berrih.et a l . , 
1981; Koethe et al., 1981; Dropcho et al., 1982; 
Richards et al., 1986). The proliferative
responses of lymphocytes from myasthenic patients 
to AChR has, however, consistently been reported 
as being significantly greater than that observed 
in normal controls (Abramsky et al., 1975 a,b;
Richman et al., 1976 , 1979; Conti-Tronconi et a l . ,
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1977, 1 9 7 8 , 1979, 1982, 1983).
1 .3.10 The role of anti-acetylcholine receptor antibody 
in the pathogenesis of MG
Loss of active AChR from the post-synaptic 
membrane has been suggested to represent the major 
factor resulting in impaired neuromuscular 
transmission in MG (Fambrough et al, 1973). A 
large proportion of the work that has identified 
the mechanisms involved in this loss was carried 
out on animal models, and further discussion of 
the mechanisms may be found in Section 6.5.
The mechanisms involved in the loss of 
functional AChR from the post-synaptic membrane 
may be:
i) Direct block of AChR
ii) Increased degradation or decreased
synthesis, or both
iii) Complement-mediated lysis of the
post-synaptic membrane.
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i ) Direct Block
The lack of morphological changes at the 
muscle end plates and alleviation of symptoms 
with anticholinesterases suggests that direct 
block may be contributory in the early stages 
of the disease process (Nielson et al., 
1982.) However, in contrast to the findings 
in Experimental autoimmune myasthenia gravis 
(EAMG), few reports have observed the direct 
block of the electrophysiological response, 
and those that have may, at least partly, be 
explained by increased receptor degradation 
(Bevan et al., 1978).
Reduction in mepp amplitudes by 
myasthenic sera have been reported with 
normal human intercostal muscle (Ito et a l ., 
1978 b), myasthenic human intercostal muscle 
(Sanders et al., 1981), rat diaphragm
(Shibuya et al., 1978), and mouse diaphragm
(Lerrick et al., 1983). No such reduction
in mepp amplitudes by myasthenic sera was 
observed in rat muscle by Albuquerque et
al., (1976).
Studies on the binding of cholinergic 
ligands to AChR in the presence of myasthenic
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sera have utilised the binding of
labelled (X -toxin. However, the large size
differences between acetylcholine and 
tf-bungartoxin does not necessarily mean 
that the behaviour of the two ligands is 
similar. By using different sources of AChR, 
Fulpius et al., (1980, 1981), Drachman et
al. , (1 9 8 1 ) and Mittag et al., (1984) have
observed some correlation between blocking 
ability of the serum and the clinical state 
of the donor. However, the observations of 
Cull-Candy et al., (1982), O jH UAcVycxif^ecA 
myasthenic muscle response to acetylcholine 
after several days in the
absence of anti-AChR antibody, suggests that 
reversible AChR block does not contribute to 
reduced neuromuscular function.
ii) Increased degradation of AChR
The increased degradation of muscle AChR 
in the presence of myasthenic
immunoglobulins has been shown to be
dependent on temperature, metabolic and 
cytoskeletal activity but not on complement 
(Appel et al., 1977; Kao and Drachman, 1977 
a). Drachman et a l ., (1978, 1 9 8 0 , 1982)
observed accelerated AChR degradation by
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purified myasthenic IgG and by F(ab)2 
fragments but not by Fab fragments. However, 
cross-linking the Fab-labelled AChR with 
anti-Fab second antibody resulted in 
accelerated degradation. The findings of 
Lowenadler et al., (1981) supported the
above observations when, in contrast to 
myasthenic IgG, the corresponding Fab 
fragments were found to protect the 
recipient against EAMG induced by subsequent 
injection of anti-AChR IgG and did not 
effect the passive transfer of EAMG to mice. 
Tzartos et al ., (1985) have similarly shown
protection of AChR modulation on the mouse 
muscle cell line, BC3H1, by a Fab fragment 
directed at the main immunogenic region of 
the AChR.
Conflicting findings have been reported 
on the synthesis of AChR. Whereas one 
report suggested decreased synthesis (Appel 
et al . , 1 9 7 9 ), no difference from control
synthesis (Drachman et al., 1978 a; Clementi 
et al. , 1982; Sher and Clementi, 1984) and 
increased synthesis (Fulpuis et a l ., 1980;
Wilson et al ., 1983) of AChR by cultured 
muscle cells in response to- myasthenic IgG' 
have been observed.
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iii) Complement-mediated membrane lysis
A suggestion of a role for complement in 
the pathogenesis of MG came with the 
observation of a fall in complement 
activity during exacerbation of symptoms in 
MG patients with normalisation during 
remission periods (Nastuk et a l ., 1956,
I960). Evidence of the lytic action of 
myasthenic serum was noted by Nastuk et a l ., 
(1 9 5 9 ) with 2 of 22 myasthenic sera showing 
higher than normal lysis of cultered frog 
muscle cells. Liveson et al , (1976) reported
the lysis of mouse muscle cells by 3 of 17 
myasthenic serum samples. An assay 
developed by Cambridge and Stern (1981)
using the specific uptake of
radiolabelled carnitine by muscle cells was 
employed by Childs et al., (1985) to show
the lysis of cultured rat myotubes b.y 9 out 
of 13 myasthenic sera. These results support 
the ultrastruetural studies of Engel and 
co-workers (Sahashi et al ., 1980) indicating 
the involvement of complement-mediated 
membrane lysis in the pathogenic process in 
MG.
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1.4. Aims of the project
The pathogenic effects of anti-acetylcholine 
receptor antibody in myasthenia gravis are well 
established, despite the debate over the exact
mechanism by which these effects occur. As the
other autoimmune diseases, abnormal production of 
autoantibodies could reflect a breakdown in
control exerted by immunoregulatory cells. The
AMLR has been suggested as an in vitro correlate 
of in vivo immune control (Lattime et al., 1982)
and, as such, may serve as an important model for 
examining the defective cellular interactions 
responsible for a number of autoimmune diseases.
The primary aim of this project was to 
determine the nature of the defect in cellular
immunoregulat ion in MG, using the AMLR as an
indicator. A fundamental requirement for this is
the establishment of the normal response in
healthy individuals, including the intra- and
inter-individual variation in the response. The 
immune responsiveness of both normal and
myasthenic individuals, as assessed by the AMLR, 
will also be supported by the lympho proliferative 
responses of the two groups to several mitogens.
A study of the AMLR in humans with clinically
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manifest autoimmune disease precludes the study of 
disease initiation and development. In an attempt 
to understand the underlying cellular defects that 
may occur in the initial stages of the disease, 
the second aim of this project was to study the 
AMLR during the induction and subsequent 
maintenance of EAMG in an animal model. Disease 
progress can be monitored by both clinical 
symptoms and the presence of serum
anti-acetylcholine receptor antibody. In
parallel, the cellular immune responsiveness as 
assessed by the AMLR and mitogen responsiveness, 
may indicate the effects of the disease on the 
immune system.
Whilst the induction of EAMG in an animal by 
immunisation with the autoantigen, the AChR, may 
not relate to the aetiology of the disease in 
humans, the study of the immune responses in EAMG 
may help in understanding the lack of 




CK-Bungaro tox in was supplied by the 
Boehringer Corporation, Lewes, Sussex, U.K.
Naja naja siamensis venom was obtained from 
the Miami Serpen tarium, Miami, Florida, U.S.A.
12 5 3Carrier free Na I and (methyl- H) thymidine
were obtained from the Radiochemical Centre,
Amersham, Bucks, U.K.
The following were obtained from the Sigma 
Chemical Co. Ltd., Poole, Dorset, U.K.:-
2-aminoethylisothiouroniura bromide hydrobromide; 
Papain (EC 3.A .22.2 ) (Type 111) from Papaya latex, 
16-40 units per mg protein; Neuraminidase (EC 
3.2.1.18)(Type V) from Clostridium perfringens, 
0.5-1.5 units per mg protein; Complete and 
Incomplete Freunds' Adjuvant; Heparin (Grade 1) 
from Porcine Intestinal Mucosa; L-cysteine 
hydrochloride.
Sterile filter units (0.2 pm) were obtained 
from Sera-Lab., Crawley Down, W. Sussex, U.K.
DEAE-cellulose filter discs (DE-81), GF/C
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filters and DE52 ion-exchange resin were obtained 
from Whatman Biochemicals Ltd., Maidstone, Kent, 
U.K. Benzoquinonium chloride was a gift from 
Sterling Winthrop, Rensselaer, New York, U.S.A.
The following were obtained from Flow 
Laboratories, Irvine, Scotland:-
RPMI 1640 (Dutch Modification); Penicillin 
/Streptomycin; Human AB serum; multi-well cell 
harvester; glass fibre cell harvester filter 
mats; sterile screw-top centrifuge tubes (10ml); 
sterile plastic Pasteur pipettes; lymphocyte 
separation medium (Ficoll-Hypaque).
Foetal Calf Serum and NUNC 96-well 
microtitre plates were obtained from Gibco Ltd, 
Paisley, Scotland.
NU-SERUM was obtained from Collaborative 
Research Inc., Lexington, M A , U.S.A.
Phytohaemagglutinin-P and LPS (Type W from 
S. typhimurium) were obtained from Difco Ltd., 
Detroi t , U.S.A.
........Sephadex-G25 and Concanavalin-A ' were'
obtained from Pharmacia Ltd., Milton Keynes,
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Bucks, UK.
Rabbit anti-human IgG (F(ab)2 fragment) 
fluorescein conjugate was obtained from 
Behringwerke AG, Marburg, W. Germany.
Mouse anti- (rabbit T cell) monoclonal 
antibody (IgG2a), as ascitic fluid, was obtained 
from RIA (U.K.) Ltd., Tyne & Wear, U.K.
Sheep red blood cells and ox red blood cells 
were obtained from Tissue Culture Services, 
Slough, Berks, U.K.
Folin and Ciolcalteus1 phenol reagent was 
obtained from BDH Chemicals Ltd, Poole, Dorset, 
U.K.
LKB Optiphase ’Safe* Scintillation fluid was 
obtained from Fisons pic, Scientific Equipment 
Division, Loughborough, U.K




Tris ammonium chloride erythrocyte lysis buffer
Tris (hydroxyraethyl) aminoraethane 0.17M 
(20.6 g/L) ammonium chloride 0.16M (8.3 g/|_) •
Add 0.17M Tris buffer (10ml) to 0.16M 
ammonium chloride (90ml) and adjust pH to 7.2. 
Sterilise by autoclaving to 201bs/sq inch for 20 
min.









Make up with double distilled water and 
adjust to pH 7.2. Sterilise by autoclaving at 
2 0 1bs/sq inch for 20 min.





MgSO^ 7H2 0 0.2g/L
MgCl2 6H20 0.2g/L
KH_ PO, 
2 4 0 . 06g/L
Na 0 HPO, 2 4 0.24g/|_
Membrane filter (0.22|im) to sterilise
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3. METHODS
3.1. Aseptic manipulation of lymphocytes and media
All aseptic techniques were performed in an 
InterMed Microflow Pathfinder class II laminar 
air flow cabinet.
3.2. Separation of peripheral blood mononuclear cells
Mononuclear cells were isolated by the 
method of Boyum (1968). Peripheral venous blood 
(20ml) was taken and mixed with heparin (20U/ml). 
Heparinised blood (4ml) was diluted with balanced 
salt solution (4ml), layered onto lymphocyte 
separation medium (3ral) (Ficoll-Hypaque) in
sterile, 15ml polycarbonate screw-top centrifuge 
tubes and centrifuged at 400g for 30 min at room 
temperature. The mononuclear cells were
harvested from the interface, washed three times 
in RPMI 1640 and then resuspended at 3 x 10^ 
cells/ml in medium consisting of RPMI 1640, 1mM
L-glutamine, 100 U/ml Penicillin, and 100 p,g/ml 
Streptomycin, (complete medium).
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3.3. Separation of human T and non-T leucocytes by
rosette formation
3.3.1 Papain treatment of sheep’s red blood cells (SRBC)
SRBC were treated with papain according to the
method of Wilson et al (1975). Packed, washed 
SRBC from whole sheep’s blood (approximately
10ml) were resuspended in RPMI 1640 to their 
original volume. A sample of the SRBC suspension 
was removed and resuspended to 10% (v/v in PBS) 
in RPMI 1640. A sterile solution of papain (1.0% 
v/v in PBS) was mixed thoroughly with a 2% (w/v)
solution of cysteine hydrochloride in PBS and
then mixed with an equal volume of the 10%
suspension of SRBC. The mixture was incubated
for 12 min at 37°C and the cells were then washed 
twice in RPMI 1640 and resuspended to 2.5% (v/v)
in RPMI 1640. The cells were suitable for use
for up to 5 days after papain treatment.
3.3.2 AET-Treatment of SRBC
SRBC were treated with AET according to a
modified method of Kaplan and Clark (1974). 140mM
2-aminoethylisothiouronium bromide hydrobromide
........(AET)' was' prepared by dissolving crystalline AET
(0.5g) in double-distilled water (12.5ml). The
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pH of this solution was adjusted to pH 9.0 with 
10M NaOH. Packed, washed SRBC from whole sheep's 
blood (approximately 10ml) in Alsever's solution 
were resuspended in freshly prepared,
filter-sterilised, AET solution (10ml). During 
washing of the SRBC, care was taken to ensure the 
complete removal of the buffy coat cells. The 
cell suspension was then placed in a 37°C water 
bath for 15 min, following which the treated 
SRBC were washed in PBS four times, or until any 
residual haemolysis ceased. A stock suspension of 
the SRBC-AET was produced by resuspending the 
packed cells to their original volume -in complete 
medium containing 10% FCS (v/v). A 2% (v/v)
suspension of SRBC-AET in complete medium 
containing 40% FCS (v/v) was produced from the 
stock suspension and this was used as the 
rosetting medium. When stored at 4°C, untreated 
SRBC suspensions were suitable for use for up to 
2 weeks and AET-treated SRBC suspensions were 
suitable for use for 1 week.
3.3.3 Neuraminidase-treated SRBC
The preparation of neuraminidase-treated SRBC was 
carried out according to a modified method of 
Galilu and Schlesinger (1974). A suspension of 
SRBC in Alsever's solution was washed three times
60
in RPMI 1640 care being taken after each wash to 
remove the buffy coat layer. The packed, washed 
SRBC were then resuspended to their original 
volume in RPMI 1640 and an aliquot was removed 
and resuspended to 10% (v/v) in RPMI 1640.
Neuraminidase (EC .3.2.1.18) type V was then added 
to the 10% (v/v) SRBC suspension at a
concentration of 10 U/ml. The solution was mixed 
and incubated for 45 min at 37°C. After 
incubation, the cells were washed twice with RPMI 
1640 and then resuspended to 2.5% (v/v) in RPMI 
1640. Neuraminidase-treated SRBC were suitable 
for use for up to two weeks when stored at 4°C.
3.4. Separation of human T-lymphocytes and non-T
leucocytes using native or treated SRBC
The isolated human PBL were separated by 
rosetting with SRBC. SRBC suspension (2ml) and 
the suspension of human PBL (3 x 10^ cells/ml; 
2ml) were mixed thoroughly in sterile 15ml 
polycarbonate screw-top centrifuge tubes and left 
overnight at 4°C. The pellet was then carefully 
resuspended in the supernatant by using a sterile 
glass Pasteur pipette. The resuspended cells 
(4ml) were carefully layered onto Lymphocyte
■ ■ ■ Separation- Medium (-3ml) in sterile, polycarbonate
screw-top centrifuge tubes and centrifuged at
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400g for 30 min at room temperature. The
unrosetted non-T cells were removed from the
interface by carefully aspirating off the grey
band by using a sterile, glass Pasteur pipette. 
The supernatant was removed from the remaining 
cell pellet and the cells were resuspended in 
RPMI 1640 before transferring to a sterile 30ml 
plastic universal container. These cells 
(putative T cells) and the non-T cells (interface 
cells) were washed once with RPMI 1640,
resuspended in Tris-buffered ammonium chloride
(0.83%) lysis buffer, and left for 10 min at room
temperature. Both cell populations were then
washed twice in RPMI 1640. The cell
concentration was, in each case, determined by
using a counting chamber and the viability of
each population was determined by trypan blue dye 
exclusion. Both cell populations were then
resuspended to the desired cell concentrations in 
the appropriate culture medium. Non-T cells and 
a proportion of the T cells were inactivated in a 
calibrated ^ C o  gamma ray source (see Methods
p 69 ).
All cell suspensions were plated out, by 
using- alcohol-cleaned Hamilton repeater- syringes, 
into sterile, plastic, 9 6-well round bottom
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microtitre plates with lids. Each well contained
a total of 200|j.l of culture medium. The
cultures were incubated at 3 7°C in a humidified
atmosphere of 2 .5% CO^ in air for the whole of
the culture period.
3.5. Separation of T and non-T cells by nylon wool
passage
The method of Julius et al (1973), utilising
nylon wool to separate T and non-T cells was
investigated as an alternative method to 
rosetting with SRBC. Human PBL from heparinised
venous blood were isolated as previously
described (Methods, p 57 ). Nylon wool was
vigorously washed alternately in distilled water 
and 0.9M HC1 over a period of 2-3 days. The
washed wool was then boiled in several changes of 
distilled water, dried in an oven and pieces
(0 .6g) were packed into the barrels of 20ml
syringes up to the 6ml mark. These nylon wool
columns were then separately packaged and
autoclaved. When required, each column was
washed through with complete medium (25ml). 
Medium (approximately 2ml) was allowed to remain 
on the top of the nylon wool and the column was
sealed at both ends. The sealed column was
incubated at 37°C for 1hr, and then flushed with
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fresh complete medium (5ml).
The isolated PBL (20-30x1 0^ *) were 
resuspended at 1-5x 10  ^ cells/ml in complete
medium, placed on the column and allowed to drain 
into the nylon wool. The column was resealed and 
incubated at 37°C for 45 min, following which the 
cells were eluted from the column with complete 
medium (20ml). A sterile hypodermic needle (23G) 
was attached to the end of the syringe to control 
the rate of flow of the eluate. The eluted cells 
were washed in RPMI 1640 and resuspended at 1x10^ 
cells/ml in complete medium containing 10% (v/v)
NU-SERUM. The nylon wool non-adherent eluate 
cells were classed as T cells. The nylon wool 
was removed from the syringe barrel and teased in 
warm complete medium (10ml) on a sterile Petri 
dish (9cm). The cells obtained from the nylon 
wool were washed twice in RPMI 1640 and
resuspended at a concentration of 1x 10  ^ cells/ml
in complete medium containing 10% (v/v) NU-SERUM.
3.6. Determination of surface markers
The surface markers present on separated and 
unseparated PBL populations were determined in 
. . order • to- characterise the cells • present. • The
E-rosette test, surface immunoglobulin staining,
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and endogenous peroxidase staining were employed 
to detect T cells, B cells and monocytes 
respectively.
The E-rosette test was performed in
duplicate according to the method of Madsen and 
Johnson, (1979). A 2% (v/v) suspension of
AET-treated SRBC in complete medium containing 
40% (v/v) FCS (100pl) was mixed with the
leucocyte populations at 3x10^ cells/ml in
complete medium ( 1 00pi 1) in LP3 tubes. The tubes 
were then centrifuged at 50g for 5 min and 
incubated overnight at 4°C. Immediately prior to
counting, one drop of toluidine blue (0 .2% w/v in
0 .9% w/v saline) was added to each tube and the 
pellet was resuspended by gentle manual shaking. 
The cell suspension was then counted as described 
(Methods, p 66 ) . At least 200 leucocytes were 
counted and those cells with three or more SRBC 
tightly bound were considered to be rosette 
forming cells.
Surface immunoglobulin-positive staining 
cells and endogenous peroxidase-positive staining 
cells were detected according to the method of 
Waller and MacLennan, (1977). Isolated PBL were 
washed three times in warm PBS and then- incubated 
for 1 hr in RPMI 1 640 . A dilution (1/4) of
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fluorescein-conjugated rabbit anti-human IgG
antibody (Fab^) (100|il) in PBS containing 0.02% 
(w/v) sodium azide was added to 2x 10  ^ pelleted 
leucocytes, mixed thoroughly and incubated for 
20-30 min on ice. The cells were centrifuged 
three times for 10 min at 200g in cold PBS,
containing 0 .02% (w/v) sodium azide, and the cell
pellet was resuspended in one drop of
heat-inactivated FCS. The cell suspension was 
smeared onto a clean, dry, glass microscope slide 
and air dried. Surface immunoglobulin positive 
staining cells were counted as those cells 
showing cell surface immunofluorescence by using 
a Zeiss fluorescent microscope with
epi-illumination. The cells were fixed in 
methanol for 10 sec, and rinsed in PBS. The
fixed cells were then stained for endogenous
peroxidase. Fresh stain solution was prepared by 
disolving 3,3' diaminobenzidine (6mg) in 
Tris-buffer (10ml), and 2 drops of 10 vol. 
hydrogen peroxide were added immediately before 
use. The smears were flooded with the fresh
stain for 10 min at room temperature and then 
rinsed in 10% (w/v) saline. The smear was mounted 
in one drop of buffered glycerol (12 parts
glycerol to 9 parts PBS) and a coverslip sealed 
above the smear by using n a i l 'varnish.' Positive 
staining endogenous peroxidase cells appeared
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brown under the light microscope (xAO
magnification).
3.7. Cell counting and cell viability
An appropriate dilution of the cell suspension
6 7
(10 - 10 cells/ml) was counted by mixing the
cell suspension ( 50|i 1 ) with 0 .01% (w/v) methylene 
blue (50|il) in 1% (v/v) acetic acid. At least 
200 lymphocytes were counted by using a 
rhodium-plated improved Neubauer haemocytometer. 
Cell viability was determined by incubating the 
diluted cell suspension (50|j,l) with 0 .2% (w/v)
trypan blue in PBS at 37°C for 5 min. Viable 
cells exclude the dye, dead cells appear 
grey-blue and have a ragged appearance.
3.8. Autologous mixed lymphocyte cultures
The AMLR was measured in both normal and
myasthenic PBL by using a modified method of
Opelz et al ,(1975).
8 5
T cells (1x10 ) were cultured with 1x10
irradiated (2500 rad) non-T cells in complete
medium (200p.l) containing 10% (v/v) NU-SERUM.
Quadruplicate cultures were carried' but in round
bottom microtitre plates in 2.5% (v/v) CO2 in air
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at 37°C, over a period of nine days, each 24h
culture period being established on a separate
5
microtitre plate. T cells (1x10 ) cultured with
5
irradiated T cells (1x10 ) in complete medium
(200|il) containing 10% (v/v) NU-SERUM were used
c;
for T cell controls. Non-T cells (2x10 ) in 
complete medium (2 00pl) containing 10% (v/v)
NU-SERUM were used for non-T cell controls. 
Culture medium replenishment was carried out on 
days 4 and 7 of the time course response. On 
each of these days, culture medium (100pl) was 
removed from each well and replaced with fresh, 
warm culture medium (1OOpl). The cultures were
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pulsed with [ H]-thymidine and harvested 24h 
later as described (Methods, P68).
3.9. Determination of optimum mitogen concentrations
The optimal concentrations of
phytohaemagglutinin-P, concanavalin-A, and
1ipopolysaccharide for stimulation of purified T 
and non-T cells were determined. Cells (2x10 ) 
were cultured in complete medium (2 0 0|il) 
containing 10% (v/v) NU-SERUM over a period of
four days. A range of concentrations was tested 
for PHA-P (0.1-1.0%), Con-A (2.5-4.Opg/ml) and 
LPS (5-25pg/ml) for both T cells alone and non-T 
cells alone. Controls consisted of T cells
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(1x10^) and non-T cells (1x10^) cultured in 
complete medium (2 0 0 pi 1 ) containing 10% (v/v)
NU-SERUM in the absence of added mitogen. Twenty 
four hours prior to harvesting, the 
mitogen-stimulated and unstimulated cells were
pulsed with radiolabel (Methods, p68 ) . The cells 
were harvested as described (Methods, P68 ).
3.10. Labelling and harvesting of the pulsed cultures
Twenty four hours prior to the termination
3
of each culture, [ H]-thymidine ( 1 pi C i, 5 Ci/mmol) 
in complete medium (2 0 (j. 1 ) containing 10% (v/v)
NU-SERUM was added to each well and the cultures 
were subsequently harvested onto glass-fibre 
filter paper, by using a multi-well 
semi-automated cell harvester. The filter mat
was left to dry and each glass fibre disc, 
corresponding to each well harvested, was punched 
out of the filter mat and placed in a 
polyethylene scintillation vial. Scintillation 
fluid was added (5ml) and the vial shaken. 
Tritiated thymidine uptake was measured in a 
liquid scintillation counter (Packard TriCarb,
3
Model 3255). The counting efficiency for [ H] 
was 3 0%.
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3.11. Calculation of the net AMLR ( A  cpm) and net 
mitogen-induced responses
The A  cpm AMLR responses were calculated by 
subtracting the mean of the duplicate T cell 
control responses from the mean of quadruplicate 
AMLR cultures (T cells with irradiated non-T 
cells) .
Net mitogen induced responses were calculated 
by subtracting the means of duplicate T cell or 
non-T cell controls from the means of duplicate 
mitogen-stimulated T cells or mitogen stimulated 
non-T cells, respectively.
3.12. Calibration of a ^°Co gamma ray source
The ^ C o  gamma ray source used for 
irradiation of the cells was calibrated by using 
the ferrous sulphate dosimetry method of Arena 
(1971). Stock solutions of 1OmM NaCl and AM
were prepared in double-distilled water. A 
fresh dosimeter was prepared immediately prior to 
use by dissolving ferrous ammonium sulphate
(0.985g) in stock NaCl (25ml) and H^SO^ (25ml).
The solution was made up to 250ml with double 
distilled water artd thoroughly ' mixed.' This 
Fricke dosimeter (10ml) was placed in a plastic
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universal tube similar to those which would be 
used for future irradiation procedures for live 
cells. The tube was irradiated for 10 min. At 2 
minute intervals, the tube was removed from the 
irradiation chamber and samples (1ml) of the 
solution were removed. The absorption of each 
sample at 305 nm was then measured by using a
CECIL CE272 UV spectrophotometer. T"Y\e, CXSSCXf^
b \on^ c o a s te d  o f  no*v \rrtxdtate.&  dosuwetec 
S oWlVio a .
3.13. Calculation of absorbed radiation dose
The absorption of ferric (Fe3+ ) ions is
strong in the ultra-violet region, whereas that 
of Fe2 + ions is negligible.
The ionization of ferrous ions by 
irradiation with y~rays relates to the
formation of free radicals in solution as below:
Fe2+ + OH* Fe3+ + OH"
Fe2+ + H02 Fe3+ + HO*
Fe2+ + H 202 Fe3+ + OH" + OH*
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The delivered dose of radiation is given by the 
equation:
Dose (rads) = A .k .
E . p . G .
where:
A = Absorbance of the irradiated solution 
k = the product of Avogadro’s number and the
Q
number of ergs/electron volt = 9.65 x 10
E = Molar extinction coefficient of
Fe (NH,)o (S0,)o 6H~0 solution at 305mm, 25°C4 2 4 2 2
= 2196 (+ 0.6 %/° C ).
p = Density of working solution = 1.024.
G = G value for Cobalt-60 = 15.5 at 15-25°C.
(ions formed per 1OOeV absorbed.
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4. RESULTS 
4.1. Separation of human T-lymphocytes and non-T 
leucocytes: E-rosette separation
The effects of various reagents on the 
ability of washed sheep red blood cells (SRBC) to 
rosette with human peripheral blood lymphocytes 
(PBL) were investigated. Unsensitised SRBC have 
been shown to bind specifically to human T 
lymphocytes, although wide variation has been 
reported in the percentage of rosette forming 
cells (RFC) found in human PBL isolated from
normal donors by different investigators (Jondal 
et al . , 1 972; Papamichail et a l ., 1 972).
Papain-treated (Wilson et al., 1975),
neuraminidase-treated (Galilu and Schlesinger, 
1974), AET-treated (Kaplan and Clark, 1974), and
native SRBC (Brain et al ., 1970), were used to
determine the most effective treatment of SRBC
for optimal rosetting with human T lymphocytes. 
Each treatment was performed on erythrocytes from 
the same SRBC sample so as to avoid variations in 
SRBC quality. All treated and native SRBC were
rosetted overnight at 4°C with PBL from three
healthy donors. The results, expressed as the 
percentages of E-RFC, surface membrane
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immunoglobulin positive, endogenous peroxidase- 
staining and null cells present in both the 
putative T and non-T cell populations are shown 
in Table 4.1.
As seen in Table 4.1, the greatest purity of 
the T cell population, according to surface 
marker studies was produced by treatment of the 
SRBC with neuraminidase, although treatment of 
the SRBC with AET yielded T cell populations of a 
very similar purity.
The T cell population obtained by using 
neuraminidase- and AET-treated SRBC resulted in 
rosettes which were very stable to manual 
manipulation and which appeared as dense
'morula'-1 ike rosettes with more than ten red 
cells bound per lymphocyte. The individual
variation between the three human PBL samples 
studied was very small for both AET- and
neuraminidase-treated SRBC, whereas the .variation 
observed with both papain-treated and native SRBC 
was considerable. Contamination by the other
cell types in the rosetted and non-rosetted 
populations was also significant for both the 
papain treated and the native SRBC. These two 
alternative rosetting methods were accordingly 
considered unsuitable for use as a routine
TABLE 4.1
The composition of separated T and non-T cell populations following separation by 
various forms of rosetting with SRBC treated as shown.
T cell (%) Non-T cell (%)
TREATMENT E-RFC Smlg+ve EP+N E-RFC Smlg+ve EP + N
PAPAIN 8 8 - 7 . 6 6 - 3 8.4 - 0.5 76 - 2.1 13.5 - 1
NEURAMINIDASE 98 - 2.1 1.5 - 0.9 0 2.9 1 0.2 87 1 1 14 - 0.4
AET 96 - 3.8 2.2 - 0.2 0 1.6 - 1 . 3  87.5 ! 1.3 12 -  0 . 9
NATIVE 82.3 - 6.8 7.4 - 1.6 2 10 - 2.7 74 - 8.3 8 - 1 . 3
Legend: Values represent means - s.e.m. on 7 observations for each treament.
Abbreviations used: E-RFC - erythrocyte rosette forming cells; Smlg+ve - surface membrane
immunoglobulin positive cells; EP+N - endogenous peroxidase positive plus null cells.
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separation procedure.
The instability of the rosettes produced 
with papain-treated SRBC and native SRBC probably 
contributed to the observed contamination of the 
T and non-T cell populations, because of the 
disruption of rosettes during the resuspension of 
the rosetted pellet. Microscopic examination of 
the rosettes in these cases showed no more than 
four red cells bound per lymphocyte, most
rosettes having 2 or 3 red cells bound.
As this rosetting procedure was intended to 
be developed into a routine assay for separating 
human T and non-T PBL, the cost of performing the
assay must not be prohibitive. However, the use
of neuraminidase in the quantities required 
resulted in its use becoming highly uneconomical. 
This, together with the similar performance of 
AET-treated SRBC with human peripheral blood 
leucocytes favoured the use of AET as the
’activating1 substance for treatment of the SRBC. 
Thus, all routine rosetting assays were carried 
out using SRBC AET as the separating red cells.
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4.2. Development of conditions for the treatment of
SRBC with AET
Various concentrations of AET over a pH
range of 7-11 were tested with SRBC to determine 
the optimum conditions necessary for AET 
treatment of SRBC.
As shown in Table 4.2, high concentrations 
of AET resulted in gross haemolysis of the SRBC. 
This may have arisen from the direct action of 
the sulphydryl compound on the membrane of the 
red cells or as a result of extreme 'stickiness1 
of the red cells. This 'stickiness' resulted in
difficult resuspension of the red cell pellet 
during the washing procedures, and the excessive 
manual manipulation required to resuspend the red 
cell pellet may have ruptured the red cell
membrane. Within the range of values tested, pH 
did not have a dramatic effect on the haemolytic
effect of AET but the most stable rosetting 
occurred at pH 9.0, (Table 4.2.). Thus, the
optimum conditions used for treating SRBC for use 




pH 35 70 140 210 280
7 + / #  + / # *  + / * # *  + + + / *  + + + + / *
8 + / *  + / * * #  + / * * *  + + + / * #  + + + + / *
9 + / * #  + / * # *  + / * * * #  + + + / * #  + + + + / *
10 + / * *  + / * * *  + + / * * *  + + + / * *  + + + + / *
11 +/** +/*** ++/*** +++/** ++++/*
Table 4.2 Chessboard titration of AET
concentration (m M ) and pH of the AET solution 
used for SRBC treatment. Each combination of 
results indicates the degree of haemolysis as the 
plus symbol (+ to + +++, slight to severe) and 
efficiency of rosette formation as the asterisk 
symbol (* to *#*#, poor to excellent). Efficiency 
of rosette formation was determined by the 
stability of rosettes formed and the number of 
SRBC-AET bound per lymphocyte.
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The centrifugation conditions used in the 
washing procedures following treatment of the 
SRBC were found to affect the degree of 
haemolysis. Centrifugation at 100g for 15 min for 
the first wash, followed by washes at 200g for 10 
min were found to produce the least haemolysis 
(data not shown).
Thus, all subsequent rosetting procedures for 
the separation of human T and non-T cells were 
performed using the optimum conditions for SRBC 
treatment.
4.3. Determination of_____ the_____ optimum____ mitogen
concentration for stimulation of T -cells and 
non-T cells by PHA-P, Con-A and LPS
The proliferative responses of SRBCAgT
separated human peripheral blood T lymphocytes
and non-T leucocytes to a range of concentrations
of the mitogens PHA-P, Con-A and LPS were
investigated to determine the optimum
concentration of each mitogen for routine use.
Fig 4.1 (a) shows the mean responses of non-T
cells, from three individuals, to a range of 
concentrations of PHA-P. T-cell proliferative 
responses were observed between 0 .1% and 0 .8%
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Figure 4.1(a )
Proliferative responses of separated T
(2x10"*) cells and non-T (2x10"*) cells, to the
mitogen phytohaemagglutinin-P (PHA-P).
Figure 4.1(b)
Proliferative responses of separated T
(2x10 ) cells and non-T (2x10 ) cells, to the
mitogen concanavalin-A (Con-A).
Figure 4.1(c)
Proliferative responses of separated T 
(2x10"*) cells and non-T (2x10"*) cells, to the
mitogen 1ipopolysaccharide (LPS).
The ordinate value represents the mean of the
5
sum of duplicate tests of cells (2x 10 ) with
mitogen minus the mean of the sum of duplicate
5
tests of cells (2x 10 ) in the absence of mitogen. 
Values are means of results obtained with cells 
from three individuals; the vertical bars 
represent the s.e.m. for the three individuals' 
responses ...............................................
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PHA-P (v/v) with a peak response at 0.2% (v/v).
Non-T cell responses were much lower at all 
mitogen concentrations, the highest response 
being at 0.A % (v/v) PHA-P. This response could 
arise from the proliferation of B cells, induced 
by minor contamination (<3%) of activated T 
cells or by direct stimulation of B cells with 
PHA-P.
T cells incubated with Con-A showed a peak 
response with 1Opg/ml mitogen (Fig 4.1(b)). 
Response was similar at 5|ig/ml but much lower at 
higher concentrations (20|j.g/ml and 40|j,g/ml) of 
Con-A. The non-T cell response with Con-A was 
very low at all concentrations.
The response of T cells and non-T cells to
LPS are shown in Fig 4.1 (c). T cells incubated
with LPS showed no response at all the
concentrations of the mitogen. However, a peak 
response at 10(i,g/ml was observed for non-T cells.
The data shown in Fig 4.1. indicate that the
rosette separated leucoctye populations were 
purified both with regard to surface markers and 
mitogen responsiveness.
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4.4. Separation of cell populations by nylon wool
The T-lymphocyte and non-T leucocyte
populations were separated by using the nylon 
wool method described by Julius et al (1973). 
Table 4.3 shows the result of surface marker 
studies and Figure 4.2 represents the optimal
mitogenic responses of the nylon wool separated 
cell populations.
As seen in both Table4.3 and Fig 4.2, the 
separation afforded by the nylon wool method was 
worse than that achieved by rosetting. This 
method was accordingly considered to be 
unsuitable for routine use and rosetting by 
AET-treated SRBC was subsequently routinely used 
for separation of human T lymphocytes and non-T 
leucocytes.
4.5. Irradiation of T and non-T cells
The ^ C o  gamma ray source was calibrated 
according to the method of Arena (1971) (Methods, 
p 69 ). Figure 4.3 shows the calibration curve
for duplicate samples of the dosimeter irradiated 
for 10 min with 2 min sample intervals. The
dose rate (rads/minute) was determined’ from the 
slope by using the equation described (Methods,
83










Table Jtl The percentages of the various cell 
types as measured by surface markers and
endogenous peroxidase activity in nylon wool 
non-adherent (NWNA) and nylon wool adherent (NWA) 
cell populations.
Abbreviations used:
Smlg+ : Surface membrane immunoglobulin
positive cells 
E-RFC : Erythrocyte rosette forming cell
E.Perox. : Endogenous Peroxide-containing cells
Null : Null cells.
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Figure A.2. Mitogenic responses of nylon wool
5
non-adherent (NWNA) (2x10 ) and nylon wool
c;
adherent (NWA) (2x10 ) cells to optimum 
concentrations of the mitogens PHA-P, Con-A and 
















Figure 4*3* The calibration curve for the Fricke 
Dosimeter. All the irradiations were carried out in a 
plastic 30ml universal tube similar to those used for 
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4.6. Development of standard conditions for use in a 
routine AMLR assay
A standard set of conditions was developed in 
order to enable the direct comparision between
AMLR responses obtained for normal healthy
individuals and myasthenic patients. The factors
which were investigated were:
1) Type and concentration of serum supplement in 
the culture medium,
2) Numbers and ratios of T and non-T lymphocytes 
in each culture.
4.6.1 Effect of serum supplement type and concentration
The responses observed for various types of 
serum supplement were studied over an eight day 
period (2-9 days in culture) and are shown in 
Figs 4.4 and 4.5.
Figure 4.4(a) represents the mean AMLR 
response observed when the cells were cultured in 
■complete medium containing 10% (v/v) ' N'U-SERUM.
The AMLR was low for the first 4 days but
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thereafter increased rapidly, reaching a peak 
value after 8 days in culture. Minimal 
incorporation of label by the T cell control was 
observed indicating the low, non-specific 
mitogenicity of this serum supplement. The 
variation between individual AMLR responses was 
very low up to day 7 of the culture period, 
but increased on days 8 and 9 *
Figure 4.4(b) represents the AMLR 
proliferative responses observed in complete 
medium containing 10% (v/v) FCS. The response 
was apparent at an earlier stage in the culture 
period and increased at a greater rate than that 
observed for cells from the same population 
cultured in NU-SERUM. Also, the peak 
proliferative response attained was approximately 
30% greater in the presence of FCS. Individual 
variations in the AMLR observed between 
quadruplicate cultures and between subjects were, 
however, substantially larger than for cultures 
containing NU-SERUM. The T cell control 
background incorporation was also greater, 
possibly reflecting the mitogenic qualities of 
the FCS.
AMLR'proliferative responses' fob cultures ' in' 
complete medium containing 10% (v/v) autologous
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Figure 4-4 Kinetic AMLR proliferative response of T
5
cells (1x 10 ) to autologous, irradiated (2500 rad)
5
non-T cells (1x10 ) when cultured in complete medium 
(see Materials and Methods p 66 ) containing (a) 10%
(v/v) NU-SERUM and (b) 10% (v/v) FCS. Each point
represents the mean - s.e.m. of responses from cells of 
three healthy individuals:
The solid lines represent Acpm AMLR responses; the
dashed lines represent background incorporation for
T-cell controls. Non-T cell controls incorporated 














serum are shown in Fig 4.5(a). Responses varied 
considerably between the three individuals 
studied, the peak proliferative response occurring 
either on day 7 or day 8 . The T cell control 
background incorporation steadily increased over 
the eight day period although the variation
between these values was not large. The
relatively high variation in response obtained
between individuals appeared to be peculiar to the
use of autologous serum. Whether this reflects 
different levels of total serum protein, a
peculiar serum protein or the presence of a
stimulatory or inhibitory factor was not
determined.
The responses observed in the AMLR in the 
presence of pooled human AB serum are represented
by Fig 4.5(b). The use of this serum supplement
presented several problems. The heat
inactivation process induced precipitation and
flocculation of serum components, which 
necessitate centrifugation of the serum and may 
have affected its nutrient content. Also, batch 
to batch variability was increased because of the 
small volume of serum obtained.
The responses obtained for the AMLR using 10% 
pooled human AB serum supplement were generally
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Figure 4 -B Kinetic AMLR proliferative responses of T
5
cells (1x 10 ) to autologous, irradiated (2500 rad)
5
non-T cells (1x10 ) when cultured in complete medium 
(see Materials and Methods, p 66 ) containing (a) 10%
(v/v) autologous serum and (b) 10% pooled human AB
serum. Each point represents the mean - s.e.m. of
responses of cells from three healthy individuals:
The solid lines represent Acpm AMLR responses; the
dashed lines represent background incorporation for
T-cell controls. Non-T cell controls incorporated
insignificant levels of radioactivity.
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similar to those observed with autologous serum, 
although the rate of growth appeared to be 
greatest between days 4 and 6 of the culture 
period, compared with a more gradual increased 
between days 4 and 7 in autologous serum. 
Background incorporation of the label into the T 
cell controls was significant after day 5 in 
culture and was also subject to wide variation in 
the case of pooled serum. The net AMLR response 
involves subtraction of the sum of the means of 
the cell control and the non-T cell control as 
described (Methods, p 69 ). Because very little
proliferation occurs in the irradiated non-T 
cell background control cultures, the net AMLR 
effectively depends upon the responses obtained 
in the AMLR cultures and the T cell control. Any 
manipulation of the culture conditions which acts 
to reduce the response of the latter will 
accordingly increase the net AMLR and increase 
the sensitivity of the assay. On these grounds, 
both human autologous serum and pooled human AB 
serum were considered unsuitable for the present 
purposes.
NU-SERUM and FCS were further investigated 
by using supplement concentrations of 2.5, 5, 1 0 ,
20 and 25% (v/v). Increasing concentrations of 
both of these culture medium supplements resulted
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in concomitant increases in the degree of 
proliferation observed Figs (4.6 and 4.7). 
Although the AMLR proliferative responses 
observed for those cells cultured in FCS (Fig
4.6a) increased with increasing serum
concentration in the culture medium, a parallel 
rise in the degree of proliferation observed in 
the background response was observed (Fig 4.6b), 
this being quite substantial at the highest serum 
concentrations. The responses observed in the 
presence of NU-SERUM (Fig 4.7a), also show an
increase in proliferative response with 
increasing supplement concentration although not 
to the same extent as that observed with FCS. 
However, the background control responses 
increased relatively less compared to the AMLR 
response than in the case of FCS. The net 
proliferative response was as identifiable and 
distinct at the 10% (v/v) concentration as it was 
at higher supplement concentrations and replicate 
variation within an individual assay was smaller 
at this concentration than at any other
concentration.
In view of all the above considerations,
NU-SERUM at a concentration of 10% (v/v) was
chosen for use as a supplement to the culture 
medium for routine investigation of the AMLR. As
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Figure 4«6(a) The mean kinetic AMLR response for
5
cells from three healthy individuals. T cells (1x10 ) 
were cultured with autologous, irradiated (2500 rad)
5
non-T cells (1x10 ) in complete medium containing FCS 
at 2.5, 5, 10, 20 and 25% concentrations (v/v). (b) T
cell controls obtained as described above except that 
irradiated non-T cells were replaced by irradiated T 
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Figure 4.7 (a ) The mean kinetic AMLR response for
5
cells from three healthy individuals. T cells (1x10 ) 
were cultured with autologous, irradiated (2500 rad)
5
non-T cells (1x10 ) in complete medium containing
NU-SERUM at 2.5, 5, 10, 20 and 25% concentrations
(v/v). (b) T cell controls obtained as described
above except that irradiated non-T cells were replaced 
by irradiated T cells. No standard error bars are
shown for reasons of clarity.
Acpm
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NU-SERUM is a well-defined artificial serum
supplement containing very low amounts (5%, v/v) 
of heat inactivated pooled human serum, batch to 
batch variability was minimal and heat 
inactivation before use was not necessary.
4.6.2 Effect of cell number per well and ratio of T to 
non-T cells
Fig 4.8 shows the variations in 7 day AMLR 
responses in 10% (v/v) NU-SERUM for different
numbers of T cells in the presence of increasing 
numbers of non-T cells. In this way, the effects 
of both the cell number per well and the cell
ratios could be studied simultaneously. Fig
4.8(a) shows the AMLR responses obtained for T
6 4cells at concentrations of 1x10 cells/ml (10x10
cells/well) and 2x10^ cells/ml (20x10^
cells/well) with varying concentrations of
stimulating non-T cells. Both T cell
concentrations respond initially in a
dose-dependent manner, reaching peak
proliferative responses at a 1:1 ratio of non-T
cells. There was little difference in the
magnitudes of the AMLR responses of the two T
cell concentrations and the lower concentration
was accordingly adopted as the standard protocol
for all of the subsequent AMLR assays. Fig
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Figure 4.8 (a ) The 7 day AMLR proliferative responses
A
of fixed numbers of T cells (10 & 20x10 cells/well) to
varying numbers of autologous, irradiated (2500 rad) 
non-T cells. Each point represents the mean responses
from cells of three healthy individuals.
Figure 4.8(b) The 7 day AMLR proliferative response of
4
fixed numbers of T cells (1,5 and 50x10 cells/well) to
varying numbers of autologous, irradiated (2500 rad) 
non-T cells. Each point represents the mean responses
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4.8(b) represents sub- and supra- optimum
concentrations of T cells per well.
4.7. Peak AMLR proliferative responses for clinically 
healthy, myasthenic and rheumatoid individuals
Figure 4.9 represents the range of peak
proliferative responses observed as the cpm,
irrespective of the time point in the culture
period on which it occurred, for 41 healthy
individuals, 22 patients with myasthenia gravis,
and 7 patients with rheumatoid arthritis. The
responses for the healthy group have a range of 
381 to 56384Acpm (12228-1674, 41; meanAcpm- sem,
n) whereas those for the myasthenic patients have
a range of 76 to 23052Acpm (3622-1128, 22; mean
Acpm - sem, n). The difference between the mean
responses of these two groups was highly
statistically significant (P < 0 . 0 0 0 1 )  according 
to an analysis of the data by the Mann-Whitney 
test. Approximately 25% of the healthy 
individuals studied responded with a low
magnitude, of less than 5,000 cpm. The control
responses appeared to fall into defined classes 
which were low ( <  5,000 A  cpm), medium
(5,000-10,000 A  cpm), and high (>10,000 A  cpm) 
responses. This appears to be a real phenomenon 
as individuals who respond in a particular manner
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Figure J u i  The distribution of peak AMLR proliferative 
responses for cells from 41 normal healthy individuals, 
22 myasthenic and 7 rheumatoid patients. The horizontal 
bar represents the mean of the group responses and the 
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tend to do so on repeat assay (see Section 4.14).
Fourteen (63%) of the twenty two patients 
with myasthenia gravis showed decreased responses 
in the AMLR whilst 7 of the patients responded in 
a manner similar to the medium range of the
control AMLR response and one patient showed a 
high range control AMLR response. Of the
seven patients studied here who had rheumatoid 
arthritis, 5 exhibited decreased AMLR and two 
responded in a manner similar to that observed 
for the medium range control-type responses. The 
range of responses observed in the rheumatoid 
group of patients was 53 to 5763Acpm (1473- 910,
7; meanAcpm - sem, n), the difference between the
mean response of this group and that of the 
control group was found to be highly
statistically significant (P <  0.0001) by the 
Mann-Whitney test.
4.8. Kinetic analysis of the AMLR for the groups of 
healthy, myasthenic and rheumatoid individuals
All the responses shown in Fig 4.9 represent 
peak proliferative AMLR responses observed during 
the eight day culture period irrespective of when 
that response occurred. Each eight day AMLR 
culture in the study can be represented as a
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profile, as shown in Fig A.10 (a-e) which
represent typical profiles for:
a) normal individual
b) high responding myasthenics
c) low responding myasthenics
d) high responding rheumatoid arthritis patients
e) low responding rheumatoid arthritis patients
The curve shown in Fig A.10(a) is from one of 
the high responder normal group ( >10,000 Acpm), 
but is representative of the general trends shown 
by all of the normal responses. The AMLR response 
for the normal group of individuals becomes 
apparent after day 5 in culture and rises rapidly 
up to day 7. The proliferative responses 
generally reached a peak on day 7 or 8 in culture 
and thereafter decreased in magnitude. The fall 
in the proliferative response did not reflect
depletion of nutrients as culture medium ( 1 00p. 1 ) 
was replenished both on day A and day 7 of the 
culture period. The normal responses
consistently showed small decreases after day A in 
culture. This was not due to the removal of 
endogenously produced growth factors as parallel
cultures carried out for both day A and day 7,
which did not undergo culture medium renewal, 
responded in exactly the same manner.
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Figure 4.10 (a-e) Typical kinetic AMLR proliferative
responses of normal, myasthenic and rheumatoid
5
subjects. T cells (1x10 ) were cultured with
5
autologous, irradiated (2500 rad) non-T cells (1x10 ) 
as described (Methods p 66 ) in complete medium
containing 10% NU-SERUM. (a) The normal response of a 
clinically healthy individual; (b) A mid-normal type 
response of a myasthenic patient; (c) A low response
of a myasthenic patient; (d) A mid-normal type
response of a rheumatoid patient; (e) A low response
of a rheumatoid patient.
Each curve is the response for a single individual but 
is considered to be representative and characteristic of 
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4.9. The AMLR of MG patients
Two types of response generally observed for 
the group of patients with myasthenia gravis are
represented by Fig 4.10(b) and 4.10(c). Clinical
details and peak AMLR responses for this group of
patients are presented in Table 4A.
As previously discussed, the peak 
proliferative AMLR responses shown by the 
myasthenic group can be classed as low (14/22), 
medium (7/22), and high (1/22). The one 
myasthenic patient with a high range 
response showed an essentially normal AMLR 
profile of the type discussed above. Fig 4.10(b) 
represents a typical profile shown by the 7 
myasthenic patients whose AMLR responses were in
the medium range. The profile differs from the
normal growth curve represented by Fig 4.10(a) 
in that little proliferation occurred before day 
6 in culture. The peak response, occurring on 
day 7, was both distinct and short lived as this
was generally followed by an equally rapid
decrease in the proliferative response.
Figure 4.10(c) represents the responses
observed by the 14 myasthenic patients who showed 
decreased or totally deficient AMLR reponses. No
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Table M .  The clinical details and proliferative
responses, in the AMLR and to PHA-P and Con-A, of 
myasthenic patients.
* Cinical status was assigned according to a
modified Osserman (Osserman and Genkins, 1971) 
classification and any clear progression (i.e.
exacerbation or remission) was noted.
** AAChE - anti acetylcholinesterase;
Thy - thymectomy;
Aza - azathioprin
Anti-acetylcholine receptor antibody titres were
determined by radioimmunoassay.
TABLE JJt. Proliferative responses In AMLR and to PHA-P and to ConA for myasthenic patients
PATIENT AGE/SEX CLINICAL
STATUS*











( A  cpm)
ConA 
(A  cpm)
1 25/F lib AAChE/Thy 0.7 570 8059 40000 N.D.
2 30/F Ila AAChE 3.5 1288 5648 28130 N.D.
3 35/F I AAChE 1.6 143 76 106200 N.D.
4 56/F Ilb/E AAChE/Thy 11.5 84 4332 37430 N.D.
5 51/M I AAChE 3 56 106 31861 16077
6 52/M I/R - 5.7 25 23052 86358 25478
7 36/F Ila/E AAChE 2.4 111 1801 103253 58553
8 29/F Ila/R - 2.8 N.D. 212 97261 40853
9 A3/F I Thy 4.3 3.4 117 64498 52986
10 27/F I AAChE 4.1 528 131 73878 52441
11 35/F Ilb/R AAChE 7.2 172 3842 115798 14020
12 38/F I/E - 8 N.D. 6539 80539 11928
13 A9/M Ila/R - 3.3 28.6 494 31962 5542
14 Al/F Ila
(diabetes)
AAChE/Thy 3 3.5 2209 73798 N.D.
15 26/F Ila/E AAChE/Thy/Aza 4 240 9472 25204 N.D.
16 AO/M I/E - 0.5 N.D. 339 62106 N.D.
17 52/M Ilb/E AAChE 6.5 242 6250 75521 N.D.
18 67/F Ila/R AAChE 3.5 256 111 48586 N.D.
19 A2/F I - 1.9 0.7 83 N.D. N.D.
20 33/F Ila/E AAChE/Thy 4 137 5815 103022 55328
21 A6/M I - 0.9 15 703 53200 N.D.
22 A6/M I AAChE 2.8 91 290 N.D. 1348
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peak response was apparent and consequently the 
growth curve was flat. Despite this total
unresponsiveness, the cells present in all of 
these cultures were responsive to the mitogens 
PHA-P and Con-A (see Fig 4.11), and greater than 
95% of the cells were viable at the beginning of 
the culture period. Thus, the cells were capable 
of responding to certain types of stimuli but 
were unable either to induce an AMLR response or 
to respond in the AMLR.
4.10. The AMLR of rheumatoid arthritis patients
Clinical details of the 7 rheumatoid
arthritis patients studied are presented in Table 
5 together with their peak AMLR responses. Fig
4.10(d) shows a representative AMLR growth curve 
for the two rheumatoid patients whose peak
proliferative responses could be classed as being 
in the mid-range of the normal AMLR responses. 
The AMLR responses for these two patients were
generally similar to those observed for the 
myasthenic patients who also responded with a 
mid-range normal AMLR response (Fig 4.10c).
Five of the seven rheumatoid patients
studied showed very low AMLR responses similar to 
those observed in the low responding group of
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Table The clinical details and AMLR and mitogenic
proliferative responses of rheumatoid arthritis patients. 
Clinical status was assigned according to standard 
clinical evaluation methods.
TABLE A 1  Proliferative responses in the AMLR and to PHA-P and to ConA for rheumatoid arthritis patients
PATIENT AGE/SEX CLINICAL
STATUS




CLINICAL DETAILS AMLR 
( A  cpm)
PHA 
( A  cpm)
ConA 
( A  cpm)
1 40/F MILD SALAZOPYRINE 2.0 SERO-POSITIVE
(1:128)
5763 N.D. 34696










4 51/F MILD - 2.0 SERO-NEGATIVE 139 36240 13890
5 54/M SEVERE SALAZOPYRINE 1.0 SERO-POSITIVE
EROSIVE
72 54029 6503
6 55/M ACUTE - NEWLY
DIAGNOSED
SERO-POSITIVE 64 126450 31346
7 55/F MILD - 2.0 IgG RF POSITIVE 
LATEX NEGATIVE
4089 N.D. 34275
N.D. « NOT DETERMINED
: INDICATES NO TREATMENT
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myasthenic patients. The degree of proliferation 
in the AMLR test cultures was similar to that 
observed in the corresponding background T cell 
controls and consequently, the cpm was 
minimal. The slightly increased response on day 
4 indicates the possible initiation of an AMLR 
response but the response thereafter diminishes. 
This ’peak' on day 4 is not likely to represent a 
change in the kinetics of the AMLR response for 
this group of patients, but may represent the 
inability to sustain the response after this 
time. As in the case of the myasthenic group of 
patients, this apparent unresponsiveness was not 
due to reduced viability, as assessed by trypan 
blue dye exclusion at the beginning of the 
culture period and supported by mitogen 
responses.
4.11. Mitogenic responses of purified T lymphocytes 
from healthy individuals and from patients with 
myasthenia gravis or rheumatoid arthritis
The peak proliferative responses for 
purified T cells to the mitogens
phytohaemagglutinin-P and concanavalin-A are 
presented in Figure 4.11. Because of the limited 
number of cells isolated from the peripheral
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blood of various individuals, not all of the
subjects whose AMLR responses were studied were 
included in this study.
The variation of the T cell response to
PHA-P in the healthy group is quite considerable. 
The responses in this group range from 26204 to 
1 58746 Acpm (1 03978-5474 , 35; meanAcpm -  seoi, n). 
The variation in the response to PHA-P for 
myasthenic subjects was also large, ranging from 
25204 to 1 1 5798Acpm (66930-6499 , 20; mean Acpm- 
sem, n) as was that for the rheumatoid subjects 
(36240 to 1 26450Acpm; 74209- 1 5359 , 5 ; range,
mean Acpm- sem, n). The differences between the
mean responses of each of the two disease groups 
and that of the healthy group were statistically 
significant (P<0.0001 for MG, P<0.0001 for R A ) .
The proliferative responses to optimum
concentrations of Con-A (1Opg/ml) were also 
studied on the same populations of purified T 
cells that were employed in the PHA-P study. As 
for the study of the PHA-P induced responses, the 
peak proliferative response to Con-A generally 
occurred on day 4, although variations of 1-2 
days were occasionally observed. The responses 
for healthy individuals ranged ■ between 
5997-108999 Acpm (63310-5588, 30; mean Acpm -
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Figure 4-11 Peak mitogenic responses of purified T 
lymphocytes (2x10^) from normal, myasthenic and 
rheumatoid subjects to 0.2% PHA-P and 1Opg/ml Con-A. 
The horizontal bar represents the mean response for each 
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s.e.m., n) and those for the myasthenic patients 
between 1 348-58553Ac pm (3041 4-661 9 , 1 1; mean Acpm 
- s.e.m, n). The range of peak proliferative 
responses to Con-A for the rheumatoid T cells was 
6503-34696 Acpm (22350-4636,7, meanAcpm - s.e.m.,
n). The means of the proliferative responses for 
the myasthenic and rheumatoid group were both
significantly different from that of the healthy 
group (P<0.006 and P <0.001 respectively).
4.12. AMLR of healthy individuals: Associations between
age, sex, and the immunological parameters 
studied
Previous investigators have reported 
conflicting findings regarding the effect of the 
age and sex of an individual on the AMLR response 
(Fournier and Charriere, 1981, Fernandez and 
MacSween, 1980, Moody et al ., 1981). In this
study, the associations between age, sex, peak
AMLR response, peak PHA-P response, and peak
Con-A response for 41 healthy individuals (25
males : 16 females) were investigated.
Fig 4.12 and 4.13 show that there is
little correlation between most of the parameters 
studied. However, there is a significant 
positive correlation (P<0.05) between the peak
119
PHA-P response by the purified T cell population 
and the age of the donor subject (Fig 4.12b).
This is also observed when the PHA-P data is log
transformed. The use of these logarithmic 
transformations reveals a correlation between the 
peak PHA-P response and the peak Con-A response
which was not apparent when the raw data were
compared. Similar apparent correlation also
occurs between log. transformed peak PHA-P data 
and raw AMLR data. The AMLR appears to be
unaffected by the various parameters studied and
any changes in the other immunological responses 
may reflect alterations in immunoregulatory 
mechanisms distinct from that of the AMLR.
4.13. AMLR of patients with myasthenia gravis:
Associations between age, sex and the 
immunological parameters studied
The degree of association between the 
immunological responses studied and the age, sex, 
anti-AChR antibody titre and duration of disease 
in the group of patients with myasthenia gravis 
was determined by correlation and regression 
analysis.
The correlation coefficients and statistical 
significance of these correlations are shown in
Figure 4-«12(a-d) Correlations between various paired 
parameters for cellular responses from normal, healthy 
individuals:
(a) AMLR proliferative response versus Age.
(b) PHA-P induced T cell response versus Age
(c) Con-A induced T cell response versus Age
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Figure 4-13 (a ) The degree of correlation between the 
AMLR proliferative response ( A cpm) and the Con-A 
induced T cell response for normal, clinically healthy 
individuals .
Figure - £•13 (b ) The degree of correlation between the 
PHA-P induced T cell response and the Con-A induced T 
cell response for normal, clinically healthy
individuals.
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Table4.6- No correlation was found between any of 
the parameters tested. Only three of all the 
pairs of associations tested showed significance 
values less than 0.1 but these were always 
greater than 0.05 and so were not considered to
be significant. These three associations were 
PHA-P vs Con-A (slight positive correlation), 
Con-A vs age (slight negative correlation), and 
titre vs age (slight negative correlation). A
positive correlation may be expected between 
PHA-P response and Con-A response although, as
the two mitogens may stimulate separate or
overlapping cell populations, the degree of
correlation may not be high. The slight negative 
correlation between Con-A response and age may 
reflect an age-related loss of Con-A induced T 
suppressor cells and may account for the general 
increase in autoimmune states observed with 
increasing age. The slight negative correlation 
observed between the titre of anti-AChR antibody 
and age may be due to the existence of
autoaggressive states, represented by increased 
humoral activity, which later diminishes as the 
whole immune system enters into the final stages 
of the autoimmune process. However, as the 
significance values are not less than 0.05, these 
associations cannot be interpreted as being 
important although their lack of significance may
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T a b l e d  Correlation matrix of the parameters studied 
for the group of myasthenic subjects. None of the
correlation coefficients shown was statistically
significant unless stated otherwise.







Con-A -0.086 0.337 ***
Titre 0.103 -0.335 0.338 ***
AGE ’ -0.021 -0.212 -0.578 -0.452 ***
( 0 . 1 0 < P > 0 . 0 5 )  ( 0 . 1 < P > 0 . 0 5 )
DURA- 0.306 0.057 -0.133 -0.078 0.291 ***
TION
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be due to the relatively small population number 
studied.
4.1 A . Reproducibility and variation of the normal AMLR 
response - a longitudinal study
The AMLR of ten healthy individuals (6 
males, 4 females) of age range 22-40 years, were 
studied at least three times and up to 14 times 
over a period of 3 years. Figure 4.14 shows the
range of responses with the mean response and
s.e.m. for each of the ten individuals. Large
variations in the response may be observed for
several of the individuals which may not
necessarily be due to experimental variation. Fig
4.15 shows the response observed for two
individuals studied over a period of three years 
and suggests that a seasonal variation in the
AMLR response may account for the
intra-individual range observed in Fig 4.14
Although the data required to construct a 
complete picture of the possible variations that 
may occur over a 12 month period were not
available, there are indications that some type
of cyclical response may be occurring, possibly 
involving a peak of activity during the summer 
months. Although this presents an intriguing 
possibility, it is clear that a meaningful
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Figure 4.14 The range of peak AMLR responses measured 
over a period of three years in 10 normal, healthy 
individuals. Sex (M/F) and age of subject are noted on 
the abscissa. The horizontal bars represent the mean 
of the responses for each individual and the symbol (|“ ) 
represents the s.e.m.
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Figure 4-15 (a-c) The variation in the peak AMLR
response for two clinically healthy male individuals 
studied over a period of three years. The closed 
circles( 9 9 ) represent the responses of a 22 year old
male and the open circles ( o o ) represent the
responses of a 35 year old male. Month 1 represents 
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investigation would involve much more extensive 




The establishment of standard culture
conditions is fundamental for any comparison of 
the AMLR in normal individuals and in 
myasthenics. A comprehensive study of the 
factors affecting the AMLR in normal individuals 
was carried out by Ng and Russell (1982), who 
examined the AMLR with respect to duration of 
culture, the type and concentration of 
stimulating cells and the day-to-day variation in 
the results. The results obtained in the present
study will be compared with those of Ng and
Russell (1982), and also with those of other 
authors.
Although the responding cell type in the 
AMLR is agreed to be a T lymphocyte (Opelz et 
al. , 1975 ; Kuntz et al ., 1976 ; Sakane et al.,
1978), controversy remains over the identity of 
the stimulating cell. The conflicting results
obtained, showing maximum proliferation using
different stimulating cell populations, may be
due to the different methods of cell purification
and cell classification used in various studies
(Beale et al., 1980). The study of Smolen et 
al., (1982), (see Introduction, p 20 ),
supported the view that more than one type of
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stimulating cell exists. In an attempt to
avoid the complications generated by further
fractionating both the T cell and Non-T cell
populations, the AMLR culture conditions were
established by using whole T-cell and whole non-T
cell populations. The various aspects of the
culture conditions that were studied were:-
i) The fractionation method used for 
separating T cells and non-T cells.
ii) The effects of various serum supplements.
iii) The effects of cell number per culture.
iv) The effects of the ratio of T cells to
non-T cells.
v) The length of the incubation period.
All of the aspects outlined above were studied
using PBL isolated from normal, healthy
individuals.
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5.1. The method of T cell/non-T cell fractionation
Although no attempts were made to 
identify the stimulating cell within the non-T
cell population, an attempt was made to ensure
that the fractionated T and non-T cell 
populations were as highly purified as possible. 
Analysis of cell surface markers and responses to 
the mitogens Con-A and PHA-P were used as 
indicators of the degree of purity attained in 
each cell population following separation. The
two general methods of purification tested were 
nylon wool passage and rosette formation with 
density gradient centrifugation. Each method 
depends on the presence of a particular surface 
marker. Nylon wool selects for B cells expressing 
immunoglobulin on their surface (Julius et a l ., 
1973) while rosette formation, using SRBC, depends 
on the presence of a SRBC receptor on T
lymphocytes (Coombs et al., 1970).
The results generated in this thesis
indicate that E-rosette separated T and non-T
cells yielded cell populations of significantly 
higher purity than that achieved by using nylon 
wool passage. Further, treatment of the SRBC
with the sulphydryl compound, 2-AET, or with
neuraminidase, prior to their use in a rosetting
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procedure yielded rosettes which were both larger 
and more stable. This observation was in
agreement with those of Kaplan and Clark (1974) 
and of Madsen and Johnsen (1979) who described 
the SRBCa e t technique as ’effective, reliable and 
time saving'.
Inherent in any separation and
isolation procedure is the possibility of
challenging the lymphocytes with xenoantigens. 
This was discussed in the Introduction in terms 
of whether the AMLR is a true phenomenon, or is
the result of xenoantigenic challenge. However
xenoantigens affect the AMLR, the method used for 
separating the cells may influence this 
contribution. Thus, nylon wool (being a 
polyamide) could be considered to provide an 
excellent polymeric antigenic structure for the 
direct activation of B cells (by cross-linking 
surface receptors) and possibly even T cells and 
macrophages. Further, if E-rosette separation 
methods are employed, it is possible that the 
isolated T cells are activated during the 
rosetting procedure by the treated SRBC.
Whatever the role of xenoantigen in the AMLR, a 
significant difference was observed between the 
AMLR in normal individuals on the one hand and
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in myasthenic and rheumatoid patients on the 
other. Thus, in the patients with autoimmune 
diseases, a change in a particular cell subset 
may have occurred resulting in the deficient 
autologous, or deficient anti-xenogeneic, 
response observed. All that can be claimed for the 
present work is that it has attempted to keep
experimental manipulations of the cells used in 
the AMLR to a minimum, and hence reduce the 
effects of xenoantigenic contact.
5.2. The effects of serum supplement type
The presence of xenoantigens in media may 
also be regarded as another source of
proliferative stimulus for the AMLR. These 
xenoantigens may be present in the separation 
media (during isolation procedures) or in the
culture media. A precautionary note was sounded 
by Heilman and Stobo (1982), who suggested that 
the specificity of the AMLR assayed in culture 
medium containing FCS is different from that 
assayed in either autologous or heterologous 
serum. More recently, xenoantigens have been 
suggested as, at least, augmenting (MacDermott
and Bragdon, 1983), and, at worst, causing the 
response (Huber et a l ., 1982; Kagan and Choi,
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1983).
The data presented in this thesis showed 
that the use of FCS resulted in a greater degree 
of cell proliferation in the AMLR than that 
observed with autologous, pooled AB, or NU-SERUM. 
It is possible, however, that FCS was acting in 
a mitogenic manner, as both the AMLR and T cell
control responses were increased. The use of
NU-SERUM, a well — defined low serum protein 
supplement, yielded AMLR responses of similar
magnitude to those observed with complete medium 
containing FCS, but with low T cell control 
responses and was consequently preferred. 
NU-SERUM is a commercially available serum 
substitute containing a number of growth factors, 
vitamins, hormones, trace elements and various
cell nutrients. It has been compared favourably 
with FCS, in terms of lower batch-to-batch 
variation and less mitogenic qualities, when used 
in the murine allogeneic MLR (Gibb et al . , 1985).
NU-SERUM was also shown here to support the 
AMLR to a greater extent than either autologous 
serum or pooled human AB serum, while yielding 
lower background T cell control responses. The
background responses observed in the presence of 
autologous serum and pooled human AB serum appear
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to follow the proliferative responses observed 
for the AMLR, albeit in a diminished manner. 
These gradually increasing responses may have 
been due to particular stimulatory constituents 
of the serum samples, and did affect the net AMLR 
observed in most cases.
Thus, NU-SERUM was chosen for routine
analysis of the AMLR. The ability to obtain a 
supply of culture medium supplement of low 
batch-to-batch variability, low non-specific 
mitogenicity, yielding satisfactory AMLR responses 
at a relatively low cost enabled the normal AMLR 
to be investigated in a controlled manner, with 
reasonable expectations that the response can be 
attributed to the stimulator cells, rather than to 
non-specific mitogenic substances present (Gibb et 
al., 1985) in serum.
5.3. The effects of cell number and the ratio of T 
cells to non-T cells per culture
Fundamental to the elucidation of the
interactions that occur in the AMLR, is the 
observation by Opelz et al ., (1975) that the
amount of [ H]-Tdr incorporated by unfractionated 
lymphocytes in culture can be dramatically 
increased by increasing the ratio of T and non-T
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cells; an observation confirmed by Ng and Russell 
(1982).
In the present study, an increase in the 
proliferative response was observed with
increasing numbers of unfractionated non-T cells.
Among the five concentrations of responding T
5 5cells tested, the assays using 1x10 and 2x10 T 
cells/well showed the highest dose-dependency on 
non-T cell concentration, and, in both cases, 
peak responses occurred with 1:1 ratios of T to 
non-T cells. Assays involving eithe.r high or 
low concentrations of T cells resulted in very 
low proliferative responses.
Most of the data published to date use cell
5
concentrations of 2x10 cells in a total volume 
of 0.2ml culture medium, and cell ratios of 1:1 
(ie 1x10 T cells and 1x10 non-T cells). These 
conditions were used here and combined the 
effects of maximum response with efficiency of 
cell usage. In contrast to these findings, both 
Kuntz et a l ., (1976), and Kalden et al . , (1983),
reported optimum proliferative responses using 
stimulating cell to responding cell ratios of 
2:1.' Gupta ' (1984), on the other hand, carried out 
AMLRs in which B cells and macrophages were used
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as stimulating cells, over a range of T cells to 
non-T cells ratios of 1:8 to 1:1 and found that 
equal numbers of cell types yielded the maximum 
response, although no higher T cell to non-T cell 
ratio was investigated.
Low proliferative responses observed at
non-optimal cell concentrations and ratios may 
result from the effects of substrate exhaustion, 
toxic metabolites, altered pH at higher cellular 
concentrations or excessive or inadequate 
cell-cell contact, as proposed by Knight (1982).
Knight (1982) emphasised that the proximity 
of cells in culture, culture vessel shape, 
proportion of responding to stimulating cells, 
and the length of the culture period may all play 
important roles in the observed responses of many 
assays involving lymphocyte proliferation.
It is also possible that high responses to
stimulation may occur within a narrow range of
doses of stimulant and only at certain times 
during the culture period (Ling and Kay, 1976).
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5.4. The length of the culture period
In the majority of studies which have 
investigated the AMLR in normal, healthy 
individuals and in patients with autoimmune 
diseases, the response has only been determined on 
one day, usually day 6 of the culture period. 
This has been the case, with few exceptions, since 
Kuntz et a l ., (1976) followed kinetics of the
AMLR over a nine day period, and observed the
greatest stimulation index on day 6.
The comprehensive study by Ng and Russell 
(1982) of 30 normal subjects showed that the
maximal response was evenly distributed between 
days 6, 7 and 8 of the culture period; for the
majority (26) of the subjects studied. The 
present study noted that the peak responses 
occurred on the eighth day and less frequently, 
on the seventh day of the culture period.
Other studies that have noted the peak AMLR 
response from kinetic investigations were based on 
results from low numbers of normal subjects. 
Miyasaka et al ., (1980) noted a peak AMLR response
on day 7 of a nine day culture period for five 
normal subjects, whilst Pope et al., (1984)
suggested that the maximal AMLR response occurred
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Fig 5.1. A schematic representation of the 
possible cellular interactions that may occur in 
the AMLR.
Initial macrophage or B cell stimulation of T4 
cells through la antigens may result in the
activation of these T4 lymphocytes. Release of 
IL-2 may then act to stimulate T4 inducer cells to 
activate both T4 suppressor cells and T8
suppressor cells. The T8 suppressor cells may act 
by suppressing T4 cell help in Ig synthesis and 
may suppress natural killer cell activity.
Cytotoxic T8 cells may also be generated. T4
suppressor may negatively feedback and suppress T4
cell activation. Increased la antigen expression 
or foreign antigen processing by macrophages may 
result in increased T4 activation.
Key: M0 macrophage
T4 act Activated T4 lymphocyte
IND T4 Inducer cell
T4s T4 Suppressor cell














on day 7 of a seven day culture period, using only 
two normal subjects. Further, Ransohoff and 
Dustoor (1983) claimed that the peak AMLR response 
occurred on day 6 of a ten day culture period.
However, no data points were recorded for days 7, 
8 or 9, which must cast doubt on such conclusions.
The results obtained by Ng and Russell,
(1982), on 30 normal subjects, would appear to 
be, in part, substantiated by the results
presented in this thesis on 41 normal subjects. 
These observations may form the basis for future 
investigations of the normal AMLR, and -enable the 
appropriate comparisons to be made correctly.
Apart from identifying the true peak 
response, a kinetic profile yields further 
information about the AMLR. Differences in the 
kinetics of the AMLR have been observed between
the various connective tissue diseases (Laffon et 
al. , 1983) and in primary biliary cirrhosis
(James et al., 1980). Laffon et al., (1983)
suggested that analysis of the day to day 
kinetics of the response gave information about 
differences in immunoregulatory circuits. 
Indeed, if the AMLR had only been measured on day 
7 in the study of Laffon et a l ., (1983), early
low responses in some disease group subjects
would have been missed.
Although no gross changes in kinetics for the 
AMLR responses were observed in the present study 
of myasthenic or rheumatoid subjects, it was 
evident that the responses did not occur until 
much later in the course of the culture period 
for the disease groups, when compared to the 
responses of the normal subjects. These 
observations further support the view of Ng and 
Russell, (1982), that the results obtained in the 
AMLR should be expressed in terms of the peak 
response based on a variable duration of culture.
The variation in the normal AMLR
Using a similar stimulating cell population 
(ie unfractionated non-T cells) to that employed 
in the present study, Ng and Russell (1982) 
observed that, in some subjects, the time to peak 
AMLR responses and the magnitude of that response 
varied significantly, even when blood samples 
were obtained on consecutive days from the same 
individual. However, despite the variability of 
response patterns and the time to peak response, 
the magnitude of the maximal response was shown 
to be relatively reproducible with blood taken on
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consecutive days in 6 normal subjects (Ng and 
Russell, 1982). Further, the reproducibility of 
the response was markedly improved when 
non-adherent non-T cells rather than
unfractionated non-T cells were used as 
stimulators.
The data presented in this thesis are in 
accordance with previous reports (Sakane et al , 
1978; Dock and Davey, 1980; Ng and Russell, 1982), 
which showed a wide range of AMLR responses 
amongst normal controls. Using unfractionated 
non-T cells as the stimulating fraction, Ng and 
Russell (1982) showed that the maximal response 
of 30 normal individuals ranged from 400 Acpm to 
over 18,000Acpm, with a mean of 5,700 - 4900. In 
the present study, a range of 38lAcpm to 56,384 
Acpm was found, with a mean of 12,228 - 1674, for 
41 normal subjects. This higher range and mean
peak AMLR response may be a consequence of a
different control population, or of the
optimisation of the culture conditions discussed 
previously (see sections 5.2 - 5.4). Indeed, the 
responses reported here for unfractionated non-T 
cell stimulated AMLR are almost as high as those 
of non-adherent non-T cell stimulated AMLR 
responses, reported by Ng and Russell (1982).
Similarly, the range of peak AMLR responses found
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in the study of Sakane et al . , (1978) were
obtained using non-adherent non-T cell stimulated 
AMLR. All of the 38 normal subjects responded 
vigorously, having a range of 5,100Acpm to 27,500 
Acpm with a mean of 9,500Acpm (Sakane et a l ., 
1978).
Kalden et al . , (1983) found wide variation in
the AMLR of 56 normal controls using 
unfractionated non-T cells as the stimulating 
fraction. Although no values were stated for the 
range, graphical values were shown which ranged 
from approximately 3,000 Acpm to approximately 
36,000A,cpm, having a mean of 10,830Acpm - 13,490.
This wide variation is similar to that reported in 
this thesis.
Both Kalden et al., (1983), and Dock and
Davey, (1980), found that approximately 20% of 
clinically healthy controls exhibit decreased 
AMLR. The results presented in this thesis 
sugges ted that approximately 25% of all
clinically healthy individuals responded with a 
low magnitude. The results presented here 
suggested that control responses could be
categorised, as low ( < 5  , 000 Acpm), medium 
' ('5,000-1 0 , 000 Acpm) and ' high ' ( >  1 0,000 Acpm) .' 
Although no previous studies have categorised the
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observed responses as such, it is possible that 
the results obtained in other reports may be 
treated in a similar manner. Indeed, the study by 
Kalden et al., (1983), reports peak AMLR
responses which could be placed into similar 
categories of low (<8,000 Acpm), medium 
(8,000-1 6,000 A c p m ), and high ( >1 6,000 Acpm ) 
responses. Such classification may aid in the 
identification of real types of responsiveness in 
different individuals. These types of
responsiveness may then correlate with genetic 
background or other factors which may affect the 
AMLR (Davey et al., 1984).
Despite the normal variation observed from 
day-to-day, the AMLR has been shown to be 
relatively reproducible with blood taken on 
consecutive days for normal individuals (Ng and 
Russell, 1982). However, the intra-individual 
variation in the AMLR over a much longer period
of time has not yet been addressed. . In the
present study, the AMLR of ten clinically healthy 
individuals were studied at least three times and 
up to fourteen times over a period of three
years. While several of the individuals' 
responses studied longitudinally were shown to be 
relatively reproducible, the responses of other 
individuals (6/10) showed wide variation ' on
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repeat assay. These data, and the results of the 
AMLR for two individuals studied longitudinally 
over a period of three years, suggested that some 
form of seasonal variation in the AMLR
response may account for the intra-individual 
variation. As discussed in the 'Results' section, 
a peak response appeared to occur in the summer 
months, although this may also be a reflection of 
the prevailing health conditions for each 
individual.
The variation in the normal AMLR must be 
established in order to compare normal AMLR and 
those found in autoimmune disorders. It has been 
shown that several physiological and genetic
factors may affect the AMLR response even in
normal individuals. Plasma cortisol (Ilfeld et
al . , 1977; Yu et a l ., 1978; Hahn et a l ., 1980;
Indiveri et al., 1985), age and sex (Moody et 
al., 1981) and genetic (HLA-DR) phenotype (Davey
et al., 1984) have all been implicated as 
contributory factors. Other endogenous factors, 
including hormones, may also affect the level of
the AMLR, and these factors are subject to not 
only diurnal, but also seasonal or yearly
cyclical variations. Further investigation of 
these parameters and their effects on the AMLR, 
may lead to a more complete understanding of not
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only how the immune system becomes disrupted in 
autoimmune conditions, but also how, the 
immune system communicates with the nervous 
system and other tissues (see Besedofsky et al . , 
1983) .
5.6. Comparison of the AMLR in normal, myasthenic and 
rheumatoid subjects
The mean peak AMLR response of 22 myasthenic 
subjects with varying degrees of clinical 
symptoms has been shown in this report to be 
significantly decreased from the mean peak AMLR 
responses of 41 normal, clinically healthy 
individuals. A significantly decreased mean 
response was also shown for the AMLR responses of 
subjects with varying degrees of rheumatoid 
arthritis.
The AMLR has been shown to be depressed in 
individuals with SLE (Sakane et al. , 1978; Kuntz 
et a l . , 1979), multiple sclerosis (Hafler et a l . , 
1985) rheumatoid arthritis (Smith and
Dehoratius, 1982), Hodgkins disease (Engleman et 
al ., 1980) and Sjogren's Syndrome (Miyasaka et
al ., 1980), all diseases with an autoimmune
ae tiology.
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The findings of this thesis are at variance 
with those of a previous report by Greenberg et 
al., (1984), that the AMLR was significantly
increased in 11 of 15 pre-treatment MG patients. 
At least part of the apparent conflict 
may be accounted for by a difference in the 
classification of low and high responses be tween 
the two studies. In this thesis, low responses 
of the normal AMLR are classed as being less than
5.000 Ac pm. High responses are classed as greater 
than 10,000 Acpm with the majority of normal 
responses falling into the medium range of 5,000
Acpm to 10,000Acpm. In the study of Greenberg et 
al , (1984), of 15 patients studied
pre-thymectomy, 8 patients had AMLR of less than
4.000 Acpm, 4 patients had net AMLR of between
5.000 Acpm and 10,000Acpm, and 3 patients showed 
net AMLR greater than 10,000 Acpm. The 
classification of this group of myasthenics as 
'hyperactive' with regard to the AMLR is 
equivocal. The AMLR of ten patients, followed 
post-thymectomy over a two year period, were 
suggested to have normalised. However, of these 
ten patients with 'normal' AMLR, eight patients 
exhibited net AMLR responses of less than 3,000
Acpm. One patient had an AMLR slightly less than
5.000 Acpm whilst the remaining patient had a net
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AMLR response in the mid-range. Seven other MG 
patients who were not studied pre-thymectomy were 
also studied post-thymectomy. Of these seven
post-thymectomy MG patients, only one responded 
in the AMLR in the 5,000 Acpm - 10,000 Acpm
mid-range. All of the remaining six patients 
showed net AMLR responses of less than 3,000 Acpm. 
Thus, when conclusions are drawn from the data 
generated in a study, care must be taken to 
derive these conclusions from comparisons with
established standards and controls. No such 
normal controls were presented in the study of 
Greenberg et al., (1984), resulting in the
difficulties described above with regard to 
classification of response type.
As stated in the ’Results’ section, the 
majority of the myasthenics studied in this thesis 
responded in the low ( <  5 , 000 Acpm ) manner (14/22). 
All of these fourteen patients showed almost flat 
kinetic profiles for the AMLR over the nine day 
culture period. The seven myasthenics who 
responded in the mid-range, and the one myasthenic 
who responded with a high range normal-type 
response showed normal kinetic AMLR growth curve 
characteristics for medium responder, and high 
responder normal individuals respectively.
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The limited study of the AMLR carried out on 
a group of seven patients with rheumatoid 
arthritis showed a depressed mean peak AMLR 
response in these patients in comparison to that 
of the normal group of individuals. Five of the 
seven R.A. patients responded with very low 
( <1,000 Acpm) AMLR, whilst the remaining two
exhibited mid-range normal type responses. 
However, the kinetic profiles for the two
mid-range R.A. responders were different to those 
observed for normal mid-range responders. A slow 
increase in the proliferative response for these 
two R.A. patients up to the peak response was 
followed by a rapid decrease in the response after 
the peak. This change in kinetics may be 
representative of an alteration in the cellular
interactions that occur in the AMLR in disease 
states, and lends further support to the use of 
kinetic rather than single point studies of the 
AMLR.
The classification of the normal AMLR 
response into low, medium and high responder
groups, and the observation of approximately 20% 
of the normal population responding in the low 
manner, may identify normal individuals who are 
predisposed to some form of immune dysfunction. 
Although the individuals who were identified ' as
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responding in a low manner were all clinically 
healthy (Kalden et a l . , 1983; Richards etal;1986 ) , 
the low AMLR response observed may serve as a 
predictor of future immune dysfunction by 
recognising individuals who are:
i) already developing immune dysfunction but 
have no clinical symptoms of such internal 
dis turbances,
ii) predisposed by their low immune
self-responsiveness to develop autoim’mune or 
other diseases following sensitation by an 
external or internal agent (eg virus or 
hormone).
Thus, despite the repeated observations of 
abnormal immunoregulation, as represented by the 
AMLR, in patients with diseases of the immune 
system, future efforts should be concentrated on 
the elucidation of the ’normal1 AMLR and its 
significance.
5.7. Conclusion; Immunoregulatory mechanisms in the 
AMLR
The significance of the AMLR in vivo, as well
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as in vitro, has been questioned by several groups 
of workers who have suggested that the phenomenon 
is an artefactual response to xenogeneic antigens 
or to changes in cell populations during cell 
fractionation procedures (Huber et al ., 1982;
Kagen and Choi, 1983; MacDermott and Bragdon,
1983). However, the consistent and significant 
differences found between the AMLR of normal 
individuals and those of patients with various 
autoimmune diseases may argue against the 
’artefactual AMLR1 theory, proposed above. A 
major difficulty in the interpretation of results 
presented by different groups is the lack of 
standard culture conditions and separation 
protocols. Clearly, these operational differences 
could lead to some discrepancies between groups. 
However, the data presented in this thesis and 
those of many other studies on the AMLR in normal 
and disease states would suggest that the AMLR may 
play a significant role in the immunoregulation of 
the human immune system.
The major part of this thesis established the 
finding that the AMLR is defective in patients 
with myasthenia gravis, but no attempt was made to 
further dissect the AMLR to elucidate the nature 
of the defect. The theories and mechanisms which 
may account for the normal AMLR and how any defect
155
may arise will be discussed here.
The generation of helper activity by 0KT4 + 
cells and suppressor activity by 0KT8+ cells in 
the AMLR is established (Damle et al., 1981;
Smolen et al., 1981). It has also been shown that 
0KT4 + cells are necessary at the initiation of an 
AMLR (Damle et al ., 1981; Smolen et al., 1981;
Reinherz et al, 1982) and that 0KT8+ cells can
only proliferate in the presence of interleukin-2 
(IL-2) or autologous 0KT4 + cells (Smolen et a l . , 
1982 ) .
More recently, Kotani et a l . , (1984) have
found that:
i) T cell subsets capable of proliferating in 
AMLR mainly reside in 0KT4+ , but not 0KT8+ 
cells.
ii) Cells recoverable from the AMLR express 
helper as well as suppressor activity.
iii) 0KT4+ cells activated in the AMLR are able 
to mediate both the helper and suppressor 
functions.
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iv) Helper function mediated by 0KT4 + cells is 
generated early in the course of an AMLR.
v) Suppressor function in turn emerges from
the activated 0KT4 + population.
The observation that two distinct
functions mediated by 0KT4 + cells occur 
successively upon activation in AMLR, indicates 
that either there may exist both helper and 
suppressor subsets within 0KT4 + cells, or that 
upon activation in AMLR, the same 0KT4 + cells can 
become cells capable of expressing both helper 
and suppressor activities. Kotani et al., (1984) 
ruled out the latter possibility after finding 
that irradiation of 0KT4+ cells that had been
activated for 6 days in AMLR led to loss of all 
suppressor function but retention of substantial 
helper activity. However, their results 
indicated that a part of the AMLR may represent 
an important immune circuit among cells in the 
0KT4+ subset. These results may support those of 
Eardley et al., (1978) who suggested that a
’feedback suppression1 mechanism may exist in the 
immune systems of mice.
The existence of some form of feedback- 
suppression mechanism within the immune system
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would allow far greater flexibility for the
responsiveness of the system. If the system was 
considered to be in constant, dynamic interaction 
then one may postulate that the response to a 
foreign antigen would be far quicker than if the 
system were in a resting state prior to antigenic 
challenge. Perturbation of the autologous
interactions by the foreign antigen would result
in a rapid amplification of specific helper 
subsets. In vitro, this would result in the 
generation of suppressor activity after 
approximately day 6 in culture (Kotani et al.,
1984). However, in vivo, helper activity may
continue to be stimulated whilst antigen persists 
in the body. Only after the majority of the
antigen had been cleared would suppressor 
activity become apparent and feedback on the 
helper activity generated.
Alternatively, initial helper activity may 
stimulate suppressor activity after 6 days in
vivo. However, due to the presence of stimulatory 
levels of antigen in the body, helper activity 
would overcome any suppressor activity generated 
and allow the clearance of the antigen. Following 
the clearance of the antigen, helper activity
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would no longer be generated and suppressor 
activity would act on the effector functions 
generated during the initial helper phase. Fig
5.1 shows the possible interactions that may occur 
in the AMLR.
Whichever of these mechanisms may exist, if 
indeed they do exist, it is clear that some form 
of balance occurs between the level of help, 
suppression and antigen concentration. The term 
antigen concentration may be applied equally to 
foreign antigen or self-antigen ( la). Thus, 
foreign antigen may tip the balance- towards a 
conventional response to antigenic challenge, and 
self-antigen may, under the right conditions, 
upset the dynamic equilibrium established between 
help and suppression and result in the generation 
of an aggressive autoimmune state.
With regard to autoimmune states, very little 
data exists to support the above hypotheses . 
However, Sakane et a l ., (1983) demonstrated a
completely defective AMLR activated 0KT4+ 
suppressor cell circuit in patients with SLE, a 
disease in which a defective AMLR has been found 
(Sakane et al ., 1983, Takada et al., 1985). 0KT4+
cells were shown to be incapable of producing IL-2 
and of expressing IL-2 receptors after activation
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by autologous non-T cells. However, 0KT8+ cells 
from SLE patients were shown to be responsive to 
exogenous IL-2 (Takada et al., 1985). Defective 
non-T cell stimulatory capacity was ruled out by 
the addition of normal monocytes or exogenous IL-1 
to SLE AMLR cultures, resulting in very little 
IL-2 production by SLE 0KT4+ cells.
Thus, if SLE 0KT4+ cells are effectively 
activated but fail to induce 0KT4 + suppressor
cells, initial helper activity may continue to be 
stimulated. This may allow the uncontrolled
expression of a pathological influence 
(autoantibodies, autoaggressive macrophages, 
natural killer cells, cytotoxic T cells).
It is possible that one or another aspect of 
the AMLR may be defective in different disease 
states. Thus, some patients may have excessive 
suppression of AMLR by macrophages, others may 
have a defect in the early stages of the AMLR, 
poor recruitment of cells, defective helper
activity or suppressor function, or combinations 
of all these. Abberations in the levels of 
soluble factors (interleukins, interferons) may 
also play a role in different diseases.
Studies of these details of the AMLR in
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various disease states should shed light upon the 
cellular basis of immune abnormalities, and may 
provide a basis for a more effective investigation 
and ultimately, treatment.
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6.0 EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS
INTRODUCTION
The AMLR was suggested in Section One as
representing a possible mechanism for immunoregulation 
in humans. This view has been supported by the 
increasing amount of data which have shown a decreased 
AMLR in diseases known to be associated with 
immunoregulatory dysfunction.
The aetiology of many autoimmune diseases is
unclear and it is thought that most of these diseases 
have multi-factorial causes. Myasthenia gravis is
unique as an autoimmune disease in the amount of data 
that have been generated on the autoantigen, the AChR. 
This has enabled the development of an animal model of 
the disease which bears similarities to the human 
condition.
The aim of the second part of this thesis is to 
study the AMLR in an animal model of MG, as the disease 
state is induced and possibly maintained. A study of 
the cellular immune responses, represented by the in 
vitro AMLR and mitogen responsiveness is intended to 
show the cellular changes that may occur during the
establishment of EAMG, both in terms of anti-self 
immunoregulation (AMLR) and more general polyclonal 
responses (mitogen). Monitoring the humoral response,
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represented by the serum anti-AChR antibody titre, is a 
measure of B cell activity in the immune system, and 
thus of the degree of immunoregulation.
6.1 History of EAMG
Experiments carried out in 1973 by Patrick and
Lindstrom, and Patrick et al, yielded early 
experimental evidence that an autoimmune response to 
AChR was the pathogenic mechanism occurring in MG. 
Experimental autoimmune myasthenia gravis (EAMG),
discovered in these experiments, has been 
comprehensively reviewed by Lindstrom (1979), Vincent
(1980), and Harrison and Behan (1986) and the model in 
alternative animals will be discussed here.
6.2 Rabbits
The induction of EAMG in rabbits immunised with 
AChR purified from electric eel or electric ray has
been demonstrated by many workers (Sugiyama et al, 
1973? Heilbronn and Mattson, 1974; Aharonov et al, 
1975? Green et al, 1976? Heilbronn et al, 1976? Penn et 
al, 1976? Sanders et al, 1976? Valderama et al, 1976; 
Fumagalli and Clementi, 1978? Takamori et al, 1979; 
Ueno et al, 1980; Niemi et al, 1982) following the
initial observations of Patrick and Lindstrom (1973).
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EAMG generally becomes apparent about 1 month 
after immunisation with 100-400ng of purified AChR in 
complete Freunds' adjuvant (CFA), or a few days after a 
booster injection given 2-4 weeks after the initial 
immunisation. High serum anti-AChR antibody titres are 
obtained by using frequent booster injections 
(Lindstrom et al, 1981? Elfman, 1984).
The clinical symptoms of EAMG include a flaccid 
paralysis which affects the head, neck and back 
muscles. Affected animals show drooping head and ears, 
have difficulty in sitting and often lie flat with 
extended limbs. Severe cases can exhibit wheezing and 
loss of appetite. Rabbits with EAMG commonly die 1-2 
days after the onset of symptoms, often as a result of 
respiratory failure with associated pneumonia (Elfman,
1984). Muscular weakness is shown by decremental 
electromyographic responses to repetitive nerve 
stimulation and is temporarily alleviated by 
anti-cholinesterase therapy.
EAMG has also been induced in rabbits by using 
AChR purified from denervated rat muscle (Wonnacott et 
al, 1982), foetal calf muscle (Lindstrom, 1979) , chick 
muscle (Sumikawa et al, 1982? Dolly et al, 1983), cat 
muscle (Dolly et al, 1983) and a mouse muscle cell line 
(Boulter and Patrick, 1977).
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Immunisation of rabbits with SDS-denatured AChR or 
its denatured subunits (Lindstrom et al, 1978) or with 
reduced and carboxymethylated whole Torpedo AChR 
(Bartfeld and Fuchs, 1977) did not result in clinical 
signs of EAMG. However, Fuchs et al, (1981) showed the 
induction of EAMG in rabbits immunised with a tryptic 
fragment (MR 27,000) of Torpedo AChR.
6.3 Rats
In general, rats are slower to develop clinical 
symptoms of EAMG than rabbits (Vincent, 1980), although 
different strains of rats show varying degrees of 
susceptibility to disease induction (Green et al, 1975; 
Vincent, 1980). Lewis and Lou rats being most 
susceptible in this respect (Lennon et al, 1978; 
Lindstrom et al, 1981).
A single immunisation of l-100ng of purified 
Torpedo AChR in CFA at multiple intradermal sites, was 
shown to produce chronic EAMG, in Lewis rats, although 
frequent booster injections were required to produce 
high antibody titres (Lennon et al, 1975; Lindstrom et 
al, 1981).
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Resistance to EAMG has, however, been reported in Lewis 
rats immunised with Torpedo AChR in CFA (Sanders et al, 
1976? Kim and Sanders, 1981). Lou rats immunised with 
purified bovine and human AChR in CFA (Einarson et al,
1982) show EAMG and Wistar rats have shown weakness 
when immunised with Narke (an electric ray) receptor in 
the absence of CFA (Ueno et al? 1982). However Wistar 
rats have failed to show clinical weakness when 
immunised with Torpedo AChR, despite evidence of serum 
anti-AChR antibodies and reduced m.e.p.p. amplitudes 
(Green et al? 1975? Alema et al, 1981).
Mild EAMG has been induced in Lewis rats by 
immunisation with individual subunits of Torpedo AChR. 
Using high doses (50ug) and frequent boosters (4-5 over 
7-10 weeks), Lindstrom et al., (1978, 1979) were able 
to show that all of the subunits were immunogenic 
although the Of and 6 subunits proved to be the most 
effective. This is in contrast to the efforts of the 
same and other groups (Lindstrom et al, 1978? Mehraban 
et al, 1982? Dolly et al, 1983) who were unable to 
induce EAMG by immunisation of rabbits with AChR 
subunits. Claudio and Raftery (1977, 1980 a, b) also
failed to induce clinical EAMG in rats or rabbits by 
similar means.
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Clinical EAMG in rats immunised with eel AChR in 
CFA becomes apparent about 1 month after the initial 
injection (Lennon et al, 1975). Weakness persists 
until the animal dies but it may survive and remain in 
this condition for more than 80 days (Lindstrom, 1977). 
The clinical features of chronic EAMG in rats closely 
resemble those of MG in humans.
Lewis rats immunised with eel AChR, together with 
both B.pertussis and CFA, develop a transient acute 
phase of muscular weakness between 8 and 11 days after 
the injection. Although this stage is characterised by 
massive phagocytic infiltration of the muscle endplates 
(Engel et al, 1976 a,b), weakness lasts only for a few 
days before the animal regains clinical normality. 
This apparent normality is maintained until the onset 
of the chronic phase of EAMG, 30 days after 
immunisation. It is not known whether the acute phase 
is an artifact of the use of pertussis, or whether the 
additional adjuvant enhances cellular mechanisms that 
normally occur in EAMG. It is of interest that acute 
EAMG can be induced in the absence of pertussis in 
rabbits injected with Torpedo AChR (Fumagalli and 
Clementi, 1978) and in mice injected with denatured rat 
muscle AChR (Granato et al, 1980) .
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6.4 Mice
The involvement of genotype in the susceptibility 
of animals to EAMG is highlighted by the use of the 
various inbred, congenic and recombinant strains of 
mice that are available. Fuchs et al. , (1976)
demonstrated that 10 (out of 14) strains of mice that
*  u  J
developed EAMG possessed haplotypes H-2 , H-2 , H-2
and H-2 of the major histocompatibility complex (MHC).
Haplotypes H-2^ and H-2S were shown to be present in
resistant strains (Fuchs et al, 1976). This strain
dependence of clinical weakness was later confirmed by
Berman and Patrick, (1980 a,b; Berman et al, 1981) who
also showed that specific haplotypes, particularly 
b bH-2 , Ig-1 accounted for the incidence of paralysis.
An additional experimental advantage that mice 
offer as an animal model of EAMG is their well
characterised and manipulatable immune system. In 
early studies of congenic mice by Christadoss et al,
(1981) , clinical muscle weakness and mean m.e.p.p. 
amplitude reduction correlated well with the mean
cellular immune responses to Torpedo AChR mice. De
Baets et al, (1982), showed that the magnitude of the 
in vitro cellular response to Torpedo AChR was directly 
proportional to the total amount of serum anti-AChR
antibody and severity of disease as measured by muscle 
AChR content. However, in a later study, Christadoss 
and colleagues failed to demonstrate a correlation
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between AChR-specific lymphocyte responses and muscle 
AChR loss when individual B6 mice were tested 
(Christadoss et al, 1985).
Anti-AChR responses, both cellular and humoral, 
and susceptibility to EAMG were found to be I-A region 
(MHC) controlled (Christadoss et al, 1981). Anti-(la 
antigen) antiserum can eliminate or partially suppress 
proliferative responses against the AChR (Christadoss 
et al, 1981, 1982, 1983a; Waldor et al, 1983). More
detailed discussion of murine cellular responses in 
EAMG will follow later. The review of Harrison and 
Behan (1986) concluded that the variation in strain 
susceptibility may depend upon differences in the 
specific anti-AChR immune response, rather than on 
differences in neuromuscular transmission sensitivity.
6.5 Mode of action of anti-AChR antibodies
Impaired neuromuscular transmission in EAMG, and 
indeed in MG, has been considered by many workers to 
result from a decrease in the number of active 
receptors at the muscle endplate. Experiments in which 
rats have been injected with immunoglobulin from 
'chronic-phase EAMG1 rats i.e. passive transfer, have 
indicated that anti-AChR antibodies play a major role 
in the decrease in the number of functional receptors 
(Toyka et al., 1975, 1977, 1978, 1980).
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Although it is generally assumed that anti-AChR 
antibodies play an important part in the pathogenesis 
of EAMG, inconsistent results have been obtained in 
correlating the impairment of neuromuscular 
transmission with anti-AChR antibody titre. The vast 
excess of antibody over receptor that may exist in the 
chronic phase (1000:1) (Lindstrom et al, 1976 a) 
appears to support the existence of particularly 
important sub-populations of antibodies. However, the 
recent report of Bionda et al, (1984) showed no 
difference between the isoelectric focussed patterns of 
serum anti-AChR antibodies and those eluted from the 
muscle of rats with EAMG.
Antibodies of particular importance in the disease 
process have been suggested as those that are directed 
against the acetylcholine binding site, so-called 
anti-'site' antibodies. Anti-site antibodies are 
normally assayed by the level of blocking of 
(X -bungarotoxin to AChR. However, several groups have 
shown the presence of anti-'site' antibodies by using a 
modified radioimmunoassay which does not employ 
radiolabelled (X -bungarotoxin (which blocks the 
acetylcholine binding site). (Sugiyama et al, 1973; 
Lindstrom et al, 1976; Trotter et al, 1977; Alema et 
al, 1978). Binding of antibodies to sites around the
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acetylcholine binding site could result in blocking
access of the acetylcholine to the binding site (Barkas 
et al, 1982).
The existence of a single myasthenogenic 
determinant is made less likely by the observations 
(Lindstrom et al, 1978, 1979? Elfman et al, 1983) that 
all four subunits ( (X ,(3, 'jf, 5 ) of Torpedo AChR are
capable of inducing EAMG, despite observations to the 
contrary in a later study by Claudio and Raftery
(1980b). However, various groups of workers have 
described the induction of EAMG by the passive transfer 
of monoclonal antibodies directed at different 
'non-site' AChR antigens. (Richman et al, 1980; Burres 
et al, 1981, Gomez et al, 1981, Lennon and Lambert,
1981; Kamo et al, 1982; Gomez and Richman, 1985).
A phylogenetically conserved main immunogenic 
region (MIR) on the Of-subunit of Torpedo, eel, foetal 
calf and human AChRs has been described by Lindstrom 
and colleagues (Tzartos and Lindstrom, 1980? Tzartos et 
al, 1981, 1983, 1985; Lindstrom et al, 1981, Lindstrom, 
1982, 1984) which is distinct from the acetycholine and 
toxin binding site. The majority of anti-AChR 
antibodies (approximately 60-70%) in experimental rats 
(Tzartos and Lindstrom, 1980? Tzartos et al, 1981,
1983) and in MG patients (Tzartos et al, 1982) are 
directed to this region.
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While the antibody binding site(s) on the AChR is 
graduallly being determined, the way in which the 
antibody reduces the functional ability of the receptor 
remains unclear. The studies carried out so far have 
been comprehensively reviewed by Harrison and Behan 
(1986) .
As for MG itself, the mechanisms by which these 
anti-AChR antibodies act have been suggested to be:
i) Direct block of AChR function.
ii) Increased degradation or decreased synthesis of 
the AChR, or both.
iii) Complement-mediated lysis
or any combination of these possible mechanisms, 
i) Direct Block of AChR function
The pathogenic activity of anti-AChR 
antibodies may reside in their ability to reduce 
or inhibit the electrophysiological response, or 
their inhibition of the binding of cholinergic 
ligands. The electrophysiological response to 
carbamoylcholine after pre-incubation of isolated 
eel electroplaques with rabbit (Patrick et al, 
1973; Sugiyama et al, 1973? Penn et al, 1976; 
Karlin et al, 1978), or rat and goat
172
(Lindstrom et al, 1976, 1977) anti-eel AChR
antisera has been found to be inhibited. 
Complement is not involved (Lindstrom et al, 1977) 
and toxin binding activity is only slightly 
impaired (Lindstrom et al, 1977; Karlin et al,
1978).
Various reports have suggested that 
inhibition of the electrophysiological response 
may be due to a freezing of the ion channel in a 
closed conformation (Hess et al., 1975; Karlin et 
al., 1978; Desouki et al. , 1981). Inactivation
of the ion-channel may also be due to uncoupling 
of the active site and the ion-channel by binding 
of antibody to a site distinct from the 
acetylcholine or toxin binding sites. (Eldefrawi 
et al., 1978; Eldefrawi and Eldefrawi, 1980).
Anti AChR antibody inhibition of the binding 
of (X-toxin or cholinergic ligand to membrane 
bound receptor has yielded variable results 
(Lindstrom et al, 1976, 1977; Sanders et al, 1976; 
Eldefrawi et al, 1979; Martinez-Carrion et al, 
1981; Farach et al, 1982; Desouki et al, 1983), 
although findings with solubilised eel or Torpedo 
AChR have been more consistent. Autologous 
antibodies (Penn et al, 1976; Aharonov et al, 
1977; Zurn and Fulpius, 1977; Karlin et al, 1978; 
Claudio and Raftery, 1980a), or Ffab'^ fragments 
(Wonnacott et al, 1980) have yielded 50-100%
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inhibition of (X-toxin binding to detergent 
solubilised AChR, similar results being found for 
the inhibition of acetylcholine binding (Sanders 
et al, 1976).
Inhibition of tf-toxin binding to soluble or 
membrane bound Torpedo receptor has been shown by 
using Fab fragments (Martinez-Carrion et al, 1981; 
Farach et al, 1982) and by using whole antisera or 
Fab fragments (Claudio and Raftery, 1980a). It 
was proposed that antigenic modulation of the AChR 
was unlikely to account for the observed block of 
AChR function following these observations 
(Claudio and Raftery, 1980a).
Anti-'site1 antibodies have been suggested to 
be physiologically important in the pathogenesis 
of EAMG (Zurn and Fulpius, 1977; Claudio and 
Raftery, 1980 a,b) despite observations in passive 
transfer experiments to the contrary (Lennon and 
Lambert, 1980, 1981; Richman et al, 1980; Gomez et 
al, 1981; Kamo et al, 1982).
Evidence exists both for the inhibition of 
agonist-mediated responses without affecting the 
acetylcholine binding site and also for the direct 
blockade of binding of (X -toxin or cholinergic 
ligands to their binding sites. Whether the 
pathogenic effect is produced by antibodies 
directed at the acetylcholine binding site, at an 
adjacent site, or both, remains unclear.
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ii) Receptor turnover
The dynamic replacement of receptor in the 
membrane has been followed by using radiolabelled 
IX -bungarotoxin and measuring the release of 
radioactivity into the extracellular fluid
(Devreotes and Fambrough, 1975). Studies with 
normal muscle cells have shown that the half-lives 
of both junctional and extra-junctional receptors 
are reduced in the presence of anti-receptor 
antisera (Heinemann et al, 1978; Reiness et al,
1978). A two-fold increase in the rate of 
degradation of both junctional and
extra-junctional receptor has also been observed 
in the diaphragm tissue of rats with chronic EAMG 
in comparison to normal controls (Merlie et al,
1979).
Increased degradation of the receptor in 
cultured rat muscle cells was earlier shown to be 
caused by IgG purified from rat anti-eel AChR 
antiserum from animals with EAMG (Heinemann et al, 
1977) . This was prevented at 223C or by the 
presence of metabolic inhibitors. Accelerated 
degradation of AChR on cultured muscle cells was 
induced by anti-AChR IgG (Lindstrom and Einarson, 
1979) and (Fab^ fragments, Prives et al, (1979) 
but not by Fab fragments (Lindstrom and Einarson,
1979).
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Fumagalli and co-workers (Engel and 
Fumagalli, 1982? Fumagalli et al, 1982) found 
that increased receptor degradation may be 
accompanied by a relative decrease in receptor 
synthesis 'in vivo', and suggested that a 
disorganised cytoskeleton or post-synaptic 
membrane may prevent the 'normal' rate of 
replacement.
iii) Complement
The role of complement in EAMG was indicated by 
Toyka et al (1977) and Howard and Sanders (1980) who 
showed that C-3 depleted mice and rats were less 
sensitive to the effects of the passive transfer of 
EAMG by human myasthenic sera. However, mice 
genetically deficient in C-5 were shown to react 
similarly to normal controls (Toyka et al, 1977) 
suggesting that lysis initiated by activation of C-5 
was not involved in the pathogenesis of EAMG. The role 
of complement in EAMG is however, equivocal. Ultra 
structural studies by Engel and colleagues showed the 
presence of IgG and C-3 on the junctional folds of 
Lewis rats injected with immunoglobulin from rats with 
EAMG and in EAMG rats themselves (Sahashi et al, 1978: 
Engel, 1979). However, Lennon (1978) was unable to 
show that serum from rats with EAMG could lyse cultured 
foetal rat muscle cells in the presence of complement.
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Which mechanism, or combination of mechanisms is 
involved in the pathogenesis of EAMG remains unsolved. 
It would seem very likely that, in a disease caused by 
many factors, the pathogenesis would occur as a result 
of various mechanisms.
6.6 Cellular reactivity in EAMG
One of the distinctions between the 'acute' and 
'chronic' phases of EAMG in rats is the presence of 
inflammatory cells or macrophages that infiltrate the 
muscle endplates in the acute stage (Engel et al, 
1976). Why phagocytic infiltration presumably caused 
by the IgG and C-3 bound to the membrane, is seen in 
the acute phase, and not in the chronic phase (in which 
IgG and C-3 are also present) is not known. Massive 
phagocytic invasion of the synaptic cleft is also 
observed in passive EAMG, and closely resembles that 
seen in acute EAMG (Engel et al, 1978) . This indicates 
that the cellular invasion in acute EAMG is not 
produced by anti-AChR cells, but by non-specific cells 
responding to bound antibody and complement. During 
the acute phase only, delayed-type hypersensitivity to 
intradermal injection of AChR occurs (Lennon et al, 
1976) . The importance of this hypersensitivity to the 
cellular events occurring at the endplates, is not 
known. Rats depleted of C-3 prior to injection with 
anti-AChR antibodies from chronic EAMG rats, or with 
purified AChR, do not show clinical signs of EAMG, nor
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do they show phagocytic invasion of the muscle 
endplates (Lennon et al, 1978).
A specific role for macrophages in the on-going 
pathogenesis of EAMG cannot readily be envisaged.
Lennon et al, (1976) showed, by cell depletion 
experiments in rats, that the response to AChR was 
T-cell dependent. Thymectomy and whole body 
X-irradiation followed by reconstitution with non-T 
cells only, prevented the development of anti-AChR 
antibodies or signs of EAMG (Lennon et al, 1976). 
These observations were supported by the report of 
Tarrab-Hazdai et al, (1975) who showed that the 
transfer of lymph node cells from affected animals 
could induce EAMG. Induction of EAMG by this adoptive 
transfer was shown to be suppressed by the removal of 
T cells from the donor cells (Fuchs et al, 1978).
Lymphocytes isolated from rats immunised with 
Torpedo AChR proliferate in response to both purified 
Torpedo AChR and unpurified rat muscle AChR (Noguchi et 
al, 1980). Further studies using murine lymph node 
cells showed that AChR-induced proliferation was 
blocked by alloantisera that identified a Lyt-l+ ,23 
helper T cell (Christadoss et al, 1981). Stimulation 
of the T cells was shown to be dependent on 
macrophages, a later study indicating that macrophages 
presented the AChR to specific T cells in association 
with la antigen on the surface of the macrophage 
(Christadoss et al, 1982).
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AChR-activated blast cells (Hohlfeld et al, 1981a,b; 
Wekerle et al, 1981) and AChR-activated murine
lymphocytes (Christadoss et al, 1981; Bogen et al,
1984) have been identified in different assay systems 
as helper T cells. The study of DeBaets et al, (1982) 
identified the proliferative cell in the in vitro 
anti-AChR response as a helper T cell, both
phenotypically and functionally. Reasonable
correlation was observed between the in vivo anti-AChR 
antibody responses, in vitro anti-AChR production and 
the loss of muscle AChR. Both T helper cells and 
macrophages were found to be necessary for.the observed 
effects (DeBaets et al, 1982). Defective macrophage
activity in the adherent cell population of mice with 
EAMG was suggested as a possible cause of the reduced 
T-cell mitogen responses of the affected animals 
(Christadoss et al, 1983b). Excessive suppression of 
the Con-A induced T cell response was observed by 
AChR-sensitised macrophages, whereas AChR-sensitised T 
cells responded normally to Con-A in the presence of 
non-sensitised, syngeneic macrophages (Christadoss et 
al, 1983b). The cause of the expression of this 
macrophage suppression is not known, although
macrophage suppression has been observed in mixed 
lymphocyte responses (Weiss and Fitch, 1978), AMLR 
(Smolen et al, 1981) and mitogen induced 
lymphoproliferation (Raff and Hinrichs, 1977).
179
Pachner and Kantor (1984) and Bogen et al, (1984) 
have both described AChR-specific suppressor T cells in 
mice immunised with Torpedo AChR. Both groups 
underlined the possible importance of the specific 
suppression of the anti-AChR response in humans.
6.7 Choice of the rabbit model
The present study of the AMLR in EAMG was 
initiated using New Zealand white rabbits because these 
animals are susceptible to the disease (Patrick and 
Lindstrom, 1973) and provide a relatively good source 
of PBL which may be separated (Wilson et al, (1975b) . 
Repeated determinations on PBL from the same animal 
allow the longitudinal study of various parameters 
(Sheppard et al, 1977) . This is not possible with the 
low blood volumes of mice or rats, and the use of other 
organs as sources of T and non-T cells was considered 
to be less relevant.
12 six week old animals were immunised with AChR 
purified from Torpedo marmorata and levels of 
circulating anti-AChR antibodies were measured by 
R.I.A. Changes in the cellular immune responses of the 
rabbits were also studied during the induction and 
maintenance of the disease state. Although the humoral 
immune responses to heterologous AChR have been well 
documented (reviewed in Harrison and Behan, 1986), 
changes in immune cellular properties following the 
induction of EAMG have not been so extensively studied.
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The alterations in cellular responses in rabbits with 
EAMG are the subject of this section.
Although the immune systems of mice and man have 
been investigated in detail, much less is known about 
the participating cells in rabbit immune responses. 
The advantages and disadvantages of studying the rabbit 
immune responses are summarised below:-
Advantages
i) Responses of rabbit PBL to PHA and Con-A are 
well-documented. (Teodorescu et al, 1976? Ozer
and Waksman, 1974; Shek et al, 1974).
ii) An AMLR has been demonstrated between mesenteric
lymph node cells (responders) and autologous 
spleen cells (stimulators) (Watkins et al, 1984).
iii) Rabbit one-way MLR has been consistently
demonstrated with PBL, and AMLR may be induced in
PBL under certain circumstances (Milthorp and 
Richter, 1979).
iv) Rabbit T cells have been phenotypically identified 
by anti-rabbit T cell monoclonal antibodies 
(McNicholas et al, 1981; Watkins et al, 1984).
v) Mouse anti-rabbit T cell ascites fluid (R.I.A.,
U.K. Limited) is commercially available
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vi) PBL can be repeatedly isolated from the same
animal in sufficient quantities, allowing 
longitudinal studies to be performed.
Disadvantages
i) Very little experimental data exist for rabbit 
AMLR.
ii) Difficulties in obtaining mixed lymphocyte 
reactions with rabbit PBL have been reported 
(Harrison et al, 1971; Knight et al, 1971; Ling 
and Kay, 1975; Sheppard et al, 1977; Watkins et 
al, 1984), although improved culture conditions 
may overcome this potential problem.
iii) Inbred strains are not available.
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7.0 METHODS
7.1 Iodination of 0( -bungarotoxin to high specific activity
Iodination of (X -bungarotoxin was carried out 
according to the method of Hunter and Greenwood (1962).
0.05M potassium phosphate, pH 7.5, (reaction buffer, 
250ml), and 0.01M potassium phosphate, pH 7.5 (elution 
buffer, 100ml) containing 1% (w/v) bovine serum albumin 
were prepared as stock solutions and stored at 4°C. 
Immediately prior to use, solutions of chloramine T 
(5mg/ml, 10ml), sodium metabisulphite (0.16 mg/ml, 
10ml) and potassium iodide (lOmg/ml, 10ml) were 
separately prepared in reaction buffer.
Sephadex-G25 (4g) was allowed to swell in reaction
buffer (30ml) for 30 min and packed in a glass column
(lcm x 30cm) . The packed column was washed with
elution buffer (30ml) and drained until the top of the
column was just covered with buffer. (X -bungarotoxin
(2.5 nmol) in 0.1M sodium phosphate buffer, pH 7.5 20ul
125was added to the reaction tube together with Na I 
(20|llX, 2mCi) . The reaction was started by adding 
chloramine T (10-1) and, after stirring for 60 sec at 
room temperature, was stopped by the addition of sodium 
metabisulphite (0.75ml) and potassium iodide (0.2ml). 
The reaction mixture was then transferred by glass 
pasteur pipette to the top of the column and allowed to 
drain in. The iodinated toxin was eluted from the 
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Of-bungaro toxin and free I from a
Sepbadex G-25 column.
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of the column eluate were collected. Aliquots (5^1) 
from each fraction were placed in stoppered LP2 tubes 
and counted for gamma emmissions in an LKB 1280 
Ultrogamma counter. Fractions corresponding to the 
major peak (Fig. 7.1) were collected.
A final specific activity of the pooled samples 
was typically found to be 760 Ci/mmol which represents 
approximately 80% incorporation of the radiolabel into 
the (X-toxin.
7.2 Preparation of the anti-AChR affinity column
Affinity columns used for the purification of AChR 
are most commonly prepared by coupling (X -toxin to 
activated agarose through some of the many lysine 
residues present on the toxin. Naja naja siamensis 
toxin is used because it is available in large 
quantities and its binding to AChR is more reversible 
than that of (X -bungarotoxin. The method of Lindstrom 
et al, (1981) was followed.
Sepharose 4B (2 50g wet beads) was washed with 
water (1-2L) under reduced pressure, and the beads were 
resuspended in water (500ml) at 10°C. The pH was 
adjusted to 11.0 with 2M NaOH and cyanogen bromide 
(25g) was added to the stirred solution, care being 
taken to maintain the pH at 11.0, (by addition of 
NaOH) and the temperature at approximately 103C. After 
all the cyanogen bromide had dissolved, the suspension
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was applied to a Buchner funnel. The beads were washed 
with ice-cold water (1L) followed by 0.2M sodium 
carbonate buffer pH 9.5, (2L) at 4*C. The beads were
not allowed to dry out at any time. They were then 
resuspended in 0.2M sodium carbonate buffer, pH 9.5 
(500ml) at 4°C and, while the suspension was gently 
agitated, the Of -toxin (lOmg/ml, in 0.1M sodium
phosphate, pH 7.5, 12.5ml) was added dropwise. The
suspension was agitated gently at 4°C overnight, after
which the absorbance (280nm) of the supernatant changed 
from an initial value of 0.265 to a final, complete
conjugation value of 0. Glycine (1M, 500ml) was added
and the suspension was left at room temperature
overnight with gentle agitation. The suspension was 
then poured into a chromatography column (3 cm x 20 
cm) , washed with lOmM potassium phosphate buffer
containing Triton X-100 (2% v/v), lmM EDTA and 0.02%
w/v NaN^ at pH 7.4 and stored at 4*C until use.
7.3 Preparation of AChR from Torpedo marmorata
Acetylcholine receptor was purified from the 
electric organs of the electric ray Torpedo marmorata 
by a modified method of Wonnacott et al, (1980).
Frozen electric organ (200-300g) was homogenised 
in 0.4M NaCl (300ml) containing lOmM potassium 
phosphate, lmM EDTA, and 0.02% (w/v) NaN^, pH 7.4
(buffer A) using a Sorvall Omnimix. The homogenised 
tissue was centrifuged at 100,000g for 30 min in a
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Beckman L5-50B Ultracentrifuge (S35 rotor). The 
pellets were resuspended in lOmM potassium phosphate
(300ml) containing 2% (v/v) Triton X-100, lmM EDTA, and
0.02% (w/v) NaN^, pH 7.4 (buffer B), stirred overnight
at 4°C and then centrifuged at 100,000g for 45 min 
(Beckman L5-50B, S35 rotor). The supernatant was
stirred with Naja naja siamensis (X -toxin coupled
covalently to Sepharose 4B (50ml packed beads) for 4 h 
at room temperature. The beads were then washed 
alternately with 200mM NaCl (1L) and 1M NaCl (1L) both 
containing 50mM potassium phosphate, 0.1% (v/v) Triton
X-100, lmM EDTA, and 0.02% (w/v) NaN3, pH 7.4. The
beads were packed into a chromatography column (3 cm x 
30 cm) and the AChR was eluted with 10 mM
benzoquinonium chloride, containing lOmM potassium 
phosphate and 0.1% (v/v) Triton X-100, pH 7.4. The
eluted AChR was passed directly onto a
equilibriated DE52 ion-exchange column (3 cm x 10 cm) 
and the eluate from this column was recycled onto 
the toxin-bead column. The eluates from both columns 
were recirculated in this way overnight at 4°C by using 
a Gilson peristaltic pump. The DE52 column was washed 
with lOmM potassium phosphate containing 0.1% Triton 
X-100, pH 7.4 and and AChR was eluted from this column 
with 1M NaCl (100ml) containing lOmM potassium 
phosphate, 0.1% Triton X-100, pH 7.4. The receptor 
preparation was assayed for protein content and 
CX -bungarotoxin-binding activity and extensively
dialysed against PBS, pH 7.2 before use in any 
immunisation procedures. The amounts of receptor
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present in the crude extract and in the supernatant 
from the toxin beads (after incubation) were determined 
by using the ammonium sulphate assay (Meunier et al, 
1972). The amount present in the final preparation was 
determined by using the toxin binding assay described 
by Schmidt and Raftery, (1973) . A summary of the 
purification for AChR may be seen in Figure 7.2.
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7.4 Determination of toxin binding activity in the crude
AChR preparation by the ammonium sulphate precipitation 
assay
For the assay of crude receptor preparations, an
ammonium sulphate precipitation assay has been
developed from the method of Meunier et al, (1972). A
125crude receptor sample (100^1) was mixed with I-
0( -bungarotoxin (Of-BGT) (1.5 nM, 50ml) and incubated
for 45 min at room temperature. Saturated ammonium
sulphate (133 nl) was added to yield a final
concentration (v/v) of 40%. The samples were left for
16 h at 4°C, before addition of 40% (v/v) ammonium
sulphate solution (1ml) and the samples were filtered
on Whatman GF/C filter discs. Each filter disc was
washed with 40% (v/v) ammonium sulphate solution (3ml)
and counted in an LKB 1280 Ultrogamma counter. The
specific binding was measured by carrying out all
assays in the presence and absence of 0.1M
125benzoquinonium chloride (50nl) , and the I- Of -BGT
that remained bound in the presence of this competing
ligand was defined as non-specifically bound. Receptor
125activity was expressed as the molarity of I- O' -BGT 
binding sites.
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7.5 DEAE - Cellulose Filtration Assay
Assay of purified acetylcholine receptor was 
performed by filtration on DEAE-cellulose discs, 
essentially as described by Schmidt and Raftery, 
(1973).
125Purified receptor (100|il) was incubated with I 
(X -BGT (1.5nM, 50jil) for 90 min at room temperature, 
in the presence and absence of 0.01M benzoquinonium 
chloride (50^1). The reaction was terminated by the 
addition of lOmM potassium phosphate (1ml, pH 7.4), 
containing 1% (v/v) Triton X-100, and 0.1% (w/v) bovine 
serum albumin. The sample was filtered through two 
DE81 cellulose filter discs (2cm diameter) and the 
discs were washed with the above buffer (3ml) . The 
discs were then counted in an LKB 1280 Ultrogamma 
counter and the specific activity calculated and 
expressed as above.
7.6 Preparation of the AChR for immunisation
The AChR prepared by affinity chromatography (see 
Results, p 198 for specific activity) was extensively 
dialysed against several changes of PBS, pH 7.2, (5L)
in Visking tubing at 4°C over 3 days. The dialysed 
AChR preparation was then filter-sterilised through a 
0.2nm sterile filter unit and stored at 4°C in sterile 
bijou bottles until used. A water-in-oil emulsion of 
the AChR was prepared by forcing the AChR preparation
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(1 vol) at the required concentration into Complete 
Freund's adjuvant (3 vol) by using a double hubbed 
glass syringe apparatus. An adequate state of 
emulsification was judged by the inability of a drop of 
the emulsion to disperse when placed on water. In all 
subsequent secondary immunisation procedures, the AChR 
protein in PBS was emulsified in Incomplete Freund's 
adjuvant (IFA).
7.7 Immunisation with the AChR
In an attempt to avoid a sudden, acute phase of 
EAMG in the rabbits, repeated low doses of AChR in 
adjuvant were given. Thus, AChR protein (80|ig) in PBS 
emulsified in CFA (1ml) was injected intra-muscularly, 
(0.5ml) in each hind limb, by a trained animal 
technician.
Subsequent secondary immunisations consisted of a 
similar protocol, except that AChR 50ug in IFA was 
injected, split between the two hind limb sites. Each 
AChR preparation had a specific activity of 
approximately 5pmol/ng.
All control rabbits were injected with an emulsion 
(lml) of PBS in CFA or IFA (1 vol : 3 vol) , split
between the two hind limb sites.
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7.8 Radioimmunoassay for rabbit anti-(AChR) antibodies
The radioimmunoassay for the detection of rabbit 
anti-(AChR) antibodies was a modification of the method 
of Lindstrom (1977).
Solubilised AChR from Torpedo marmorata (0.05nM)
125
in PBS was incubated with I- (X -BGT (0.5nM) in PBS
for 45 min at room temperature. Test serum (5nl) was
added, diluted when necessary with normal rabbit serum,
and the mixture was incubated overnight at 4°C, or for
2h at room temperature. Goat anti-(rabbit IgG)
antiserum (25-30jil) was added and a precipate was
allowed to form overnight at 4°C or for 2 h at room
temperature. The precipitate was separated by
centrifugation at 3000g for 10 min, the pellet was
washed twice with 0.01M NaCl containing 1% Triton
X-100, and counted in an LKB 1280 Ultrogamma counter.
Control samples were pre-incubated with 25mM
125benzoquinonium chloride before addition of I-
(X -BGT; the counts that remained after addition of
this competing ligand were defined as non-specifically
125bound. Titres were expressed as moles I- CX -BGT 
binding sites precipated per litre of serum.
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7.9 Isolation of rabbit peripheral blood leucocytes
Rabbit blood (20ml) was taken by cardiac puncture 
from an anaesthesised New Zealand white rabbit and 
collected in a sterile heparinised (400U) universal 
tube. The blood was mixed with sterile 3.5% (w/v)
dextran in PBS (pH 7.2) and incubated at 37°C for 30 
min, occasionally tapping the sides of the tube to 
dislodge any erythrocytes. The leucocyte-rich 
supernatant (8ml) was layered carefully onto a 
Ficoll-Hypaque density gradient (3ml) and centrifuged 
at 400g for 30 min. The band of leucocytes at the 
interface was harvested by using a sterile, glass 
Pasteur pipette and washed twice with RPMI 1640 before 
counting the cells in a haemocytometer counting chamber 
as described (Methods, p66 ). The cell suspension was
c
then resuspended to 3 x 10 cells/ml in RPMI 1640.
7.10 Preparation of antibody-coated ox red blood cells
Antibody-coated ox red blood cells (ORBC) were 
prepared according to the method of Ling et al, (1977), 
with slight modifications. ORBC in Alsevers' solution 
were washed five times in PBS by centrifugation at 200g 
for 10 min, taking care to remove the buffy coat cells 
after each wash. The packed erythrocytes were 
resuspended to 10% (v/v) in RPMI 1640. Goat anti-mouse 
IgG (3ml, lmg/ml) was added to the washed ORBC (10ml) 
and mixed well. During mixing, matured chromic
chloride solution (6ml, O.lmg/ml, pH 5.0) was added 
dropwise and mixing was continued for a further 10 sec. 
The red cell suspension was covered with PBS (1ml) and 
left to incubate at 4°C overnight. The supernatant was 
removed, the ORBC-antibody conjugate (EA) was washed 
twice with RPMI 1640, and then resuspended to 2.5% 
(v/v) in RPMI 1640. The EA conjugate was suitable for 
use for up to 2 weeks in this condition.
11 Separation of rabbit T and non-T leucocytes
The isolated rabbit PBL suspension was pelleted by 
centrifugation at 200g for 15 min in a sterile, 
V-bottomed centrifuge tube. The pelleted cells were 
resuspended in a minimal amount of medium and mouse 
anti-rabbit T cell IgG in PBS was added at a ratio of 
2jig of protein/10^ cells. The cell suspension was 
incubated on ice for 30 min and then washed twice in 
ice-cold RPMI 1640. Equal volumes of treated rabbit 
PBL cell suspension (3 x 10^ cells/ml) and 2.5% EA 
conjugate at 43C were mixed. Aliquots (3-4mls were 
placed in sterile centrifuge tubes and incubated 
overnight at 4°C. The supernatant was removed and the 
cell pellet was gently resuspended, by using a sterile, 
glass Pasteur pipette, in fresh RPMI 1640 (2ml). The
cell suspensions were combined, carefully layered (8ml) 
onto Ficoll-Hypaque density gradients (3ml) and 
centrifuged at 400g for 30 min. Non-T leucocytes were 
harvested from the interface with a sterile, glass 
Pasteur pipette, washed twice and resuspended to the
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required cell concentration in RPMI 1640. The 
overlaying density gradient was discarded and the T 
lymphocytes were recovered from the red cell pellet by 
incubation with 0.83% (w/v) NH^Cl - Tris buffer (10ml) 
(see Section 2) for 5 min at 23°C. The T cell 
population was washed twice and resuspended in RPMI 
1640 to the required cell concentration for plating 
out.
Non-T leucocytes and a sample of the T lymphocytes 
were inactivated by irradiation (2500 rad) by using a 
^ C o  gamma ray source. Culture conditions and 
harvesting and pulsing procedures were as described for 
the human AMLR cultures (Methods, p68 ).
7.12 Purification of mouse-anti-(rabbit T cell) (MART-cell) 
immunoglobulin G from ascites fluid
The commercially obtained ascitic fluid (RIA U.K. 
Ltd., Tyne and Wear) was extensively dialysed against 
0.04M potassium phosphate containing 0.3M NaCl, pH 8.0 
(200 vol.). A DE52 column (5ml of DE52/ml of ascites) 
was equilibrated with the above buffer and the dialysed 
ascitic fluid was diluted with an equal volume of the 
buffer. The diluted, dialysed ascitic fluid was 
applied to the column and eluted with the buffer. 
Fractions (0.5ml) were collected arid the absorbance ' of 
the solution at 280nm was measured in a 
UV-spectrophotometer. The fractions containing IgG
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were pooled and the ^ g g  of the pooled fractions 
was measured. The concentration of IgG present 
was determined by dividing the observed A£gQ of 
the pooled fractions by the extinction coefficient 
of a solution of IgG (lmg/ml).
7.13 Treatment of cells with MART-cell antibody and 
complement
Cells were suspended in complete medium containing
7
10% FCS (v/v) at a concentration of 1 x 10 cells/ml. 
Cell suspensions were incubated with MART cell antibody 
(0.5 mg/ml) at a ratio of 10|ig antibody/10 cells at 
room temperature for 20 min with occasional gentle 
mixing. Sterile guinea pig complement (2 vol. 1:4 
dilution) was then added with shaking, and the cells 
were incubated at 37°C for lh. Dead cells were removed 
by centrifugation (900g, lOmin) of the cells through 
FCS (Mishell and Shiigi, 1980), and the cell pellet was 
treated a second time with MART-cell antibody and 
complement in the same way.
Control experiments using normal mouse serum (NMS) 
and complement were performed as for the MART-cell 
antibody and complement as described above.
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8-° Results
The 'in vitro' lymphoproliferative characteristics 
of the rabbit immune system have not been as 
extensively investigated as those of mouse or man. 
Available data are based on the responses of the cells 
of the lymph nodes, spleen or thymus and other lymphoid 
organs (Wilson et al, 1976? Watkins et al, 1984).
The effects on the rabbit immune system resulting 
from the induction and maintenance of EAMG are 
presented.
8.1 The preparation of AChR from Torpedo Marmorata
Typical results obtained during the purification 
of the AChR from frozen tissue at (-80°C) from the 
electric organs of the electric ray, Torpedo marmorata, 
are shown in table 8.1.
As shown in table 8.1, greater than 99% of the 
receptor present in the crude extract bound to the 
Ot -toxin labelled Sepharose 4B beads. Recovery was 
approximately 70% in both preparations and specific 
activities of the purified receptor were 8.55 and 9.38 
pmol/ng.
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Table 8.1: The results of two preparations of AChR from
the frozen electric organs of Torpedo Marmorata.
TOXIN BINDING (NON-BOUND) 
(pmol/ml)
EXPT. 1 EXPT. 2
FROZEN TISSUE WT. (g) 300 250






PROTEIN CONC. (DE-52 ELUATE) 
(ug/ml)
1500 704












Numbers in brackets represent the volumes (ml) of each sample as 
the crude extract and DE-52 column eluate containing the 
major toxin binding activity.
* Ammonium Sulphate Assay
+ DEAE Filtration Assay
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8.2 Separation of rabbit PBL: Assay selection
The use of a 3.5% solution of Dextran in 0.9% 
saline cleanly removed the rabbit RBC from the whole 
blood sample. Following application of the leucocyte 
rich supernatant to a Ficoll-Hypaque gradient to remove 
any residual rabbit RBC, a yield of 2.2 ± 0.6 (mean ±
g
S.D.) x 10 PBL per ml of whole blood was obtained, 
over 60 determinations.
Various methods for separating rabbit T and non-T 
leucocytes were investigated. Table 8.2 represents the 
efficacy of each of these treatments. As shown in 
Table 8.2 all the rosetting methods using native, 
enzymically or chemically-treated autologous rabbit 
RBC, SRBC or ORBC yielded very low numbers of rosette 
forming cells.
Only those ORBC which had been coupled to goat 
anti-mouse (GAM) antibody by the chromic chloride 
method of Gold and Fudenberg (1967) , and then 
indirectly rosetted with mouse anti-(rabbit T cell) 
antibody (MART antibody) produced strong rosettes 
containing greater than 3 red cells per lymphocyte. 
Following separation from non-rosetted non-T cells on a 
Ficoll-Hypaque gradient, the rosettes yielded cell 
populations which responded vigorously to stimulation 
by Con-A. Cells at the interface (non-rosetted), on 
the other hand, responded very poorly to stimulation by 
the T cell mitogen Con-A.
The Cell Surface Markers and mitogen responses of rabbit PBL after various rosetting technieques
TABLE 8.2
METHOD RED CELL WHOLE PBL WHOLE PBL Con-A RESPONSE
% MART +ve % Smlg +ve OF PELLET CELLS
(cpm)
NATIVE AUTOLOGOUS RABBIT 10 52 5025
PAPAIN-TREATED
AUTOLOGOUS
RABBIT 10 50 5340
NEURAMINIDASE
AUTOLOGOUS
RABBIT 15 51 5999








MART/GAM TREATED OX 42 52 36256
KEY: MART/GAM; mouse anti-rabbit T cell/goat anti-mouse double antibody method
2-AET; 2-aminoethylisothiouronium bromide hydrobromide
PBL; Peripheral blood lymphocytes
Smlg + ve; Surface membrane Immunoglobulin positive cells
MART + ve; Mouse anti-rabbit T cell positive staining cells
Con-A RESPONSE 












In contrast, PBL populations rosetted with either 
native, papain-treated or neuraminidase treated 
autologous RBC showed similar Con-A responses for both 
the interface and the pelleted cells, indicating that 
very little fractionation of T cells from non-T cells 
had occurred. Attempted cell fractionation using 
AET-treated autologous rabbit RBC, papain-treated SRBC, 
or papain-treated ORBC also showed little or no 
separation of T cells from non-T cells. In these 
cases, low Con-A inducible responses were found in the 
cells isolated from the cell pellet and high Con-A 
responses were found in the cells taken from the 
interface, following Ficoll-Hypaque density gradient 
fractionation.
In view of the above results, the indirect double 
antibody method was chosen for use as a means of 
routinely separating rabbit T and non-T cells.
8.3 Identification of separated cell types
In an attempt to support the results of the 
previous experiment, the MART/GAM-ORBC purified T cells 
were treated with mouse anti-rabbit T-cell antibody and 
complement (Methods, p196 ) , and then tested for their 
ability to respond to Con-A and anti-immunoglobulin 















Figure 8. 1 The mitogenic proliferative responses of 
purified putative T cells and non-T cells to Con-A and 
anti-Ig ( Cf-Ig) antibody. Purified T cells (2 x 105 
or non-T cells (2 x 10^) were incubated for 4 days in 
complete medium containing 10% FCS (v/v) and 
sub-optimal concentrations of Con-A (4ug/ml) or anti-Ig 
(50ug/ml). Each bar represents the mean response of 
three individual normal rabbit T-cell and non-T cell 
populations ± s.e.m. Pre-treatment with MART cell 
antibody plus complement or normal mouse serum (NMS) 
plus complement was performed as described (Methods,
P 196 > .
Legend 
186: Con-A.
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As shown in figure 8.1, treatment of the purified 
T cells with MART antibody plus complement resulted in 
complete abrogation of the Con-A induced T cell 
response. This, together with the completely absent 
response to anti-Ig antibody treatment indicates that 
the MART/GAM-ORBC rosetting population is indeed the T 
cell population. Treatment of the T cells with normal 
mouse serum plus complement did not affect the 
mitogenic responses of the T cells, and no changes in 
the non-T cell mitogenic responses were observed as a 
result of the anti-T cell antibody plus complement 
treatment.
8.4 The development of culture conditions for the 
rabbit AMLR
Following the establishment of a satisfactory 
method for the separation of T and non-T cells, the 
conditions required for optimal cell proliferation in 
the normal rabbit AMLR were determined.
Preliminary studies showed only a low 
proliferative response in the rabbit AMLR and 
enhancement of the AMLR by optimisation of the culture 
conditions was considered essential. The effects of 
FCS, NU-SERUM, and autologous rabbit serum as culture 
medium supplements were accordingly investigated. 
Figure 8.2 shows the effect of 2.5% - 25% serum 
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Figure 8.2 The effect of FCS, NU-SERUM and ARS on the
5
AMLR proliferative response. Rabbit T cells (1x10 ) and
irradiated (2500 rad) autologous rabbit non-T cells
5 o(1x10 ) were incubated at 37 C for 9 days in complete
medium (200pl) containing FCS, NU-SERUM, or ARS at
concentrations of 2.5%, 5%, 10%, 20% and 25% (v/v).
Each point represents the mean of three individual
rabbit PBL responses - s.e.m.
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The proliferative responses observed in the 
presence of a range of concentrations of autologous 
rabbit serum (ARS) were substantially lower than those 
in the presence of NU-SERUM or FCS. Of the latter two 
supplements, FCS gave the higher responses and so was 
chosen for subsequent experiments.
8.5 The effect of cell concentration and ratio of T- 
to non-T cells
T cells at concentrations of 0.5 x 10^ cells/ml,
6 61.0 x 10 cells/ml, and 2.0 x 10 cells/ml were
incubated with non-T cells at concentrations between
0.5 x 10^ cells/ml and 2.5 x 10^cells/ml, as shown in
figure 8.3. The combinations of the T cells and non-T
cells at these concentrations yielded T cell to non-T
cell ratios of between 1:5 and 4:1.
Optimal proliferative responses were yielded by T
cells and non-T cells at equal concentrations, both at
6 6 1 x 10 cells/ml and 2 x 10 cells/ml. The cultures
c
containing 0.5 x 10 cells/ml of T cells generally 
yielded lower AMLR responses.
Thus, for routine rabbit AMLR cultures, T cells
g
and non-T cells both at cell concentrations of 1 x 10 
cells/ml, in complete medium containing 20% FCS, were 
employed.
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Figure 8.3 The effect of different cell
concentrations and ratios of T cells to autologous, 
irradiated (2500 rad) non-T cells on the rabbit AMLR.
T cells (lOOul) at concentrations of 0.5 x 10^
6 6 cells/ml, 1.0 x 10 cells/ml, and 2.0 x 10 cells/ml
(arrows) and irradiated (2500 rad), autologous non-T
g
cells (100nl), at concentrations between 0.5 x 10
g
cells/ml and 2.5 x 10 cells/ml, were incubated in
complete medium containing 20% FCS (v/v) at 37°C for 9 
days.
Each point represents the mean, peak proliferative AMLR 
response (± s.e.m.) of cells from three normal rabbits. 
Each individual rabbit AMLR response was represented by 
the mean of quadruplicate AMLR cultures minus the sum 
of the AMLR of T cells cultured with irradiated (2500 
rad) , autologous T cells and that of irradiated (2500
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8.6 AMLR in normal and EAMG rabbits
The rabbit AMLR presents a much lower 
proliferative response than that observed in the human 
equivalent, ranging between 252Acpm and 452 Acpm 
( 359 ± 10.6, 39; mean ± s.e.m. , n) for the normal
rabbit. Figure 8.4 shows the scatter of normal, 
pre-immunisation responses and post-immunisation 
responses.
The kinetic AMLR response for normal rabbits shown 
in figure 8.5 (a) resembles the AMLR proliferative 
response observed in the normal human PBL population. 
However, as already noted the magnitude of the rabbit 
AMLR response is dramatically reduced in comparison to 
that observed in the human. Also, the peak AMLR 
response appears to occur slightly earlier than the 
human peak AMLR response, appearing rapidly between 
days 5 and 6 rather than gradually between days 4 and 
7.
Figure 8.6 shows the kinetic AMLR response of a 
rabbit with EAMG. This response was considered to be 
representative of the kinetic AMLR responses shown by 
myasthenic rabbits and has a profile which is different 
in many ways to that seen in normal rabbits. Very 
little proliferation occurs before day 5 of the culture 
period and no distinct, rapid increase is observed 
after this time point. A small, gradual increase in 
the proliferative response occurs, with a plateau
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Figure 8.4 A scatterplot of the peak AMLR 
proliferative responses observed between T cells (1 x
5
10 ) and irradiated (2500 rad), autologous non-T cells
5
(1 x 10 ) , for six control rabbits and for rabbit 
numbers 57-62 at the various stages of the immunisation 
procedures. Each point represents the peak AMLR 
proliferative response during the 9 day culture period, 
irrespective of the day on which it occurred. Each 
point represents the mean of quadruplicate AMLR 
cultures. The horizontal bars represent the means of 












Figure 8.5 The kinetic AMLR response of
5
a) Normal rabbit T lymphocytes (1 x 10 ) and 
autologous, irradiated (2500 rad) non-T leucocytes 
(1 x 10^) in complete culture medium (200ul).
Figure 8.6
5
Myasthenic rabbit T lymphocytes (1 x 10 ) and 
autologous, irradiated (2500 rad) non-T leucocytes
5
(1 x 10 ) in complete culture medium (200nl) .
Each point represents the mean of quadruplicate 
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rather than a peak at the time of the maximal 
proliferation. This plateau occurs later than the peak 
observed in normal rabbits and decreases to a lower 
value on day 9 than its normal counterpart. Overall, 
the profile is flat and the peak response is of a low 
magnitude for the AMLR in rabbits with EAMG.
8.7 Longitudinal studies of immunised rabbits
The effects of the induction and maintenance of 
EAMG on the humoral and cellular immune responses of 
rabbits 57-62 are shown in figures 8.7 - 8.12. The
upper diagram (a) of each figure represents the 
anti-AChR antibody titre development and the 
longitudinal monitoring of the AMLR. The lower diagram 
(b) of each figure represents the mitogen-induced 
cellular proliferative responses for Con-A and PHA-P at 
sub-optimal concentrations.
8.7.1 Anti-AChR antibody titres and physical 
state
The humoral responses to the immunisation with 
solubilised AChR from Torpedo marmorata appear to fall 
into two groups.
i) those rabbits which develop substantial titres 
following the initial antigenic challenge and,
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ii) those rabbits which develop substantial titres
only after the second, 'booster* immunisation.
The former group consists of rabbits 58, 59 and 
60, all of which had post-primary immunisation serum 
titres of at least 30nM anti-AChR antibody. Detectable 
anti-AChR antibody levels were present 3 weeks after 
the initial immunisation in all three of these rabbits.
A peak anti-AChR antibody level occurred 6 weeks 
after the initial immunisation in all of the rabbits 
except rabbit 62, which showed a peak at week 5. 
Following the booster immunisation in week 7, 
substantial responses were detectable in all of the 
rabbits. However, rabbits 58 and 59 which had 
previously exhibited substantial humoral responses 
following the initial immunisation, rapidly developed 
acute EAMG and had to be destroyed. Rabbits 57, 60, 61 
and 62 gradually developed substantial humoral 
responses of the order of 30-60nM serum anti-AChR 
antibody. Clinically, these four animals exhibited the 
classical characteristics of EAMG in rabbits, drooping 
neck and ears and slight paralysis of the fore and hind 
limbs. Loud respiratory noises may have been due to 
laryngeal paralysis and these often disappeared when 
muscular strength was regained. Clinical signs were 
not apparent until after the second immunisation in any 
of the rabbits.
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The continually increasing humoral response 
following the secondary immunisation in rabbits 57, 60 
and 61 did not result in such a marked decline in these 
animals' well-being, symptoms being restricted to 
drooping neck and ears.
8.7.2 The AMLR
AMLR responses for those rabbits in which EAMG was 
induced were studied over a 16 week period (Figs. 8.7 - 
8.12). Each point represents the peak proliferative 
response during a nine day AMLR culture. Cellular 
responses were studied for each animal at two-weekly 
intervals to allow the animal to recover from the 
cardiac puncture procedure.
No significant differences could be seen in the 
AMLR responses from week to week for any individual 
rabbit, except for rabbit 62. Following a slight 
increase in the somewhat lower than normal AMLR 
response at week 4, a substantial decrease in the AMLR 
occurred between week 10 and week 12. This 
corresponded with a marked decline in the physical 
well-being of rabbit 62, paralysis of the hind limbs 
and an apparent loss of appetite being notable at this 
time.
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All of the rabbits exhibited AMLR over the 
longitudinal study which were significantly different 
from those observed in the normal group. Figure 8.4 
shows a scatterplot of all the pre-immunisation 
(including control rabbits) AMLR responses and those 
AMLR responses observed following the primary and 
secondary immunisations.
The mean peak AMLR response following the initial 
immunisation are statistically significantly decreased 
(P < 0.04) whereas the mean peak AMLR response
following the second immunisation procedure was not 
significantly decreased. Rabbits 57 (Figure 8.7 (a)),
59 (Figure 8.9 (a)), and 61 (Figure 8.11 (a)) all
exhibited AMLR responses which gradually increased 
towards normal, pre-immunisation levels following the 
significant initial decrease. Rabbits 58 (Figure 8.8 
(a)) and 60 (Figure 8.10 (a)) both exhibited
significantly reduced AMLR which remained low 
throughout the study period.
8.7.3 Proliferative responses of rabbit T cells
Concurrent with the monitoring of the humoral and 
AMLR responses, the responses of rabbit T cells to the 
mitogens Con-A and PHA-P were studied. These responses 
are shown in Figs. 8.7-8.12.
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As with the AMLR, the proliferative responses of 
rabbit T cells to the mitogens Con-A and PHA-P were 
substantially lower than those observed for human T 
cells. In contrast to the responses observed with 
human T lymphocytes, the responses induced by Con-A 
were greater than those induced by PHA-P. The PHA-P 
responses were generally unaffected by the induction 
and maintenance of EAMG. Con-A-induced responses 
showed greater variation during the period of study, 
the most dramatic changes being observed for rabbits 58 
and 62. For rabbit 58, a rapid decline in the response 
following the initial immunisation did not correlate 
with changes in any of the other cellular responses, 
although it did accompany an increase in anti-AChR 
antibody levels.
For rabbit 62, a rapid decline in Con-A induced 
responsiveness occurred following the second AChR 
immunisation, again concomitant with an increase in 
anti-AChR antibody levels. At a later stage in the 
study period, the AMLR responses of rabbit 62 also 
decreased.
Despite occasional fluctuations, the T cells 
isolated from the PBL of rabbits 57, 59 and 61 did not 
show any dramatic changes in mitogen induced 
responsiveness during the study period. This was 
reflected in the stability of the AMLR response 
throughout this period despite variations in levels of 
anti-AChR antibodies.
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Figures 8.7 - 8.12
a) Longitudinal studies of the anti-AChR antibody
titre ( • ■ ) and the AMLR response
( D - □  ) and,
b) the longitudinal studies of the Con-A response
( • • ) and the PHA-P response ( D — □  )
in normal rabbits following immunisation with 
Torpedo AChR in CFA and a booster immunisation of 
Torpedo AChR in IFA.
The AMLR, Con-A and PHA-P responses represent the 
means of quadruplicate cultures ± s.e.m. The 
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As shown in figure 8.13, no significant 
differences were observed between the pre-immunisation 
and post-primary or post-secondary immunisation Con-A 
induced responses of rabbit T cells. The 
pre-immunisation Con-A induced responses ranged from 
13,500Acpm to 48,500Acpm (31,900 ± 1,720, 29; mean ± 
s.e.m., n) whilst the post-primary immunisation 
responses ranged from 8,000Acpm to 47,500Acpm (32, 300 ± 
2,040, 23; mean ± s.e.m., n) and the post-secondary
immunisation responses ranged from 4,011Acpm to 48,051 
Acpm (27,041 ± 2,444, 22; mean ± s.e.m., n).
Similarly, no significant differences were 
observed between the pre-immunisation and post-primary 
or post-secondary immunisation PHA-P induced responses 
of rabbit T cells. The pre-immunisation PHA-P induced 
responses ranged from 9,000Acpm to 33,989Acpm (19,005 ± 
1,221, 29; mean ± s.e.m., n) whilst the post-primary 
immunisation responses ranged from 11,250Acpm to 32,500 
Acpm (21,400 ± 1,506, 24; mean ± s.e.m., n) and the
post-secondary immunisation responses ranged from 9,240 
Acpm to 33,003Acpm (18,751 ± 1,340, 23; mean ± 
s . e . m ., n ) .
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Figure 8.13 A scatterplot of the mitogen-induced
responses observed during the pre-, post-primary
(post-1*), and post secondary (post-2°) immunisation
periods. Sub-optimal concentrations of concanavalin-A
(Con-A) (4ng/ml) and phytohaemagglutinin-P (PHA-P)
5
(0.1%) were incubated with rabbit T cells (2 x 10 ) in 
complete medium (200^1) containing FCS (10% v/v). Each 
point represents the peak mitogen-induced response 
observed during a 5 day culture period, irrespective of 
the day on which it occurred. The horizontal bars 
represent the means of each group and the symbols 


































The ability to induce and maintain an animal model 
of MG does not guarantee the elucidation of the 
immunoregulatory changes that may occur during the 
development of this autoimmune state. The comparisons 
with the autoimmune state in man may also be limited. 
However, EAMG has provided a useful model for advances 
in therapeutic drug development and has enabled the 
confirmation of the hypothesis that MG is an autoimmune 
or immunopathologically mediated disease (Lisak and 
Zweiman, 1975). EAMG has proved to be an excellent 
model of the effects of the autoimmune response to AChR 
on neuromuscular transmission in MG, but investigation 
of the events that induce this response has been less 
successful.
Some of the immunoregulatory events in EAMG in 
vitro have been defined. These include antigen 
presentation to T helper cells by macrophages, T helper 
stimulation of primed B lymphocytes to antibody 
production and the observation that in vitro, the 
AChR-responsive T cell is both phenotypically and 
functionally a T helper cell (De Baets et al. , 1982) . 
The immune response to AChR in EAMG has been shown to 
be thymus dependent (Lennon et al., 1976), neither a 
full anti-AChR antibody response nor the development of 
weakness will occur in the absence of a thymus gland or 
T cells. One of the most critical questions that 
remains unanswered is what provides the primary and
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sustaining stimuli in human MG and how may endogenous 
control mechanisms be manipulated to suppress this 
anti-self response. Studies on the mechanisms 
regulating the immune responses to AChR in EAMG may 
provide approaches to establishing the cause and 
possible cure of MG.
Despite the wealth of immunological data that 
exists for the murine model of EAMG, and the 
established disease induction and maintenance protocol 
that exists for the rat model of EAMG, the rabbit model 
of EAMG was chosen for study. The rabbit model was 
chosen primarily because sufficient PBL could be 
obtained from each animal for a repetitive assay of the 
cellular immune responses. This was considered to be 
essential if comparisons with the human condition in MG 
were to be drawn.
9.1 Induction and maintenance of EAMG
Rabbits are one of the best species of animals 
available for the production of precipitating 
antibodies and are known to develop often fatal forms 
of EAMG. An intramuscular route for the immunisation 
of the emulsified AChR antigen was used, this being the 
route of choice for CFA. Previously published 
protocols involved subcutaneous or intradermal 
immunisation routes for rats and guinea pigs (Lennon et 
al., 1975), but CFA injected via those routes will 
cause ulceration of the site within 2-3 days and the 
loss of the antigen depot. The induction of EAMG was
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monitored by using the serum anti-AChR antibody titre. 
No clinical signs developed in any of the 
AChR-immunised rabbits until after the 'booster' 
immunisation.
Of the six rabbits in which EAMG was induced, two 
animals (numbers 58 and 59) had to be destroyed 
following the sudden development of muscular paralysis 
and breathing difficulties. Both of these rabbits 
exhibited high anti-AChR antibody titres shortly before 
the onset of the clinical signs. This observation is 
similar to that of Elfman (1984), who reported 
precipitous death in rabbits with EAMG, as a result of 
weakness of the lung muscles which led to pneumonia. 
However, rabbits 57, 60, 61 and 62 also developed
substantial anti-AChR antibody titres following the 
booster immunisation and survived, despite showing the 
classical signs of EAMG, such as paralysis of the hind 
limb muscles, drooping of the neck and ears, and loud 
respiratory noises. The rapidly developing humoral 
responses following the booster immunisation appeared 
to plateau during the latter stages of the study.
Thus, EAMG (as indicated by anti-AChR antibody 
titres and clinical signs), was induced in rabbits and 
maintained for six weeks. This was achieved by using 
AChR in adjuvant in dosages of 80|ig (400pmol toxin 
binding activity) for initial immunisations and 50ng 
(250pmol) for booster immunisations. These levels of
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AChR protein are relatively low in comparison to those 
commonly used in rats and mice (200ng) (De Baets et 
al., 1982; Christadoss et al., 1983a), which may 
account for the disease maintenance in an animal model 
which is noted for its difficulty in this respect 
(Elfman, 1984).
9.2 Cell separation
The investigation of cellular immune responses in 
any animal model may require the fractionation of PBL 
subsets. Indeed, the study of the AMLR necessitates 
the separation of non-T and T lymphocytes. Thus, in 
order to compare the AMLR responses of normal rabbits 
and myasthenic rabbits with those of normal and 
myasthenic humans, the separation of rabbit T and non-T 
leucocytes must be attained.
The separation of rabbit T cells from non-T 
leucocytes has been effected by using a rosette forming 
reaction between rabbit T cells and papain-treated 
autologous erythrocytes (Wilson et al., 1975a), similar 
to that observed between human T cells and sheep 
erythrocytes (Jondal, 1972). The report of Wilson et 
al., (1975b) claimed increased strengths of rosetting 
and increased numbers of erythrocytes bound per 
lymphocyte when the erythrocytes were pre-treated
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with papain. However, in the present study, use of 
identical conditions for the treatment of autologous 
erythrocytes and rabbit PBL gave no results comparable 
to those published by Wilson et al., (1975b). Table 8 
shows the various treatments of both autologous and 
heterologous erythrocytes and their subsequent 
rosetting characteristics. As shown in this table only 
10% of the whole leucocyte population rosette with 
papain-treated autologous RBC, the same percentage that 
rosette with native RRBC. Indeed, neuraminidase 
treated RRBC bind in greater numbers to rabbit T cells 
than do papain treated RRBC.
The most effective method of separation of rabbit 
T cells from rabbit non-T cells utilised an indirect 
rosette technique. Mouse anti-rabbit T (MART) cell 
antibody was used to identify rabbit T cells, and goat 
anti-mouse IgG coupled ORBC were used to rosette and 
select out the T cell population. Using this protocol, 
a Con-A responsive, MART cell positive staining 
population was fractionated from the PBL population. 
Abrogation of the Con-A responsiveness of this T cell 
population was accomplished by treating the selected 
cells with MART cell antibody plus complement.
Despite the use of the same antibody for 
identification and separation purposes, the mitogen 
responses (and their abrogation as described above) and 
the selection of a cell population whose proportion
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corresponds to that of the T cell population (see page 
200 ) t would appear to support the view that this 
separated population was the T cell population.
9.3 Culture conditions
In general, it has been found that rabbit 
leucocytes respond less vigorously or not at all in the 
MLR when compared to the responses of the cells of
other organs, notably the spleen (Knight et al., 1971? 
Ozer and Waksman, 1974; Ling and Kay, 1975). However, 
Milthorp and Richter (1979) presented evidence that
rabbit leucocytes responded well in the MLR and that an 
autologous MLR could be induced with modifications to 
the culture conditions.
Preliminary studies indicated that problems were 
associated with measuring the AMLR proliferative 
responses in rabbits. In an attempt to overcome these
problems, the culture conditions were modified in terms
of serum supplementation. The culture medium 
recommended in the report of Milthorp and Richter 
(1979) (RPMI 1640) was already in use in the assay 
system. Although the overall AMLR response in normal 
rabbits remained relatively low in comparison to that 
observed in normal human individuals, an increase was 
apparent upon increasing the FCS concentration, in 
contrast to the observation of Milthorp and Richter 
(1979).
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In contrast to human PBL, no significant 
differences in the AMLR were noted with changing cell 
ratios or cell densities, Indeed, only at low 
stimulating cell numbers was a decrease apparent in the
proliferative response. Optimal cell concentrations
5 5were 2 x 10 cells/well and 4 x 10 cells/well, the
optimal stimulating-to responding-cell ratio being 1:1
in both cases. This ratio was also found to be optimal
when culturing human PBL in the AMLR.
Despite the attempts to increase the degree of 
proliferation in the normal rabbit AMLR, the maximal 
net response attained was 452cpm. The mean normal 
rabbit response (see Figure 8.4) was 359cpm, 
approximately 30 fold lower than that observed in the 
normal human AMLR. Autologous MLR between normal 
rabbit PBL in the study of Milthorp and Richter (1979) 
represented the proliferation of whole PBL to 
mitomycin-C treated whole PBL. The system of Milthorp 
and Richter (1979), with 1 x 10^ responding and 0.5 x 
10^ stimulating cells yielded a proliferative response 
of approximately 600cpm. Taking into account a 10 fold 
increase in the number of responding cells, and a 5 
fold increase in the number of stimulating cells in the 
Milthorp and Richter study, the proliferative response 
observed in the normal rabbit AMLR in this thesis is 
higher.
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9.4 The normal rabbit AMLR
The proliferative response of normal rabbit AMLR, 
despite optimisation, was substantially lower than that 
observed in the controls for the normal human AMLR. 
Thus, the authenticity of the observed low response in 
the normal rabbit AMLR was only ascertained following 
numerous observations.
Considerable variation was observed in the normal 
AMLR responses, shown in the 'pre-immunisation state' 
group of Fig. 8.4, for both the control rabbits and 
those rabbits in which EAMG was to have been induced. 
However, the relative range of responses observed in 
the normal rabbit AMLR (252cpm to 452cpm; mean response 
359cpm) was substantially lower than those observed in 
the normal human AMLR discussed in the previous chapter 
(381cpm to 56384cpm? mean response 12228cpm).
The range of responses observed for the normal 
rabbit AMLR (Fig. & . A- , page 2(0, )is more normally 
distributed than the apparently skewed distribution of 
the normal human AMLR response (Fig. page (04 )♦
■_ Repeat assays of
both the rabbit (Figs. 8.7-8.12) and human (section 
5.7) AMLR's were consistently reproducible, confirming 
the different distributions in the two systems.
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The kinetic responses observed in the normal 
rabbit AMLR were similar in profile to those of the 
normal human AMLR. However, no detectable normal 
rabbit AMLR response occurred until day 6 in culture, 
in contrast to the observation of an AMLR after day 3 
in culture with normal human lymphocytes.
Whereas very little published data exist on the
normal rabbit AMLR, more data have been reported on the
mixed lymphocyte reaction (MLR) between the PBL of
different rabbits. Difficulties have been reported in
obtaining MLR using PBL (Harrison et al., 1971;
Knight et al., 1971), although MLR have been described
in New Zealand white rabbit PBL's (Sheppard et al.,
1977). The MLR reported by Sheppard et al. , (1977)
were interesting in that they fell into three main
categories? high responders (6,000cpm-9,OOOcpm
incorporated/culture), low responders
(1,000cpm-3,OOOcpm incorporated/culture), and
non-responders in which no incorporation of 
125 I-Uridine into newly synthesised RNA was found. The 
kinetics of the MLR of the responding rabbits PBL were 
also similar to those seen in the AMLR cultures of 
normal human individuals in the present study.
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The cellular mechanisms that account for the 
observed response in the rabbit AMLR can only be 
speculated upon here. The low responses observed for 
the AMLR in this report, and for the MLR noted 
elsewhere, may reflect a far less interactive cellular 
immune response in rabbits than that in man. Rabbits 
are well-known for their ability to generate antibodies 
and are used as such for research purposes. It may be 
that the rabbit depends far more than humans on an 
antibody mediated immune response. If this were the 
case, then what type of mechanism prevents an 
anti-antigen response from developing into a 
pathological anti-self response? The rabbit may depend 
on mechanisms described in the first chapter (section 
1) , such as anti-idiotypic responses, immune complexes 
and blocking factors. Other investigators have noted 
differences in the immune responsiveness of different 
populations of the same breed of animal, and 
population-specific differences cannot be excluded.
Despite the generally low AMLR's of the rabbit 
system, consistent differences were observed between 
the responses of normal and EAMG animals. Attempts to 
augment the normal rabbit AMLR were only partially 
successful. Augmentation of the normal rabbit AMLR by 
the use of FCS supplemented medium yielded some 
success, especially in comparison to the use of 
autologous rabbit serum. Ponzio (1980) augmented the 
syngeneic mixed lymphocyte reaction (the murine
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equivalent of the AMLR) in a range of inbred mice with 
4% polyethylene glycol. However, the use of such 
chemical augmentation was not considered to be
appropriate in this study.
The much lower AMLR response observed in normal 
rabbits, compared to that of normal humans, prevents 
any reasonable comparison between the possible 
immunoregulatory mechanisms that may occur in rabbits 
and that, speculated on in section 5, in humans. 
However, the low AMLR proliferative response in
rabbits, coupled with the relatively low mitogenic 
responses, suggests that the rabbit does not possess 
the level of immunoregulation that humans possess. A 
humoral form of immunoregulation, possibly utilising an 
idiotypic network or immune complex formation, or 
alternatively, a cellular form of immunoregulation may 
exist in rabbits which was not detectable with the
assay systems used in this study. Much of the work 
carried out on human immunoregulation followed similar 
studies in the murine system. Indeed,
the murine immune system has been suggested as 
exhibiting a high level of immunoregulation which is 
capable of complex feedback interactions (Eardley et 
al, 1978; Gershon et al, 1981? Green et al, 1983). 
Thus, it is possible that the rabbit immune system may 
possess an equally potent form of cellular
immunoregulation which was undetectable with the assay 
system employed in this thesis.
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9.5 Mitogen*induced responses of normal
rabbit PBL
Concurrent with the study of the AMLR in normal 
rabbits, the responses of normal rabbit T cells to the 
mitogens PHA-P and Con-A were studied. Figure 8.13 
shows the scatter of mitogen-induced T cell 
proliferative responses for normal rabbit PBL as the 
'pre-' group of responses. A considerable variation in 
the Con-A induced responses was observed; the
proliferative responses ranging from 13,500cpm to 
48,500cpm. This range is approximately half of the 
range observed when human T lymphocytes were stimulated 
under the same conditions. However, previous 
investigators have shown similar Con-A induced
proliferative responses. Sheppard et al. , (1976)
reported normal rabbit Con-A induced T cell 
proliferative responses of 16,935cpm to 19,757cpm. The 
same investigators reported normal rabbit PHA-P induced 
T cell proliferative responses of 5,071cpm to 
13,177cpm. The PHA-P induced responses of normal 
rabbit T cells studied in this thesis ranged from 
9,OOOcpm to 33,989cpm, similar in magnitude to those 
reported by Sheppard et al., (1976). The PHA-P induced 
T cell responses of normal human T cells described
earlier ranged between 26,204cpm to 158,746cpm, again 
highlighting the far higher degree of sensitivity to
stimulation that human PBL exhibit in comparison to the 
same types of responses exhibited by rabbit PBL.
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The results of lectin-induced proliferation and 
AMLR responses of rabbit T cells suggest that rabbit 
PBL are generally much less responsive to stimulatory 
signals than their human counterparts. This low 
responsiveness is difficult to explain given the 
paucity of data that presently exist on the
immunological responsiveness of the rabbit.
9.6 The rabbit AMLR in EAMG
Less published data exists for the study of rabbit 
AMLR in EAMG than was found for the study of the normal 
rabbit AMLR. No directly comparable data exists for
the autologous lymphocytic interactions in rabbits with 
EAMG observed in this thesis and any other known 
published material. Thus, the discussion of the rabbit 
AMLR in EAMG will be limited to a comparison of the 
AMLR in rabbit EAMG and human MG, and a speculative 
review of the data presented on the rabbit AMLR in 
EAMG.
The major difficulty experienced in the assessment 
of the cellular immune responsiveness in rabbits was 
the generally low response itself. Although the low 
normal rabbit AMLR had been established before the 
induction and maintenance of EAMG in rabbits, it was
not known what the result of this disease state would
be. The development of an autoaggressive state, where 
many activated lymphocytes exist in the immune system
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and high proliferative responses could occur, was 
envisaged as one possible scenario. Indeed, the 
depressed AMLR observed in humans with various 
autoimmune states may be the result of many years of 
autoaggression leading to a final state of 
non-responsiveness, in terms of self-recognition. 
Additionally, the reports of increased AMLR in certain 
autoimmune states (Birnbaum and Kotilinek, 1981; 
Greenberg et al., 1984) may have observed the high self 
reactivity of patients entering into the intial phases 
of the autoimmunie disease.
The result of the induction of EAMG in rabbits 
was, however, a decrease in the mean population AMLR 
response of approximately 30%. The range of these post 
primary immunisation responses was twice that of the 
normal rabbit AMLR responses, indicating a high degree 
of population response variation in the former group. 
These low responses, maintained in rabbits 58 and 60 
but gradually increasing to normal levels in rabbits 
57, 59 and 61, may represent the transient blocking or 
inhibition of certain cell-cell interactions in the 
AMLR. Only rabbit 62, whose AMLR increased slightly 
following the first immunisation, showed a substantial 
decrease in its AMLR following the second immunisation. 
This was accompanied by a large anti-AChR antibody 
titre increase, although rabbits 57, 60 and 61 also
showed a similarly increased antibody titre following 
the 'boost' immunisation without an accompanying 
decrease in their AMLR.
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It is possible that the time course of disease 
maintenance and study was not sufficiently long to 
monitor any real effects of the disease on the immune 
system. As is possible in the human case, the long 
term effects of serum anti-AChR antibody and possibly 
anti-T cell antibodies, together with activated 
macrophages may not have been possible to determine. 
Although initial short-term effects were observed as a 
decreased AMLR in all the rabbits except rabbit 62, 
only rabbit 62 showed any signs of a substantially 
reduced response following the 'boost1 immunisation. 
This observation was also supported by substantially 
reduced mitogen responses following the 'boost' 
immunisation. It is possible that anti-T cell 
antibodies or a breakdown in the activation processes 
of T cells had occurred in rabbit 62 as a result of the 
disease induction and maintenance.
The question remains, however, over the usefulness 
of the AMLR as an indicator of immunoregulatory status 
in the rabbit in health and disease states. If the
assays performed in the study of the rabbit AMLR in 
this thesis were carried out over longer periods of 
time, would a clearer picture be generated of the
immune system of the rabbit, or is the low AMLR
measured in normal rabbits indicative of the use of an 
assay which is unsuitable for the detection of the
rabbit immunoregulatory state. If the rabbit were to 
be used as the animal model of EAMG for the assessment
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of immunomodulatory drugs, it may be more useful to 
study the changes in specific or non-specific humoral 
responses than those defining cellular
immunoregulation.
9.7 Mitogen responses in EAMG
No differences were observed between the mean 
population responses of normal rabbit lymphocytes and 
those of rabbits with EAMG to the mitogens Con-A or 
PHA-P. The major effects of the immunisations were 
observed only following several weeks after the initial 
injection. The greatest effects were seen on the Con-A 
responsiveness of rabbits 58 and 62; in all other 
animals both of the mitogen responses remained 
approximately the same.
Although rabbit 58 rapidly developed clinical EAMG 
and had to be destroyed, its AMLR response did not 
correlate with the sudden decrease in Con-A 
responsiveness, nor with its clinical condition. Thus, 
it is difficult to reconcile any theories relating to 
the decrease in Con-A reactivity to any form of 
cellular control exerted through the AMLR. However, it 
is possible that the loss of Con-A responsiveness, 
together with the increase in anti-AChR antibody titre, 
could indicate the presence of serum anti-T cell subset 
antibodies. It was suggested in section 1.2.1 that 
within the Con-A responsive T cell subset existed 
another T subset which contains T suppressor cells.
2 4 4
Antibodies directed against this subset may lead to the 
loss of antigen specific suppressor cells and the 
uncontrolled generation of antigen specific help.
Rabbit 62, however, also exhibited a closely 
correlatable decreasing Con-A responsiveness with an 
increasing anti-AChR antibody titre, along with 
classical clinical symptoms following the booster 
injection. Approximately four weeks after the onset of 
changes in the Con-A responsiveness and anti-AChR 
antibody titre, the AMLR response began to decrease. 
This may indicate some form of loss of cellular 
immunoregulation.
It is possible that had rabbit 58 survived past 
week 10, then a change in its AMLR response may have 
been observed. However, the earlier initiation of 
changes in the Con-A responsiveness and anti-AChR 
antibody titre in rabbit 58 would argue against the 
possibility that an increased period of study of its 
AMLR might have revealed any different information.
The Con-A responses of rabbits 57, 59, 60 and 61, 
whilst showing transient fluctuations, did not exhibit 
any major trends as shown by rabbits 58 and 62. No 
appreciable changes were apparent around the mean PHA-P 
responses of any of the rabbits with EAMG. Thus whilst 
the cellular responses of rabbits 58 and 62 may have 
correlated to some extent with the onset of the
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clinical disease, as shown by the anti-AChR antibody 
titre and manifestation of the clinical symptoms, the 
remaining 2/3 of the diseased population showed no such 
correlation. Indeed, although clinical signs were 
apparent in the remaining four rabbits, little or no 
effect was observed on the cellular immune responses 
assayed.
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10.0 CONCLUSIONS AND PROSPECTS
The study of the immunoregulatory changes that may 
occur prior to, during and following the onset of 
diseases of the immune system necessitates the use of 
in vitro assays which are capable of detecting those 
changes. The AMLR has been reported to be an effective 
indicator of immune dysfunction in man (Sakane et al, 
1978; Gupta 1983; Hafler et al, 1985) and indeed, was 
shown in this thesis to be defective in patients with 
the autoimmune disease, myasthenia gravis. It would be 
extremely difficult to study the changes that may occur 
in the immunoregulatory mechanisms of man before the 
onset of the symptomatic disease state. Thus, the 
rabbit AMLR was studied during the events of the 
disease process described above in an attempt to 
elucidate the possible reasons for these changes.
The use of a rabbit system, in which adequate 
numbers of PBL may be obtained to study the AMLR, was 
preferred to the use of any other animal e.g. rat, 
mouse, guinea pig, in which other organ sources of 
leucocytes would have to be employed. Further, the 
ability to bleed repeatedly any individual rabbit 
yields additional advantages to the longitudinal study 
that was performed. Repeated bleeding of any of the 
other alternatives would have been at least technically 
very difficult and even impossible. The use of inbred 
strains of mice would have yielded a source of 
syngeneic tissue but may have resulted in other animal
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to animal variables. Thus, it was considered that the 
rabbit represented the best source of tissue for the 
type of study that was performed.
The difficulties in maintaining EAMG in rabbits, 
avoiding precipitous death whilst preventing the animal 
from entering clinical remission, were overcome by the 
use of a much lower antigen dose regimen. Although the 
longitudinal study was only carried out over a period 
of 14 weeks in the remaining four rabbits, clinical 
symptoms and a high anti-AChR antibody titre were 
attained following the booster immunisation. It is 
possible that the clinical condition could have been 
maintained for an even longer period if further 
immunisations of low doses of antigen were used.
Overall, the rabbit can be justified as an animal 
model for the study of AMLR in EAMG because of:
The ease of obtaining small blood samples at 
weekly intervals (for serum anti-AChR antibody 
determinations).
The ease of the immunisation procedure.
The obvious signs of the developing clinical 
condition.
The ability to obtain adequate samples of PBL 
repeatedly from the same animal.
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The results of the studies on the human AMLR in 
this thesis suggest a number of possible areas for 
further study.
A comprehensive study of the normal human AMLR has not 
yet been achieved and only when the normal response is 
fully understood can the abnormal response in 
autoimmune diseases be correctly interpreted. Numerous 
sections of the normal AMLR require further 
investigation:
i) Standardisation of culture conditions and 
experimental procedures that would enable closer 
inter-laboratory comparisons.
ii) Longitudinal studies of individuals to ascertain 
the variation within any individuals 
responsiveness.
iii) Classification of the response: can individuals
be placed into low, medium or high type response 
groups?
iv) Association of HLA type with the level of the 
proliferative response.
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Considering the role of immune associated self 
antigens (HLA-Dr) in the activation process of the 
AMLR, the degree of association of HLA type with 
responsiveness may possibly be high. Whilst the study 
of Davey et al, (1984) suggested an association of 
HLA-Dr type with AMLR response, further studies may 
clarify this association. This, together with the 
increasing amount of data which suggests that many 
autoimmune diseases show a high degree of association 
with particular HLA haplotypes, would support the need 
for an increased effort in this area of investigation. 
If certain HLA haplotypes predispose an individual to a 
low degree of immune surveillance, as may result from a 
low level of lymphocytic interaction as in the case of 
a low AMLR response, and the individual also carries 
haplotypes which may predispose to the development of 
an autoimmune disease (e.g. HLA-B27 and ankylosing 
spondylitis (Wakefield et al, 1983)), then the 
triggering of an autoimmune response may proceed in the 
absence of adequate immunoregulatory control.
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